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Abstract 
 
Anika Maria Sophie Hartz, Pharmacist, Oral Examination: 24. June 2005 
 
Regulation of P-glycoprotein at the Blood-Brain Barrier 
 
Supervisor: Prof. Dr. Gert Fricker 
Co-Supervisor: Dr. David S. Miller 
 
Over 1 billion people worldwide suffer from some type of central nervous system (CNS) 
disorder (WHO, The World Health Report, 2001). This includes depression, epilepsy, 
multiple sclerosis, brain tumors, Alzheimer’s and Parkinson’s disease, as well as infec-
tions of the brain such as meningitis and HIV encephalitis. Consequently, there is a 
strong demand for effective treatments. However, pharmacotherapy of CNS disorders is 
greatly impaired by poor blood-to-brain transport of a large number of therapeutic drugs. 
The structure responsible for the low CNS penetration of drugs is the blood-brain barrier. 
An important element of barrier function is the ATP-driven efflux transporter,  
P-glycoprotein (P-gp) that denies CNS entry to a myriad of therapeutics. Thus, a better 
understanding of the mechanisms regulating P-gp expression and transport function 
might provide new strategies to improve drug delivery to the brain and increase drug 
levels in the CNS. Therefore, the objective of this thesis was to study regulation of  
P-glycoprotein at the blood-brain barrier. 
P-glycoprotein transport function was assessed by measuring accumulation of the fluo-
rescent, P-gp-specific substrate, NBD-cyclosporine A (NBD-CSA), in the lumens of iso-
lated rat brain capillaries using confocal microscopy and quantitative image analysis. 
Exposing capillaries to the hormone endothelin-1 (ET-1) rapidly and reversibly reduced 
luminal NBD-CSA accumulation. Importantly, ET-1 did not affect tight junctions. Sara-
fotoxin, an ETB receptor agonist, also reduced P-gp-mediated transport; the effects of 
ET-1 and sarafotoxin were blocked by an ETB receptor antagonist, but not by an 
ETA receptor antagonist. Immunostaining localized the ETB receptor to the luminal and 
abluminal membranes of brain capillaries. NBD-CSA transport was also reduced by the 
NO donor, sodium nitroprusside (SNP), and by the protein kinase C (PKC) activator, 
PMA. Inhibition of NO synthase (NOS) or PKC blocked the effect of ET-1; PKC inhibition 
blocked the effects of SNP and PMA. Thus, P-glycoprotein function at the blood-brain 
barrier is regulated in the short-term by ET-1 acting through an ETB receptor, NOS, NO 
and PKC (Hartz et al., 2004). 
Transcriptional regulation of P-glycoprotein by the ligand-activated transcription factor, 
pregnane X receptor (PXR), was also demonstrated. PXR was shown for the first time to 
be expressed in isolated rat brain capillaries by RT-PCR, Western blot analysis and im-
munostaining. Six-hour exposure of isolated capillaries to the PXR ligands, PCN or dex-
amethasone, significantly increased expression of P-gp in the plasma membrane. Con-
sistent with this, P-gp immunostaining demonstrated significantly increased immunore-
activity at the luminal membrane of capillaries. Increased P-gp-mediated  
NBD-CSA transport into capillary lumens was also detected. No such increases in P-gp 
expression were found when capillaries were exposed to ligands that activate human 
PXR (hyperforin, paclitaxel), but do not activate rodent PXR. Importantly, an increase in 
P-glycoprotein expression and transport function was also found in capillaries isolated 
from rats injected with PCN and dexamethasone (Bauer et al., 2004). 
 
 
  
Zusammenfassung 
 
Anika Maria Sophie Hartz, Apothekerin, Tag der mündlichen Prüfung: 24. Juni 2005 
 
Regulation von P-glycoprotein in der Blut-Hirn-Schranke 
 
Referent: Prof. Dr. Gert Fricker 
Koreferent: Dr. David S. Miller 
 
Mehr als 1 Milliarde Menschen weltweit leidet an Erkrankungen des Zentralnerven-
systems (ZNS) (WHO, The World Health Report, 2001). Hierzu zählen Depressionen, 
Epilepsie, Multiple Sklerose, Gehirntumore, Alzheimer-Demenz, Parkinson-Syndrom, 
sowie Infektionen des Gehirns (Hirnhautentzündung, HIV Enzephalopathie). Die 
medikamentöse Therapie von ZNS-Erkrankungen ist wegen der schlechten Hirn-
gängigkeit vieler Arzneistoffe jedoch stark eingeschränkt. Verantwortlich für dieses 
Problem ist das Endothel der Kapillaren im Gehirn, die sogenannte Blut-Hirn-Schranke. 
Einen wesentlichen Anteil an der Schrankenfunktion hat der Efflux-Transporter  
P-glycoprotein (P-gp), der einerseits das Gehirn vor Toxinen schützt, andererseits aber 
auch zahlreiche Arzneistoffe daran hindert, in das ZNS zu gelangen. Ein 
Forschungsansatz um die Hirngängigkeit von Pharmaka zu erhöhen und somit die 
Therapie von ZNS-Erkrankungen zu verbesseren besteht darin, die Regulation von  
P-glycoprotein aufzuklären. Daher steht im Mittelpunkt dieser Arbeit die Regulation der 
P-glycoprotein Expression und Transportfunktion in der Blut-Hirn-Schranke. 
Zunächst wurde die Kurzzeitregulation der P-glycoprotein Transportfunktion untersucht. 
Hierzu wurden isolierte Gehirnkapillaren der Ratte mit dem fluoreszierenden  
P-gp-Substrat NBD-Cyclosporin A (NBD-CSA) inkubiert. Die Anreicherung der  
NBD-CSA Fluoreszenz im Kapillarlumen wurde mittels konfokaler Lasermikroskopie und 
quantitativer Bildanalyse ermittelt. Inkubation der Kapillaren mit dem Hormon 
Endothelin-1 (ET-1) verringerte die luminale NBD-CSA-Fluoreszenz innerhalb von 
Minuten; dieser Effekt war reversibel wenn ET-1 entfernt wurde. Die Abnahme der 
luminalen NBD-CSA Fluoreszenz wurde ausschlieβlich durch einen Effekt auf P-gp 
hervorgerufen, da ET-1 keinen Einfluss auf die Tight Junctions hatte. Neben ET-1 
verringerte auch Sarafotoxin, ein ETB-Rezeptor-Agonist, den P-gp-vermittelten  
NBD-CSA-Transport. Sowohl der Effekt von ET-1 als auch der von Sarafotoxin wurden 
durch einen ETB-Rezeptor-Antagonisten aufgehoben, nicht aber durch einen  
ETA-Rezeptor-Antagonisten. Die Expression des ETB-Rezeptors wurde durch 
Immunfärbung in der luminalen und abluminalen Kapillarmembran nachgewiesen. Der 
NBD-CSA Transport wurde auch durch Natriumnitroprussid (NNP), einem NO-Donor, 
sowie durch PMA, einem Aktivator der Proteinkinase C (PKC), verringert. Durch 
Inhibition der NO Synthase oder der PKC wurde der Effekt von ET-1 vollständig 
aufgehoben. Inhibition der PKC hemmte die Effekte von NNP und PMA. Diese 
Ergebnisse zeigen, dass die P-glycoprotein Transportfunktion in der Blut-Hirn-Schranke 
durch ET-1 reguliert wird. Die durch ET-1 vermittelte Kurzzeitregulation von P-gp verläuft 
über den ETB-Rezeptor, NOS, NO und PKC (Hartz et al., 2004). 
 
Im zweiten Teil der Arbeit wurde die transkriptionelle Regulation von P-glycoprotein 
durch den Nuklearrezeptor PXR (Pregnane X Rezeptor) untersucht. Zum ersten Mal 
konnte mit Hilfe von RT-PCR, Western Blot und Immunfärbung gezeigt werden, dass 
PXR in isolierten Gehirnkapillaren von Ratten exprimiert ist. Inkubation isolierter 
Kapillaren mit den PXR Liganden PCN oder Dexamethason über einen Zeitraum von  
6 Stunden erhöhte die Expression von P-gp in der luminalen Kapillarmembran 
signifikant. Dies wurde über quantitative Immunfärbung und Western Blots gezeigt; auch 
der NBD-CSA-Transport durch P-gp war erhöht. Wurden die Kapillaren mit Liganden 
(Hyperforin, Paclitaxel) inkubiert, die nur den humanen PXR aktivieren nicht aber den 
von Ratten, so war P-gp nicht verstärkt exprimiert. Auch in vivo Versuche mit Ratten, 
denen PCN und Dexamethason injiziert wurde, ergaben, dass die P-gp Expression und 
Transportfunktion in Gehirnkapillaren stark erhöht war. P-gp war ausserdem auch in 
Leber und Niere induziert (Bauer et al., 2004). 
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1 Introduction 
Over 1 billion people worldwide suffer from some type of central nervous system (CNS) 
disorder, e.g. depression, schizophrenia, stroke, epilepsy, multiple sclerosis, bacterial 
and viral infections (e.g. meningitis, HIV encephalitis), brain tumors, Alzheimer’s disease 
and Parkinson’s syndrome (Kermani and McGuire, 2002; WHO, 2001). This is more than 
twice as many people as those with diseases of the cardiovascular system. Neverthe-
less, the world wide market for CNS drugs is only half the size – around US$ 33 billion 
vs. US$ 70 billion (Pardridge, 2002). Since there are so many sufferers, there is also a 
strong demand for effective treatments. However, pharmacotherapy of CNS disorders is 
greatly impaired by the blood-brain barrier. The molecular basis of the selective, func-
tionally active barrier is a group of ATP-driven efflux transporters; the most prominent of 
which is P-glycoprotein (P-gp). Acting as a “first line of defense”, P-glycoprotein limits 
xenobiotics including a large number of drugs from penetrating into the brain. One po-
tentially useful strategy to improve drug delivery to the brain and thus increase drug lev-
els in the CNS is to manipulate P-gp protein expression and transport function. There-
fore, a better understanding of the mechanisms that regulate P-glycoprotein at the 
blood-brain barrier holds the promise of improving drug therapy of CNS disorders. 
 
The introduction following is in three parts: 
 
1.1 The Blood-Brain Barrier 
The first part gives a brief historical background and summarizes current knowl-
edge on blood-brain barrier research. 
1.2. P-glycoprotein at the Blood-Brain Barrier 
The second part is focused on the efflux transporter P-glycoprotein, its structure, 
expression, physiological function and its importance for the blood-brain barrier. 
1.3. Regulation of P-glycoprotein 
The third part summarizes current knowledge on functional and transcriptional 
regulation of P-glycoprotein, with a focus on the blood-brain barrier. 
 
 
1.1 The Blood-Brain Barrier 
1.1.1 The Blood-Brain Barrier – Historical Background 
Today’s understanding of the blood-brain barrier is the result of 120 years of intensive 
research (Figure 1.1). The first experiments go back to Paul Ehrlich, who in 1885 ob-
served that water soluble dyes injected into the peripheral circulation did not stain the 
brain (Ehrlich, 1885). Ehrlich interpreted these findings as a lack of dye affinity of the 
nervous system and did not believe that the brain capillaries could selectively exclude 
the dyes. However, experiments by Ehrlich’s student, Edwin E. Goldmann, revealed that 
the same dyes injected into the subarachnoid space stained the brain, but not peripheral 
tissues (Goldmann, 1909; Goldmann, 1913). The concept of a vascular blood-brain bar-
rier was born and it was Lewandowsky, who coined the term blood-brain barrier  
(“Bluthirnschranke”, Figure 1.1) (Lewandowsky, 1900). 
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Several years later, in 1923, Spatz hypothesized that the brain capillary endothelium had 
to be the structure responsible for barrier function; this started a discussion that would 
last for decades (Spatz, 1933). In 1946, August Krogh questioned how nutrients could 
reach the brain if the blood-brain barrier was impermeable. He therefore suggested a 
dynamic barrier involving active transport (Krogh, 1946). It took over 20 more years until 
Reese and Karnovsky (Reese and Karnovsky, 1967) and Brightman and Reese 
(Brightman and Reese, 1969; Reese and Karnovsky, 1967) using electron microscopy 
localized the barrier to the brain capillary endothelial cells and found tight junctions to be 
the responsible anatomical structure for barrier function (Figure 1.1). In 1969, Saikotos 
et al. reported the isolation of brain capillaries (Siakotos, 1969). Betz et al. isolated brain 
capillary endothelial cells and successfully established an in vitro blood-brain barrier 
model system (Betz et al., 1980). Since then, various in vivo, ex vivo and in vitro blood-
brain barrier models have been used in basic research and industrial drug screening, 
mainly with the goal of improved drug delivery to the brain (Abbott et al., 1992; Audus et 
al., 1990; Goldstein et al., 1984; Miller et al., 2000; Pardridge et al., 1985; Pardridge et 
al., 1990b). More recently, understanding underlying molecular mechanisms of blood-
brain barrier development, function and regulation have been the focus of an increasing 
number of research efforts (Grant et al., 1998; Risau and Wolburg, 1990; Staddon et al., 
1995). However, even today, well into the genomics and proteomics eras, overcoming 
the blood-brain barrier to treat disorders of the central nervous system is still a challenge. 
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1.1.2 The Blood-Brain Barrier – Physiological Function 
The blood-brain barrier is the brain capillary endothelium between the blood and the 
brain. Its major functions are protection of CNS and maintenance of CNS homeostasis. 
The blood-brain barrier prevents entry to the brain of endogenous and exogenous poten-
tially neurotoxic compounds including a large number of CNS drugs (Banks, 1999). 
However, rather than being a simple physical and mechanical obstacle, the blood-brain 
barrier is a highly active, dynamic and selective interface. As such, it regulates the ex-
change of compounds between blood and brain (Begley and Brightman, 2003). For ex-
ample, the barrier is responsible for supplying the brain with glucose, amino acids and 
other nutrients, and at the same time for the disposal of metabolic wastes from the CNS. 
Thus, one essential physiological function of the blood-brain barrier is to control cerebral 
homoeostasis and to maintain a constant osmotic pressure for proper CNS function 
(Drewes, 1999). All these characteristics combined make the blood-brain barrier both an 
extremely complex organ, and a fascinating subject for research. 
 
1.1.3 The Blood-Brain Barrier – A Microvascular Network 
Brain capillaries (cerebral microvessels) are the structural basis of the blood-brain bar-
rier. With a diameter as small as 3-7 µm, brain capillaries are the smallest vessels of the 
vascular system (Figure 1.2C) (Rodriguez-Baeza et al., 2003). The human blood-brain 
barrier is comprised of about 100 billion capillaries forming a highly branched microvas-
cular network (Figure 1.2A, (Zlokovic and Apuzzo, 1998)). Because of the high capillary 
density in the brain, single capillaries are only about 40 µm apart from each other, a dis-
tance short enough for small molecules to diffuse within 1 second (Figure 1.2B, 
(Rodriguez-Baeza et al., 2003)). In addition, this ensures that every neuron is perfused 
by its own capillary to guarantee efficient nutrient supply. Despite the huge number of 
brain capillaries, they occupy only about 0.1% of the brain volume, or 1 ml in an adult 
human brain of 1200-1400 g (Pardridge, 2003b). The total length of the capillary network 
in an adult human brain is 600-650 km (370-400 mls) with a surface area of about 20 m2 
(215 ft2), which makes the blood-brain barrier the third largest drug exchange surface 
area after intestine and lung (Pardridge, 2003a). 
5 µm500 µm
A B C
Figure 1.2 
The blood-brain barrier – A microvascular network 
 
A: Latex mold of the microvascular network of an adult human brain, from (Zlokovic and Apuzzo, 1998) 
B: Scanning electron micrograph showing human cerebral cortex: 
 (1) pial vessels, (2) long and (3) middle cortical arteries, (4) superficial, (5) middle and (6) deep capil-
lary zone, from (Rodriguez-Baeza et al., 2003) 
C: Differential interference contrast image of an isolated rat brain capillary (Hartz et al., unpublished data)
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1.1.4 The Blood-Brain Barrier – Morphology of Brain Capillaries 
The cerebral microvessels of the blood-brain barrier are constituted by endothelial cells, 
the smallest unit of brain capillaries. Brain capillary endothelial cells are polarized cells, 
with an apical membrane facing the blood (luminal membrane) and a basolateral mem-
brane facing the brain tissue (abluminal membrane) (Betz et al., 1980). Morphologically, 
brain capillary endothelial cells are long and spindle-shaped. However, they are very flat 
and thin, too, with only about 300 nm of cytoplasmic space in between the luminal and 
abluminal membranes (Pardridge, 2003b). Brain capillaries are surrounded by a base-
ment membrane, which is complex in structure, composed of collagens and proteins, 
and that provides external support for the endothelial cells (Goldstein and Betz, 1983). 
At the basement membrane, pericytes, astrocytes and neurons are in contact with the 
endothelial cell (Figure 1.3). Today, this four-cell structure termed “Neurovascular Unit” 
is thought to be responsible for the regulation of blood flow and barrier function (Begley, 
2004b). One important characteristic of the functional barrier are the so-called tight junc-
tions. They seal the inter-endothelial space and create a tight, non-fenestrated capillary 
endothelium that restricts free diffusional exchange of solutes (Nag, 2003). In addition, 
cerebral endothelial cells show low pinocytotic activity and have no intercellular clefts. 
However, capillary endothelial cells contain a large number of mitochondria to meet the 
energy demand for active processes like metabolism and ATP-driven efflux transport 
(Goldstein and Betz, 1983). 
Mitochondrium
Tight Junctions
Pericyte
Astrocyte end foot
NucleusEndothelial cell
Basement membrane
Lumen
Neuron
Figure 1.3 
Morphology of brain capillaries 
 
Brain endothelial cells are surrounded by a basement membrane. Astrocytic end feet, pericytes and neu-
rons share this basement membrane. The interendothelial space is sealed by tight junctions. 
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1.1.5 The Blood-Brain Barrier – Tight Junctions 
It wasn’t until the studies of Reese and Karnovsky in 1967 (Reese and Karnovsky, 1967) 
and Brightman and Reese in 1969 (Brightman and Reese, 1969; Reese and Karnovsky, 
1967) that tight junctions were identified as a crucial element of blood-brain barrier func-
tion. Tight junctions are cell-cell contacts between adjacent cerebral endothelial cells. 
They seal neighboring cells, thereby prevent paracellular diffusion and only allow re-
stricted passage of water, ions and molecules smaller 0.2 nm. On a molecular level, tight 
junctions are highly complex and specialized contact zones linked to the cytoskeleton 
(Figure 1.4) (Matter and Balda, 2003b). In 1984, Nagy et al. demonstrated that brain 
capillary endothelial cells possess the most intricate and extended tight junctional com-
plex in the cardiovascular system (Nagy et al., 1984). 
Tight junctions are composed of transmembrane proteins like occludin, claudins and 
junctional adhesion molecules (JAMs) and a so-called cytoplasmic “plaque” of submem-
branous adaptor and regulatory proteins (Vorbrodt and Dobrogowska, 2003; Vorbrodt 
and Dobrogowska, 2004). The adaptor proteins include zonula occludens (ZO) proteins, 
cingulin and membrane-associated guanylate kinase inverted (MAGI) proteins. They 
create a link between the junctional transmembrane proteins and actin filaments of the 
cytoskeleton (Matter and Balda, 2003b). The regulatory proteins include G proteins, 
atypical isoforms of protein kinase C (aPKC), and symplektin, all of which are involved in 
signaling to and from tight junctions (Matter and Balda, 2003b; Wolburg and Lippoldt, 
2002). On the one hand, the complex junctional composition and structure guarantees a 
tight barrier. But on the other hand it also allows rapid modulation of barrier properties 
while retaining structural integrity and thus, protection of the CNS (Kniesel and Wolburg, 
2000). However, under pathological conditions tight junctions can be disrupted leading 
to severe brain damage and impaired neuronal function (Huber et al., 2001). 
Tight Junctions at the Blood-Brain Barrier
Transmembrane proteins
Occludin, Claudins, JAMs
Adaptor proteins
ZO1-3, Cingulin, MAGI 1-3
Regulatory proteins
G proteins, aPKC
Transcriptional and
post-transcriptional regulators
Symplekin
Actin filaments
Brain capillary endothelial cell
Figure 1.4 
Tight junctions at the blood-brain barrier 
 
Major components of tight junctions at the blood-brain barrier include transmembrane proteins as well as 
adaptor and regulatory proteins: occludin, claudins, junctional adhesion proteins (JAMs), zonula occludens 
(ZO), cingulin, membrane-associated guanylate kinase inverted (MAGI) proteins, G proteins, atypical pro-
tein kinase C (aPKC) and symplekin (adapted from (Matter and Balda, 2003b)). 
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1.1.6 The Blood-Brain Barrier – Drug Transporters 
Over the past decade, it has become clear that the blood-brain barrier is a complex, dy-
namic structure with selective, active components. The molecular basis of the functional 
barrier is a number of multispecific, xenobiotic drug efflux transporters. Conventionally, 
transporters are grouped into families based on molecular and functional similarities. At 
present, mRNA for 15 drug transporters from several families has been detected in brain 
capillaries or brain capillary endothelial cell lines (Omidi et al., 2003; Zhang et al., 2000; 
Zhang et al., 2004a). This includes the multidrug resistance protein (MDR),  
multidrug resistance-associated protein (MRP), organic anion transporter (OAT), or-
ganic anion transporting polypeptide (OATP), organic cation transporter (OCT), concen-
trative nucleoside transporter (CNT), and equilibrative nucleoside transporter (ENT) 
subfamilies. However, it is very likely that this inventory of transporters is incomplete. 
About 15% of the genes expressed at the blood-brain barrier are expected to encode for 
transporters, and it is estimated that only about 50% of these are known (Pardridge, 
2003b). Indeed, there have repeatedly been reports that cannot be fully explained by the 
transporters known so-far to be expressed at the blood-brain barrier (Lee et al., 2005). 
Therefore, it is anticipated that a blood-brain barrier genomics program will identify sev-
eral new transporters (Pardridge, 2001). 
Of the 15 transporters detected at the mRNA level, seven have been immunolocalized 
within brain capillary endothelial cells (Figure 1.5, (Bauer et al., 2005). Five ATP-driven 
drug export pumps, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), 
Mrp1, Mrp2, and Mrp4 are on the luminal plasma membrane (blood side). Together, 
these transporters can handle a wide range of anionic (Mrp1, Mrp2 and Mrp4), cationic 
(P-glycoprotein and BCRP), and uncharged (all five) xenobiotics. Therefore, acting as a 
“first line of defense”, they limit xenobiotics including a large number of drugs from pene-
trating into the brain and likely also remove metabolic wastes from CNS to blood. 
Also on the luminal membrane is Oatp2 (Figure 1.5), another organic anion transporter 
that handles steroid and drug conjugates, certain opioid peptides, and the cardiac glyco-
side, digoxin (Gao et al., 1999). Oatp2 could drive concentrative efflux from the cells if 
energetically coupled to the electrical potential difference across the luminal membrane. 
Clearly, also Oatp2 could contribute to the selective component of the blood-brain bar-
rier. 
Xenobiotic transporters are also present on the basolateral plasma membrane (brain 
side) of brain capillary endothelial cells. These include Mrp1, Mrp4, Oatp2 and Oat3 
(Cisternino et al., 2003; Gao et al., 1999; Ohtsuki et al., 2002; Zhang et al., 2004a). The 
role of these transporters on the basolateral membrane is not well understood. However, 
when coupled to the appropriate ion gradients, both Oat3 and Oatp2 are capable of driv-
ing organic anions into endothelial cells. Thus, basal Oatp2 and Oat3 could pair with lu-
minal Mrp1, Mrp2, Mrp4 and Oatp2 to drive anionic xenobiotics across the endothelium 
from the CNS into blood. 
In addition, recently rat Oatp14 and human OATP-A have been detected at the  
blood-brain barrier by Northern and Western blotting, and immunolocalization tech-
niques, respectively (Gao et al., 2000; Sugiyama et al., 2003b). While Oatp14 might be 
involved in thyroid hormone transport, the function of OATP-A is unclear (Tohyama et al., 
2004). 
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Figure 1.5 
Drug transporters at the blood-brain barrier 
 
Luminal membrane (blood side): P-gp, BCRP, Mrp 1, 2, 4 and Oatp2 
Abluminal membrane (brain side): Oat3, Mrp1, Mrp4 and Oatp2 
modified from (Bauer et al., 2005) 
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1.2 P-glycoprotein 
1.2.1 P-glycoprotein – Historical Background 
In 1960, Goldstein et al. reported acquired resistance to actinomycin D in HeLa cell lines 
(Goldstein et al., 1960). This was also observed by Biedler and Riehm in a chinese 
hamster ovary cell line (Biedler and Riehm, 1970). In addition, they found that the cells 
were resistant to multiple drugs. Shortly afterwards, Dano et al. showed active outward 
transport of daunomycin by resistant cells and proposed an active efflux pump to cause 
resistance by transporting drugs out of the cell (Dano, 1973). In 1976, Juliano and Ling 
identified this efflux pump (Juliano and Ling, 1976). The glycoprotein they found ap-
peared to be unique to mutant cells that displayed altered drug permeability. Thus, they 
named it permeability-glycoprotein (P-glycoprotein or P-gp). However, it quickly became 
clear that P-glycoprotein is a primary, active efflux pump that uses the energy of ATP to 
transport its substrates out of cells, even against a concentration gradient (Sharom, 
1997). The discovery of P-gp was groundbreaking, because it explained multidrug resis-
tance (mdr, resistance to multiple chemotherapeutics), a frequently observed phenome-
non in tumors. In the mid to late 1980s, P-glycoprotein was also found to be physiologi-
cally expressed in normal excretory and barrier tissues such as liver, kidney and intes-
tine (Thiebaut et al., 1987). 
In 1989, two independent research groups found expression of P-gp at the human 
blood-brain barrier (Cordon-Cardo et al., 1989; Thiebaut et al., 1989) and several years 
later it was also found to be present in isolated brain capillaries from mouse, rat, pig and 
cow (Jette and Beliveau, 1993; Jette et al., 1993; Nobmann et al., 2001; Tsai et al., 
2002). At the blood-brain barrier, P-gp is highly expressed in the luminal membrane of 
endothelial cells, a perfect location to protect the brain from xenobiotics (Beaulieu et al., 
1997; Biegel et al., 1995; Shirai et al., 1994; Sugawara, 1990; Tanaka et al., 1994; Tsuji 
et al., 1992). Therefore, P-glycoprotein is generally recognized to be the most important 
element of the selective, active blood-brain barrier for xenobiotics and thus, has been a 
main focus of blood-brain barrier research over the last decade. 
 
 
 
1.2.2 P-glycoprotein – Expression, Structure & Function 
In humans, P-glycoprotein is encoded by the ABCB1 gene (ATP-binding cassette, sub-
family B, member 1), better known as MDR1 (multidrug resistance gene 1; Table 1.1) 
(Bodor et al., 2004; Ueda et al., 1986). Another isoform in humans is MDR2 (Chin et al., 
1989). Three isoforms have been identified in rodents: mdr1a, mdr1b, and mdr2 (Hsu et 
al., 1990). The Mdr1 gene products confer multidrug resistance, whereas the Mdr2 gene 
products secrete phosphatidylcholine into bile at the canalicular membrane of hepato-
cytes (Smit et al., 1993). The isoforms exhibit a large structural overlap and human and 
rat gene products show homology of about 80% (van der Bliek et al., 1988). 
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MDR/TAP (ABC subfamily B) 
Species Gene symbol & name Gene name Expression Function 
Human ABCB1 
(MDR1, PGY1, CLCS) 
 
Chromosome 7 (7q21, 28 exons) 
 
Protein: 1280 AA 
 
Aliases : P-gp, CD243, GP170,  
              ABC20 
Rodent Abcb1a 
(mdr1a, mdr3) 
 
Abcb1b 
(mdr1b, mdr1) 
ATP-binding cassette, 
subfamily B, member 1
Excretory and barrier 
tissues such as liver, 
kidney, intestine, 
placenta as well as 
blood-testis & blood-
brain barriers 
Protection of the body 
by ATP-dependent 
efflux transport of 
xenobiotics, including 
a large number of 
commonly used drugs 
in the clinic 
Human ABCB4 
(MDR2, MDR3) 
 
Chromosome 7 (7q21, 28 exons) 
 
Protein: 1279 AA 
 
Aliases: MDR2/3, MDR3, PFIC-3, 
             ABC21 
Rodent Abcb4 
(mdr2) 
ATP-binding cassette, 
subfamily B, member 4 
Hepatocytes Biliary phosphatidyl-
choline secretion from 
hepatocytes 
 
 
 
 
 
Table 1.1 
MDR isoforms 
 
TAP: Transporter Associated with Antigen Processing 
http://www.nutrigene.4t.com/humanabc.htm & http://www.gene.ucl.ac.uk/nomenclature/genefamily/abc.html 
The MDR1 gene product, P-glycoprotein, is a 170 kDa transmembrane protein that con-
sists of 1280 amino acids. It is organized as a single polypeptide with two homologous 
halves (Figure 1.6, (Jones and George, 2000)). Each half contains a transmembrane 
domain (TMD) with 6 transmembrane α-helical segments and one ATP-binding domain 
(ABD). Intracellular and extracellular loops connect the transmembrane spanning seg-
ments and a highly charged, phosphorylated linker region connects the two halves with 
each other. This region also contains signature motifs characteristic for ABC transporters 
(ABC family signature, Walker A and B motifs). N-glycosylation takes place at the first 
extracellular loop. 
 
Membrane
ic
ec
1 2 3 4 5 6 7 8 9 10 11 12
ABD1 ABD2H2N COOH
TMD1 TMD2
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 
P-gp protein organization 
 
P-glycoprotein consists of 2 transmembrane domains (TMD1 and TMD2), each of which has 6 transmem-
brane spanning α-helices and an ATP-binding domain (ABD). P-gp is N-glycosylated at the first extracellu-
lar loop (ec = extracellular, ic = intracellular). Modified from (Jones and George, 2000; Webb, 1997). 
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The shape of membranous P-glycoprotein has been determined by electron microscopy 
to be 6-fold symmetrical-toroidal (doughnut-shaped) with a diameter of 10 nm, and a 
large central pore of about 5 nm in diameter (Rosenberg et al., 1997). The transmem-
brane spanning segments form the central pore and mediate drug binding. They also 
direct trafficking of the protein to the cell membrane (Loo and Clarke, 1999). Loo et al. 
showed that the drug binding pocket is large enough to bind two different drugs simulta-
neously (Loo et al., 2003). Furthermore, they suggested a substrate-induced fit for bind-
ing since substrates cause size- and shape-dependent conformational changes of the 
transmembrane segments. This mechanism would also explain the broad substrate 
spectrum of P-glycoprotein. In general, P-gp substrates are mainly organic cations and 
uncharged compounds with a molecular weight between 300-2000 Da, they are amphi-
philic or lipophilic in nature, and vary greatly in their chemical structure. P-gp substrates 
include a large number of clinically relevant drugs such as opioids, steroids, antibiotics, 
calcium-channel blockers, chemotherapeutics, immunosuppressants, anti-HIV drugs, 
and miscellaneous others (Chen and Simon, 2000). At present, physiological substrates 
have not been identified yet. 
P-glycoprotein is expressed in barrier and excretory tissues, including kidney, liver, in-
testine, pancreatic duct, placenta, salivary ducts, cornea, testis, adrenal cortex, nasal 
mucosa, choroid plexus and the blood-brain barrier (Cordon-Cardo et al., 1990; Dey et 
al., 2003; Henriksson et al., 1997; Rao et al., 1999; Sugawara et al., 1988; Thiebaut et 
al., 1987; Thiebaut et al., 1989; Uematsu et al., 2001). P-glycoprotein protects the body 
from xenobiotics, by active, ATP-dependent efflux transport. Additional functions have 
been proposed such as regulatory functions in apoptosis and cell differentiation 
(Johnstone et al., 2000), indirect modulation of chloride channel activity (Valverde et al., 
1992), and putative involvement in cholesterol esterification (Luker et al., 1999). In addi-
tion, P-glycoprotein is responsive to inflammatory mediators (McRae et al., 2003) and 
immunomodulation (Richaud-Patin et al., 2004). It is not clear whether these additional 
functions are limited to certain tissues and cells or whether they are a property of all cells 
expressing P-gp. 
The species P-glycoprotein and its isoforms have been found in so far include mammals 
(human, mouse, rat, hamster, guinea pig, rabbit, dog, monkey, pig and cow) as well as 
insects, fish, amphibians and birds (Baas and Borst, 1988; Bard et al., 2002; Barnes, 
2001; Bombardi et al., 2004; Bonfanti et al., 1998; Bosch et al., 1996; Dey et al., 2003; 
Fricker et al., 2002; Melaine et al., 2002; Pardridge et al., 1997). 
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1.2.3 P-glycoprotein - A Key Drug Export Pump at the Blood-Brain Barrier 
Over the last decade, it has become clear that the multi-specific, xenobiotic drug efflux 
transporter, P-glycoprotein, plays an important role in blood-brain barrier function. Four 
factors – expression, localization, potency and multi-specificity - combine to make  
P-glycoprotein the key determinant of drug entry into the CNS (Begley, 2004a). 
First, P-glycoprotein is highly expressed in capillary membranes of the blood-brain bar-
rier (Figure1.7). Second, localization at the luminal membrane of capillary endothelial 
cells is consistent with P-gp being both a barrier to entry and a drug excretory pump. 
Third, potent ATP-driven pumping essentially prevents entry and accumulation of sub-
strates into the cytoplasm of barrier cells. Fourth, the remarkably broad substrate spec-
trum of P-glycoprotein ensures that it will handle a large number of commonly prescribed 
drugs. 
No experiments better highlight the importance of P-gp to blood-brain barrier function 
than those involving genetic modifications in which the transporter has been knocked out. 
In vivo dosing studies using genetic mdr1-knockout mice show 5-50-fold increased 
brain-to-plasma ratios of a large number of drugs that are P-gp substrates and therefore 
normally don’t get into the brain (Schinkel et al., 1996). 
Moreover, in a combined in vitro/in vivo approach, Fellner et al. used this principle to 
treat brain tumors in mice by chemically knocking out P-glycoprotein (Fellner et al., 
2002). They identified P-gp as the major factor in limiting access of the anti-cancer 
therapeutic paclitaxel into the CNS. Pretreatment of mice with the P-gp-specific inhibitor, 
PSC833, not only increased brain levels of the anti-cancer drug paclitaxel (i.v. dosing), 
but also had a dramatic therapeutic effect on a paclitaxel-sensitive, intracerebrally im-
planted human glioblastoma. This tumor is generally refractory to treatment, because  
P-gp greatly restricts CNS penetration of most anti-cancer drugs. Importantly, combined 
PSC833-paclitaxel therapy decreased tumor volumes by 90%. In contrast, paclitaxel it-
self did not affect tumor size. 
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Figure 1.7 
P-glycoprotein, a key determinant of drug entry into the CNS 
 
P-glycoprotein is a key export pump at the blood-brain barrier because of its high expression, luminal lo-
calization at the capillary endothelium, its potent transport activity and its multi-specificity (Bauer et al., 
2005). 
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1.3 Regulation of P-glycoprotein Function and Expression 
P-glycoprotein is the key drug efflux transporter at the blood-brain barrier that prevents 
successful delivery of therapeutics into the brain. Therefore, a better understanding of 
physiological and pathological mechanisms that regulate P-gp at the blood-brain barrier 
holds the promise of improving drug therapy of CNS disorders. One approach to im-
prove drug delivery to the brain and increase drug levels in the CNS in a controlled 
manner would be to manipulate expression and function of P-glycoprotein. In this regard, 
it would clearly be advantageous to be able to modulate P-gp function over the short-
term while still having its protection over the long-term. However, although P-gp is the 
most widely studied ABC transporter, little is known about its regulation at the blood-
brain barrier. Three general strategies have been used to manipulate P-glycoprotein: 
1) direct inhibition of P-glycoprotein transport function by using specific inhibitors, 
2) short-term regulation (minutes) of P-glycoprotein transport function through intracel-
lular signaling, and 
3) long-term regulation (within hours to days) of P-glycoprotein expression through 
specific manipulation of transcription. 
The following section gives an overview of mechanisms currently known to regulate  
P-glycoprotein transport function and expression. 
 
 
1.3.1 Direct Inhibition of P-glycoprotein Transport Function 
One strategy to modulate P-glycoprotein at the blood-brain barrier is by direct inhibition. 
For this purpose, several P-gp inhibitors were developed and a large number of com-
pounds have been screened for their P-gp-inhibitory potential (Avendano and Menendez, 
2002; Pleban and Ecker, 2005). First generation P-glycoprotein inhibitors include, vera-
pamil, quinidine, quinine, cyclosporin A, amiodarone and nifedipine (Ford et al., 1996; 
Leonard et al., 2002; Tsuruo et al., 1981; Twentyman, 1992). However, these com-
pounds often caused toxic side effects in vivo due to their low potency, weak effective-
ness and poor selectivity. This led to new P-gp inhibitors that were developed solely for 
the purpose of reversing drug resistance. Second generation inhibitors include valspodar 
(PSC833) and biricodar (VX-710), and third generation inhibitors include elacridar 
(GF120918), tariquidar (XR-9576), zosuquidar (LY-335979), and laniquidar (R-101933) 
(Kemper et al., 2004a; Kemper et al., 2003; Leonard et al., 2002; van Zuylen et al., 2000; 
Walker et al., 2004). Animal studies show that of the few relatively specific P-gp inhibi-
tors available, PSC833 (valspodar) is the most effective in increasing brain drug levels in 
in vivo models (Kemper et al., 2003; Kemper et al., 2004b; Mayer et al., 1997). Phase I 
and phase II clinical studies looked promising and indicate that PSC833 can be adminis-
tered safely to patients with corrected doses of chemotherapeutics (Advani et al., 2001). 
Unfortunately, phase III trials proved to be disappointing. No difference in survival rate 
between cancer patients that received chemotherapeutic plus PSC833 and patients that 
did not receive PSC833 could be observed. In addition, PSC833 caused severe hemato-
logical toxicity, even early deaths were reported (Advani et al., 2001). However, it should 
be mentioned that in these phase III studies PSC833 was administered chronically. Also, 
PSC833 was never tested in a study with brain cancer patients. The use of PSC833 to 
chemically knock out P-gp was not followed any further. It remains to be seen, how well 
other P-gp-specific inhibitors of the third and fourth generation will do in clinical studies. 
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1.3.2 Short-Term Regulation of P-glycoprotein Transport Function 
Modulation of P-glycoprotein transport function through intracellular signaling is another 
way to manipulate the transporter at the blood-brain barrier. Intracellular signaling can 
be a rapid process that takes place within minutes and triggers numerous biological 
events. These changes are referred to as “short-term” effects in this thesis. Today, we 
know little about the regulation of P-glycoprotein at the blood-brain barrier over the 
short-term. However, in other tissues, regulatory mechanisms have been described that 
signal rapid changes in P-gp transport function. These include: 
 
1) Phosphorylation of P-glycoprotein by protein kinase C 
2) Membrane trafficking of P-glycoprotein 
3) Ubiquitination triggering P-glycoprotein degradation 
4) Interaction of P-glycoprotein with caveolin-1 
5) Regulation of P-glycoprotein by endothelin-1 
 
 
1.3.2.1 Phosphorylation of P-glycoprotein by Protein Kinase C 
The protein kinase C (PKC) family is a group of homologous, phospholipase C-de-
pendent serine/threonine kinases similar in size, structure and mode of action (Azzi et al., 
1992). They modulate the biological function of their target proteins in a rapid and re-
versible manner by transferring phosphate from ATP to certain amino acid residues of 
the protein. By doing so, PKC participates in the signal transduction triggered by exter-
nal stimulation of cells by various ligands including hormones, neurotransmitters and 
growth factors. Today, twelve members of the PKC family have been identified in mam-
mals (Idris et al., 2001). They are classified as conventional (cPKC: α, β1, β2, γ), novel 
(nPKC: δ, ε, η, θ, µ), and atypical (aPKC: ι, ζ, λ) PKC isozymes. While activation of the 
conventional PKC members is Ca2+-dependent, the novel and atypical isozymes do not 
require Ca2+ to be activated. 
Numerous studies have examined the effects of PKC on P-glycoprotein transport func-
tion (Hofmann, 2001). Chambers et al. showed that activation of PKC rapidly increased 
P-gp transport function in a cell line within 15-30 min and proposed that phosphorylation 
might be an important mechanism of modulating P-gp transport activity (Chambers et al., 
1990a; Chambers et al., 1990b). In contrast, studies by Miller et al. demonstrated PKC-
mediated reduction of P-gp transport in teleost renal proximal tubule (Miller et al., 1998). 
Another study by Castro et al. confirmed PKC modulation of P-gp transport function. 
However, the findings also suggest that P-glycoprotein phosphorylation by PKC does 
not play a major role in regulating P-gp (Castro et al., 1999; Germann et al., 1995). The 
authors rather speculate on whether PKC indirectly modulates P-glycoprotein transport 
activity. Recent studies indicate that PKC isozymes differentially phosphorylate specific 
serine residues in the linker region of P-glycoprotein resulting in a change of P-gp 
ATPase activity and a modulation of P-gp-drug-binding. From the studies published so 
far, it can be speculated that regulation of P-glycoprotein transport function, thus activa-
tion or reduction of P-gp activity, through PKC depends on the PKC isozyme tissue ex-
pression pattern and therefore varies amongst tissues (Sachs et al., 1999). 
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1.3.2.2 Membrane Trafficking of P-glycoprotein 
A second mechanism that could account for rapid changes in P-glycoprotein-mediated 
transport is trafficking between vesicular compartments and the plasma membrane. 
Kipp and Arias reported membrane trafficking of several ABC transporters, including  
P-gp, bile salt export pump (BSEP), and Mrp2 at the bile canalicular membrane of hepa-
tocytes (Kipp and Arias, 2002). They showed cycling of P-glycoprotein between intracel-
lular pools and the plasma membrane by demonstrating insertion of P-gp into the cana-
licular membrane in response to cyclic AMP (cAMP) and taurocholate (Figure 1.8). This 
effect was independent from protein biosynthesis. In addition, the microtubule disruptor, 
colchicine, and the PI3 kinase inhibitor, wortmannin, inhibited membrane insertion of 
P-glycoprotein. On the other hand, it was also demonstrated that cholestasis caused re-
trieval of P-glycoprotein from the canalicular membrane into intracellular vesicles 
(Gatmaitan et al., 1997; Kipp and Arias, 2002; Kipp et al., 2001). In another study Sai et 
al. used a hepatic cell line expressing GFP-tagged P-glycoprotein to visualize P-gp traf-
ficking between the pericanalicular region and the bile canalicular membrane (Sai et al., 
1999). This study also demonstrated an involvement of microtubules and PI3 kinase in 
P-glycoprotein membrane trafficking. 
These results show that in hepatocytes, vesicular trafficking of P-glycoprotein modulates 
transport at the canalicular membrane. Whether similar mechanisms also regulate P-gp-
mediated transport at the blood-brain barrier remains to be determined. 
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Figure 1.8 
Membrane trafficking of P-glycoprotein in hepatocytes 
 
Trafficking of P-glycoprotein between vesicular compartments and the plasma membrane: cAMP, tauro-
cholate and PI3 kinase cause insertion of P-gp into the bile canalicular membrane of hepatocytes. Re-
trieval of P-gp from the membrane into intracellular vesicles was observed during cholestasis (Kipp and 
Arias, 2002). 
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1.3.2.3 Ubiquitination triggering P-glycoprotein Degradation 
Another regulatory mechanism by which P-glycoprotein transport function could be 
modulated is through ubiquitination (Figure 1.9). Since ubiquitination triggers degrada-
tion of proteins, it is also referred to as the “kiss of death” for a protein (Ciechanover et 
al., 1980). Ubiquitin is an ubiquitiously expressed, small, 76 amino acid protein, the se-
quence of which is highly conserved amongst all creatures from insects to humans. Dur-
ing ubiquitination, target proteins are first labeled with ubiquitin molecules. The ubiquitin 
tag then signals the protein-transport machinery to shuttle the ubiquitin-labeled protein to 
the proteasome for degradation (Ciechanover, 1998). The proteasome removes the 
ubiquitin tag and digests the protein into small peptides. The balance between rates of 
ubiquitination (degradation) and translation (protein biosynthesis) therefore determines 
the concentration of a protein inside the cell. 
Recently, Zhang et al. reported that P-glycoprotein stability and transport function is 
regulated by the ubiquitin-proteasome pathway (Zhang et al., 2004c). They compared a 
P-gp overexpressing breast cancer cell line with sensitive parental cells to demonstrate 
that enhanced ubiquitination resulted in reduced P-glycoprotein-mediated transport. Fur-
thermore, the study also showed that P-gp is ubiquitinated independent of phosphoryla-
tion and that the process can be enhanced by inhibiting P-gp N-glycosylation. However, 
it is not yet clear how ubiquitination affects P-glycoprotein at the blood-brain barrier. 
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Figure 1.9 
Ubiquitination triggering P-glycoprotein degradation 
 
After conjugation with ubiquitin, tagged P-glycoprotein is transported to the proteasome and degraded into 
small peptides (Ciechanover, 1998; Zhang et al., 2004c). 
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1.3.2.4 Interaction of P-glycoprotein with Caveolin-1 
Caveolae (“little caves”) are small, 50-100 nm plasma membrane invaginations that were 
discovered by Palade in 1953 (Palade, 1953). These invaginations are specialized lipid 
rafts enriched in glycosyl-phosphatidylinositol (GPI) anchored receptors such as the 
folate receptor, signaling receptors such as insulin, bradykinin and endothelin receptors, 
Src-like kinases and other signal transduction molecules (PKC, MAP kinase,  
PI3 kinase; Figure 1.10) (Anderson, 1998). The main components of caveolae, however, 
are small, 22 kDa transmembrane proteins, the caveolins; three isoforms (caveolin 1-3) 
are known today (Okamoto et al., 1998). Caveolins are directly involved in signaling. For 
example, caveolin-1α interacts with G-proteins, PKC and NO synthase. 
Interestingly, P-glycoprotein and caveolin-1α were found to be co-localized at the blood-
brain barrier of humans and rhesus monkeys (Schlachetzki and Pardridge, 2003). This 
was confirmed by Jodoin et al., who isolated caveolar microdomains from bovine brain 
capillary endothelial cells (Jodoin et al., 2003). Furthermore, they also demonstrated that 
P-glycoprotein transport function was downregulated by caveolins 1 and 2 through a 
caveolin-binding motif in the N-terminus of P-gp. It remains to be seen, whether this 
mechanism can be used to modulate P-glycoprotein transport function. 
 
 
 
Figure 1.10 
Co-localization of caveolin-1 and P-glycoprotein in caveolae of the brain capillary endothelium 
 
Caveolae are “centers for signal transduction” enriched with signal transduction molecules such as glyco-
syl-phosphatidylinositol (GPI) linked receptors, signaling receptors, Src-like kinases and other signal 
transduction molecules (PKC, MAP kinase, PI3 kinase). 
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1.3.2.5 Regulation of P-glycoprotein by Endothelin-1 
ET-1 is a 21 amino acid vasoconstrictor polypeptide hormone that was first described by 
Hickey et al. in 1985 (Figure 1.11, (Hickey et al., 1985)). However, it was Yanagisawa et 
al., who shortly afterwards revealed the primary structure, synthesis and biological activ-
ity of ET-1 and who analyzed and cloned the gene as well (Yanagisawa et al., 1988a; 
Yanagisawa et al., 1988b). Three endothelin isoforms are known today: ET-1, ET-2 and 
ET-3; these are three separate gene products. Due to 2 disulfide bonds in the molecule, 
endothelins have the appearance of a shepherd’s crook (Figure 1.11) (Highsmith, 1998; 
Webb, 1997). 
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 igure 1.11 
ndothelin-1 protein structure 
ach endothelin isoform consists of 21 amino acids and 2 intra-chain disulfide bonds. The C-terminal se-
uence is necessary for biological activity and is conserved among the isoforms. The figure depicts the 
tructure for ET-1 (Highsmith, 1998). ll endothelins are synthesized as precursors, the so-called prepro-endothelins  
212 amino acids) that are processed to “big-ETs” (38-41 amino acids). The endothelin-
onverting enzyme (ECE) then cleaves big-ET to the biologically active endothelin iso-
orms (21 amino acids) (Highsmith, 1998; Offermanns, 2004; Rang, 1999) (Figure 1.12). 
ndothelins signal through two G-protein coupled receptors, the endothelin A (ETA) and 
ndothelin B (ETB) receptors. The ETA receptor affinity of ET-1 and ET-2 is in the sub-
anomolar range (Ki ~ 20-60 pM), whereas the affinity of ET-3 to the A-type receptor is 
ore than 2 orders of magnitude lower (Ki ~ 6500 pM). However, all three isoforms have 
qual affinities (Ki ~ 15 pM) for the ETB receptor (Highsmith, 1998). ET receptors are dif-
erent in their tissue distribution, ligand binding and signal transduction (Offermanns, 
004).  
he ETA receptor is present in many tissues, but is most highly expressed in aorta, heart 
nd kidney (Webb, 1997). The ETB receptor is predominantly expressed in brain, lung, 
idney and aorta (Ogawa et al., 1991; Webb, 1997). In addition, the B-type receptor is 
ighly expressed in endothelial cells, whereas highest expression of the A-type receptor 
s in smooth muscle cells. In the vascular system, ETA and ETB have opposite effects: 
he A-type receptor causes long-lasting vasoconstriction, whereas the B-type receptor 
ediates transient vasodilation (Kedzierski and Yanagisawa, 2001; Levin, 1995). 
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In the kidney, endothelins regulate renal blood flow, glomerular hemodynamics and so-
dium and water homeostasis (Offermanns, 2004). Endothelins are also involved in the 
pathology of acute ischemic renal failure, vascular rejection of transplanted kidneys as 
well as cyclosporin, cisplatin and radiocontrast agent nephrotoxicity (Bruzzi et al., 1997; 
Clavell and Burnett, 1994; Hocher et al., 1997). 
Recently, Miller et al. described a new role for ET-1 in the kidney: regulation of ATP-
driven drug excretion by efflux transporters in the renal proximal tubule (Masereeuw et 
al., 2000; Miller, 2002). Studies with isolated tubules from killifish (fundulus heteroclitus) 
showed that short-term exposure to ET-1 activates a signaling pathway that affects 
transport function of P-glycoprotein and Mrp2 (Masereeuw et al., 2000; Miller et al., 
2002a). Endothelin-1 rapidly reduced transport mediated by these efflux transporters 
and signaling was found to be linear, going through ETB, nitric oxide synthase (NOS), 
guanylyl cyclase (GC), protein kinase G (PKG), and protein kinase C (PKC). 
 
prepro ETs
big ETs
ET-1, ET-2 or ET-3
ETB receptor
Smooth muscle cells
ET-1 =  ET-2 >> ET-3 ET-1 = ET-2 = ET-3
Endothelial cells
ETA receptor
ECE
furin-like protease
- affinity to receptor -
- highest expression -
Figure 1.12 
Biosynthetic pathway of endothelins (ETs)
 
Endothelin precursors (prepro-ETs) are 
cleaved to “big ETs”, an intermediate form. 
The endothelin converting enzyme (ECE) 
cleaves the big ETs into the biologically ac-
tive endothelins, ET-1, ET-2, and ET-3 that 
act through the ETA and ETB receptors. 
 
In the brain the endothelin system affects multiple functions: neuromodulation, neuro-
secretion, neurotransmission, control of neuropeptide release from pituitary and hypo-
thalamus, modulation of behaviour and brain metabolism (Kedzierski and Yanagisawa, 
2001; Nie and Olsson, 1996; Willette, 1995). In addition, the ET system is activated in 
several CNS disorders such as Alzheimer’s disease, multiple sclerosis, brain tumors, 
migraine, acute ischemic cerebral infarction, vasospasm, stroke, HIV-encephalitis and 
trauma (Cardell et al., 1994; Didier et al., 2002; Egidy et al., 2000; Highsmith, 1998; Mi-
nami et al., 1995; Nie and Olsson, 1996; Speciale et al., 2000). During inflammation that 
often accompanies CNS disorders, ET-1 is greatly elevated. 
With regard to the blood-brain barrier, little is known about ET-1 signaling. However, 
ET-1 was reported to be produced and released by cerebral capillary endothelial cells 
(Bacic et al., 1992; Durieu-Trautmann et al., 1993; Lee et al., 1990; Yakubu and Leffler, 
1999; Yoshimoto et al., 1990). In addition, both the ETA and ETB receptors are ex-
pressed in the capillary endothelium (Hartz et al., 2004; Rubanyi and Polokoff, 1994; 
Stanimirovic et al., 1994; Willette, 1995). These findings and the data for renal proximal 
tubule (above) suggest a possible role of ET-1 at the blood-brain barrier. Therefore, one 
part of this thesis was to examine ET-1 regulation of P-glycoprotein at the blood-brain 
barrier. 
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1.3.3 Long-Term Regulation of P-glycoprotein 
In addition to direct inhibition and functional modulation, transcriptional regulation is a 
third possibility to modulate P-gp protein expression and transport function. This mecha-
nism works over the long-term, i.e. hours to days rather than minutes. Transcriptional 
regulation of MDR1 gene expression is complex and not yet completely understood. 
Transcription of the MDR1 gene is regulated through the binding of several trans-acting 
proteins to consensus cis-elements in the promoter region. Figure 1.13 shows the pro-
moter region of human MDR1 (Labialle et al., 2002). Unlike its murine homologue, the 
hMDR1 promoter lacks a TATA-box and contains an initiator element (INR). For the 
hMDR1 gene, several promoter elements have been found so far, including a GC-box, a 
Y-box, a p53 element, an inverse MED1 element, an AP-1 element, and a heat shock 
element (HSF1), to name a few. A more detailed description can be found in (Labialle et 
al., 2004; Labialle et al., 2002). 
 
Figure 1.13 
Promoter region of human MDR1 modified from (Labialle et al., 2002) 
 
INR: initiator element –sequences between -6 and +11 are sufficient for proper initiation of transcription 
GC-Box: GC-rich region – binding site for nuclear transcription factor SP1 (specificity protein 1) 
Y-Box: inverted CCAAT element – binding site for nuclear factor Y (NF-Y) and Y-box binding protein (YB-1) 
p53: proposed binding sites for p53 tumor suppressor protein 
AP-1: activator protein 1 binding site for c-jun and c-fos transcription factors 
CAAT: CAAT element binds a complex of nuclear factor κB, p65 and c-fos proteins 
C/EBP: binding site for CCAAT-box/enhancer binding proteins (C/EBP) 
HSE: heat shock elements – binding sites for heat-shock transcription factors (HSF) 
TCF: T cell factor elements – involved in over-expression of P-gp in tumor cells 
invMed1: inverted mediator-1 element cis-activates hMDR1 
MEF1: MDR1 promotor-enhancing factor 1 upregulates hMDR1 
NF-R1/2: binding site for recently discovered transcription regulatory proteins, NF-R1/2 
ETS: binding site for ets (‘E twenty-six’) proteins 
PXR: binding site for nuclear receptor PXR (pregnane X receptor) 
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Geick et al. found that the ligand-activated orphan nuclear receptor, pregnane X recep-
tor, PXR, regulates transcription of the human MDR1 (hMDR1) gene. They discovered a 
complex regulatory cluster of several binding sites for PXR in the 5’-upstream region of 
hMDR1 (Geick et al., 2001). Three DR4 motifs (direct repeats of a AG(G/T)TCA motif 
with a spacer of four nucleotides in between the binding motif), one DR3 motif, and one 
ER6 motif (everted repeat) were identified at about -8 kb. Electrophoretic mobility shift 
assays further revealed that PXR binds as a heterodimer with the retinoid X receptor α 
(RXRα) to all DR4 motifs (Geick et al., 2001). In addition, reporter gene assays con-
firmed that this cluster of response elements is responsible for PXR-mediated hMDR1 
induction. Importantly, PXR is the only ligand-activated nuclear receptor known to con-
trol transcriptional regulation of MDR1, and thus expression of P-gp. The second part of 
this thesis describes PXR regulation of P-glycoprotein at the blood-brain barrier. 
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1.3.3.1 The Pregnane X Receptor – A Ligand-Activated Nuclear Receptor 
Recently, Kliewer et al., Bertilsson et al. and Blumberg et al. identified independently 
from each other a new member of the orphan nuclear receptor family, the  
pregnane X receptor, PXR (NR1I2) (Bertilsson et al., 1998; Blumberg et al., 1998; 
Kliewer et al., 1998). Nuclear receptors (NRs) are receptors in the nucleus and the cyto-
plasm that belong to the largest superfamily of ligand-activated transcription factors. 
They are involved in a wide variety of biological functions, including cell growth and dif-
ferentiation, embryonic development as well as metabolism and efflux transport (Zhang 
et al., 2004b). 
The history of NRs is closely linked to the history of hormone research. In the mid to late 
1960s, studies showed that steroid hormones regulate gene expression through interac-
tion with cognate receptors (Aranda and Pascual, 2001; Mangelsdorf et al., 1995). Con-
sequently, the first nuclear receptors were discovered in the 1970s and named “endo-
crine nuclear hormone receptors” (Figure 1.14) (Fannon et al., 2001). With the introduc-
tion of DNA libraries, a huge resource of unidentified sequences was available for 
screening of highly conserved motifs. Thus, several nuclear receptors were found. How-
ever, their physiological roles and ligands remained unclear and therefore, were desig-
nated as “orphan nuclear receptors”. Further studies identified ligands for some of the 
orphan receptors and they were adopted (“adopted orphan receptors”) (Chawla et al., 
2001; Schmuth, 2003). Today, 49 nuclear receptors have been identified in the human 
genome. 
Figure 1.14 
 
Endocrine receptors: 
Estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), glucocorticoid receptor (GR) 
and mineralocorticoid receptor (MR). 
 
Adopted orphan receptors: 
Retinoid X receptor (RXR), peroxisome proliferator-activated receptor (PPAR), liver X receptor (LXR), far-
nesoid X receptor (FXR), pregnane X receptor (PXR), constitutive androstane receptor (CAR). 
The retinoic acid receptor (RAR), thyroid hormone receptor (TR) and vitamin D receptor (yellow box) dis-
play characteristics of both endocrine and adopted orphan receptors (Chawla et al., 2001). 
 
Orphan receptors: 
Nuclear receptors without known ligands. For more detailed information see (Maglich et al., 2001). 
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Nuclear receptors (NRs) regulate gene expression in response to extracellular and intra-
cellular signals. These signals are mediated through non-peptide, small, lipophilic NR 
ligands such as steroid and thyroid hormones that are cell-permeable and absorbable. 
Upon activation by a ligand, the NR binds to specific DNA sequences (response ele-
ments) in the regulatory promoter region of their target genes. Classic endocrine recep-
tors and most orphan receptors bind as homodimers, whereas the adopted orphan nu-
clear receptors found so far heterodimerize with the retinoid X receptor α (RXRα, Figure 
1.15) (Schmuth, 2003). The response elements (also referred to as “hormone response 
elements, HRE” or “xenobiotic response elements, XRE”) are hexameric sequence mo-
tifs, e.g. AGTTCA (Figure 1.15). They are organized either as direct, inverted or everted 
repeats (DR, IR, ER) with spacer base pairs in between the motifs (e.g. 4 bases in be-
tween a direct repeat motif: DR4) (Aranda and Pascual, 2001). 
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Figure 1.15 
DNA binding of nuclear receptors 
 
Most nuclear receptors bind as homo- or heterodimers to specific DNA binding sequences (direct (DR), 
inverted (IR) and everted (ER) repeats; (Schmuth, 2003)). 
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1.3.3.2 The Pregnane X Receptor – Structure & Ligand Specificity 
Like the protein structure of other NRs, PXR has 4 domains. (1) A modulator region har-
boring an activation function (AF-1), (2) a DNA binding domain (DBD) with two zinc-
finger motifs, and (3) a flexible hinge region connecting the DBD with (4) the ligand bind-
ing domain (LBD) that is also associated with an activation function (AF-2) (Figure 1.16) 
(Handschin and Meyer, 2003; Lazar, 2002). 
 
 
AF-1 Zn2+-finger Ligand binding, AF-2
COOHH2N Modulator DBD Hinge LBD
 
Figure 1.16 
Protein domain structure of PXR 
 
PXR protein is structured in 4 domains: (1) a modulator domain with activation function (AF-1), (2) a DNA 
binding domain (DBD) with two zinc-finger motifs, (3) a hinge domain connecting the DBD and LBD, and 
(4) the ligand binding domain (LBD) with an activation function (AF-2). 
The DBD is a highly conserved domain that is nearly identical across species. For ex-
ample, the DBDs of rat and human PXR share 96% of their amino acid sequence 
(Tirona et al., 2004; Watkins et al., 2001). The LBD consists of 12 hydrophobic α-helices 
that form a spherical, 1500 Å3 large ligand binding cavity, which is the reason for the 
broad ligand spectrum of PXR (Watkins et al., 2003b; Watkins et al., 2002; Watkins et al., 
2001). In contrast to the DBD, the LBDs of rat and human PXR share only 76% amino 
acid identity (Zhang et al., 1999) (Table 1.2). This explains the species difference with 
regard to PXR ligand specificity. For example, hyperforin, rifampicin and paclitaxel acti-
vate human PXR but not rodent PXR. On the other hand, the prototypical rodent PXR 
activator, pregnenolone-carbonitrile (PCN) does not activate human PXR (Honkakoski et 
al., 2003; Jones et al., 2000; Kliewer et al., 1999; Moore et al., 2000a; Wentworth et al., 
2000). 
 
 
 
 
 
 
 
 
 DBD LBD Ligands 
human PXR 100 100 Hyperforin, Rifampicin, Paclitaxel, Dexamethasone 
rat PXR 96 76 PCN, Dexamethasone 
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 able 1.2 
omparison of human PXR and rat PXR 
he DNA binding domain (DBD) of rat and human PXR share 96% amino acid identity, whereas the ligand 
inding domain (LBD) is only 76% identical. Therefore, PXR has species-dependent ligand specificity: hy-
erforin, rifampicin and paclitaxel only activate human PXR but not rodent PXR. PCN on the other hand 
nly activates rodent PXR but not human PXR. 
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1.3.3.3 PXR Signaling 
PXR activation occurs through binding of endogenous and exogenous ligands. Endoge-
nous ligands include metabolic precursors, intermediates and end products of steroid 
and thyroid hormone synthesis as well as bile acid synthesis; exogenous ligands include 
environmental toxins, dietary compounds and drugs (Lazar, 2002). PXR ligands are 
small, lipophilic and therefore cell-permeable molecules. Inside the cell, they bind to co-
repressor inactivated PXR, which upon ligand binding undergoes a conformational 
change causing dissociation of the corepressor. Ligand-bound, activated PXR translo-
cates into the nucleus where it forms a heterodimer with another nuclear receptor, the 
retinoid X receptor α (RXRα). The complex of PXR, RXRα and coactivators then binds to 
the xenobiotic response element (XRE) in the regulatory promoter region of PXR’s target 
genes (Watkins et al., 2003a). As a consequence, transcription of target genes in-
creases, and mRNA is translated into protein, which then is responsible for the physio-
logical effects (Jacobs et al., 2003). 
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Figure 1.17 
PXR signal transduction 
 
A ligand binds to inactivated PXR in the cytoplasm. PXR undergoes a conformational change, the co-
repressor (CoR) dissociates. Activated PXR translocates into the nucleus and heterodimerizes with RXRα 
(retinoid X receptor α). The complex of PXR, RXR α and coactivators (CoA) binds to the xenobiotic re-
sponse element (XRE) in the promoter region of a target gene. This results in increased transcription of 
the gene, and eventually increased protein expression and a physiological effect. 
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1.3.3.4 The Pregnane X Receptor – Regulation of Xenobiotic Defense 
PXR defines a novel steroid-signaling pathway, because it is activated by naturally oc-
curring steroids such as pregnenolone and progesterone, as well as synthetic glucocor-
ticoids and antiglucocorticoids. Importantly, PXR is also activated by a wide range of 
xenobiotics, including dietary compounds, toxicants, and a large number of commonly 
prescribed drugs (Schuetz and Strom, 2001; Watkins et al., 2002). Upon activation, PXR 
coordinately regulates a number of target genes that are involved in xenobiotic phase I 
and phase II metabolism as well as phase III efflux transport (Figure 1.18). Therefore, 
PXR is considered to be a ‘‘master regulator’’ of xenobiotic removal (Dussault and For-
man, 2002). Moreover, it is anticipated that PXR, xenobiotic metabolizing enzymes, and 
efflux transporters are regulated as a core network of defense mechanisms (Kliewer et 
al., 2002; Kliewer et al., 1998; Rosenfeld et al., 2003; Sonoda et al., 2003). Efflux trans-
porters regulated by PXR include organic anion transporting polypeptide isoform 2, 
Oatp2 (SLCO1A4); bile salt export pump, BSEP (ABCB11); multidrug resistance-
associated proteins isoforms 2 and 3, Mrp2 and Mrp3 (ABCC2, ABCC3); and  
P-glycoprotein, P-gp (ABCB1, MDR1) (Eloranta and Kullak-Ublick, 2005; Geick et al., 
2001; Handschin and Meyer, 2003; Kliewer et al., 1998; Sonoda et al., 2003; Synold et 
al., 2001; Teng et al., 2003). 
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Figure 1.18 
PXR – “Master Regulator” of metabolism and efflux transport 
 
PXR coordinately regulates phase I and phase II metabolism as well as phase III efflux transport. 
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2 Objectives 
Treatment of central nervous system (CNS) disorders is greatly impaired by poor CNS 
drug delivery. The structure responsible for low brain penetration is the non-fenestrated 
brain capillary endothelium that constitutes the blood-brain barrier. An important element 
of active, selective barrier function is the ATP-driven xenobiotic efflux transporter,  
P-glycoprotein (P-gp). Recently, P-gp has been shown to be highly expressed in the lu-
minal membrane of the brain capillary endothelium, where it effectively restricts entry to 
the brain of a myriad of CNS drugs. Thus, understanding mechanisms that regulate  
P-glycoprotein is a key to improve therapy of CNS disorders. At present however, noth-
ing is known about regulation of P-glycoprotein expression and transport function at the 
blood-brain barrier. 
The objective of this thesis was to uncover mechanisms of P-glycoprotein regulation us-
ing isolated rat brain capillaries as an ex vivo model of the blood-brain barrier. First, the 
model had to be characterized and validated by looking at structure, morphology and 
viability of isolated rat brain capillaries and by identifying efflux transporters and tight 
junctional proteins. The model was then used to address the following hypotheses: 
 
1)  Endothelin-1 regulates P-gp transport function at the blood-brain barrier. 
Recent studies from Miller et al. using renal proximal tubules showed that the peptide 
hormone endothelin-1 (ET-1) rapidly reduced transport mediated by P-glycoprotein 
(Miller, 2002; Terlouw et al., 2001). This was the first finding that linked ET-1 to the con-
trol of xenobiotic efflux transport and that demonstrated ET-1 regulation of P-glyco-
protein. 
The first objective was to test the hypothesis that ET-1 regulates P-glycoprotein trans-
port function in isolated rat brain capillaries over the short-term. 
 
 
2)  PXR regulates P-gp expression and transport function at the blood-brain barrier. 
Recent reports focusing primarily on liver demonstrated transcriptional regulation of  
P-glycoprotein by the ligand-activated nuclear receptor, pregnane X receptor (PXR). 
PXR is considered to be a “master regulator” of xenobiotic removal and as such to regu-
late a core network of defense mechanisms including efflux transporters. Importantly, 
PXR is the only nuclear receptor known so far to regulate transcription of P-glycoprotein. 
Since PXR is expressed in excretory and barrier tissues and since P-gp is the major 
xenobiotic efflux transporter at the blood-brain barrier protecting the CNS, PXR might be 
involved in the regulation of P-glycoprotein in brain capillaries. 
The second objective was to test the hypothesis that PXR is expressed in isolated rat 
brain capillaries where it regulates P-glycoprotein expression and transport function. 
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3 Results and Discussion 
This section is divided into three parts: 
 
3.1. The Ex Vivo Blood-Brain Barrier Model 
This part describes isolated rat brain capillaries used to examine P-glycoprotein 
regulation at the blood-brain barrier. 
 
3.2. Rapid Regulation of P-glycoprotein at the Blood-Brain Barrier by Endothelin-1 
 This part summarizes the results for rapid regulation of P-glycoprotein by  
endothelin-1 (Hartz et al., 2004). 
 
3.3. Pregnane X Receptor Upregulation of P-glycoprotein Expression and Trans-
port Function at the Blood-Brain Barrier 
In this part the results are presented for long-term regulation of P-glycoprotein  
in vitro and in vivo by the nuclear receptor PXR (Bauer et al., 2004). 
 
 
 
3.1 The Ex Vivo Blood-Brain Barrier Model 
3.1.1 Isolation of Intact Rat Brain Capillaries 
Isolated rat brain capillaries were used as an ex vivo model of the blood-brain barrier to 
study functional and transcriptional regulation of P-glycoprotein. Capillaries were iso-
lated based on a method previously published by Goldstein et al., Dallaire et al. and 
Miller et al. (Dallaire et al., 1991; Goldstein et al., 1975; Miller et al., 2000) with modifica-
tions according to Hartz et al. (Hartz et al., 2004). 
Brains were removed from euthanized rats and brain tissue was homogenized. Capillar-
ies were separated from myelin by density centrifugation. Using a glass bead column, 
capillaries were purified from red blood cells, other contaminating cells and cell debris. 
The isolation yielded about 25-30 mg of enriched capillaries per gram brain tissue (wet 
weight). Figure 3.1 shows a representative image of isolated rat brain capillaries. In ad-
dition to capillaries, the capillary enriched fraction also contained some red blood cells, 
larger vessels and some cell debris. 
10 µm 
Red blood cells 
Capillary 
Figure 3.1 
Transmitted light image of isolated 
rat brain capillaries 
 
Capillaries were predominant in the iso-
lated fraction. Besides capillaries, the 
fraction also contained some red blood 
cells and a small amount of debris. 
Debris 
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After isolation, capillaries retained their tubular structure and showed active transport for 
at least 8 hours (Bauer et al., 2004). Thus, duration of experiments was limited to about 
8 hours after isolation. Experiments were conducted by incubating isolated capillaries 
with modulators and fluorescent substrates. Transport was followed using a confocal mi-
croscope and images were analyzed with an imaging software program. The combina-
tion of isolated rat brain capillaries as an ex vivo model with laser scanning confocal mi-
croscopy proved to be a powerful tool to visualize and measure P-gp-mediated transport 
at the blood-brain barrier. (Bauer et al., 2004; Hartz et al., 2004; Miller et al., 2000; 
Nobmann et al., 2001). 
 
 
 
3.1.2 Structure and Morphology of Isolated Rat Brain Capillaries 
Isolated rat brain capillaries had a tubular structure; some capillaries were branched, 
and in some, red blood cells were entrapped in the lumens. Capillaries were 5-8 µm in 
diameter and approximately 100-200 µm in length with open lumens; capillary ends were 
collapsed. Figure 3.2 shows a representative transmitted light image of a branched rat 
brain capillary with an attached pericyte and a red blood cell in the lumen. All of the find-
ings are in accordance with previous reports on the structure of isolated brain capillaries 
by Dallaire et al. and Miller et al. (Dallaire et al., 1991; Miller et al., 2000). 
 
 
 
 
 
Branched capillary  
 
 
 
 
Red blood cell  
 
 
 Pericyte 
 
 
Nucleus  
 
 
 
 
 
 
 
 
 
 
Figure 3.2 
Transmitted light image of a branched rat brain capillary 
 
The image shows a branched rat brain capillary. A pericyte is attached to the surface of the capillary and a 
red blood cell is entrapped in the capillary lumen. 
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Transmission electron microscopy (TEM) was used to further examine the integrity of 
isolated capillaries at the ultra-structural level. Intact mitochondria were detected in most 
capillaries, indicating structural and functional integrity. Figure 3.3 shows a TEM image 
of a capillary in cross-section: nucleus, mitochondria, vesicles, endothelial plasma mem-
brane (luminal and abluminal) and the cytoplasm of the endothelial cell can be identified. 
A pericyte is attached to the endothelial cell and a red blood cell is entrapped in the cap-
illary lumen.  
1 2
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10 µm
Figure 3.3 
TEM image of a capillary in cross-section
(x 6,000) 
 
1 Endothelial cell nucleus 
2 Cytoplasm 
3 Abluminal membrane 
4 Luminal membrane 
5 Vesicle 
6 Red blood cell in capillary lumen 
7 Pericyte 
8 Mitochondrion of pericyte 
 
Tight junctions were seen at higher magnification. Figure 3.4A shows a tight junction be-
tween two capillary endothelial cells; an arrow points to the focal connection. An 
enlargement of the tight junction with the focal connection between the two interacting 
plasma membranes is shown in Figure 3.4B. 
 
Figure 3.4 
Tight junction between two brain endothelial cells 
 
A: Structure of a tight junction between endothelial cells of brain capillaries (x 87,000) 
 
B: Enlargement of the tight junction with focal connection 
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3.1.3 Viability of Isolated Rat Brain Capillaries 
Isolated capillaries are metabolically active and readily oxidize glucose, fatty acids and 
pyruvate (Betz and Goldstein, 1986; Goldstein et al., 1975). Transport of glucose, amino 
acids and ions takes place as well (Betz and Goldstein, 1986). However, unlike endothe-
lial cells in culture, isolated capillaries maintain their metabolic activity for only a short 
period of time. Limited viability of isolated capillaries is likely due to a decrease of ATP. 
Despite a period of up to 42 hours between death and isolation of the capillaries, Choi 
and Pardridge demonstrated that many biochemical functions remained in isolated capil-
laries from human (Choi and Pardridge, 1986). Capillaries from killifish were viable for up 
to 24 hours, whereas viability of capillaries from pig and rat was reported to last only for 
about 4-8 hours (Miller et al., 2002a; Miller et al., 2000). 
To test the viability of isolated rat brain capillaries, energy-dependent P-gp-mediated 
NBD-CSA transport was monitored over a period of 24 hours. 1 mM sodium cyanide 
(NaCN) was used as a metabolic inhibitor to block ATP synthesis; 5 µM PSC833 was 
used to directly inhibit P-gp. Figure 3.5 shows P-gp-mediated transport of NBD-CSA into 
capillary lumens 0, 6 and 24 hours after isolation. NaCN and PSC833 decreased luminal 
NBD-CSA fluorescence to about 50% of untreated capillaries at 0 and 6 hours. The ef-
fects of both inhibitors were the same for freshly isolated capillaries and capillaries main-
tained in buffer for 6 and 24 hours indicating complete inhibition by NaCN and PSC833. 
The uninhibited component (insensitive to NaCN and PSC833) is approximately 50% of 
control values and likely reflects non-specific NBD-CSA binding. Accumulation of  
NBD-CSA remained unchanged over a period of 6 hours. In contrast, luminal NBD-CSA 
fluorescence decreased after 24 hours to the same levels seen for capillaries treated 
with NaCN and PSC833 indicating loss of energy-dependent transport after 24 hours. 
Obviously, capillaries maintained in buffer retain transport function for at least 6 hours, 
but not 24 hours. 
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Figure 3.5 
P-gp-mediated transport of NBD-CSA into capillary lumens 0, 6 and 24 hours after isolation 
 
NBD-CSA fluorescence in capillary lumens was unchanged after 6 hours and about twice the luminal fluo-
rescence of capillaries treated with NaCN and PSC833. After 24 hours, luminal fluorescence in untreated 
capillaries and capillaries treated with NaCN and PSC833 was the same, indicating absence of energy-
dependent transport of NBD-CSA. The component insensitive to NaCN and PSC833 reflects non-specific 
binding (mean ± SEM, n=10, ∗∗∗ p < 0.001 compared to controls). 
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3.1.4 Detection of Proteins Expressed in Isolated Rat Brain Capillaries 
3.1.4.1 Tight Junction Proteins 
3.1.4.1.1 ZO-1 (TJP1) 
The zonula occludens proteins (ZO-1, ZO-2, ZO-3) are named after their localization at 
the zonula occludens (Latin: zonula occludens = tight junctions), the structure forming 
tight junctions (Vorbrodt and Dobrogowska, 2003). ZO-1 was the first tight junction-
associated protein to be identified (Stevenson et al., 1986). It is always part of tight junc-
tions but was also found in cells without the tight junction protein complex such as astro-
cytes (Howarth et al., 1992). In the brain, all ZO proteins are ubiquitously expressed 
(Dermietzel and Krause, 1991). 
The ZO proteins belong to the MAGUK protein family (membrane-associated guanylate 
kinase-like proteins). Members of this family possess 3 defined core regions: a SH3 (src-
homology 3) domain, a PDZ (postsynaptic density protein, disc-large, ZO-1) domain and 
a domain for guanylate kinase. These domains are important for the interaction of  
ZO proteins with other junction proteins like occludin and claudin (Kniesel and Wolburg, 
2000; Wolburg and Lippoldt, 2002). The ZO proteins are located submembranously be-
low the plasma membrane. They are considered to form a link between tight junctions 
and the cytoskeleton to stabilize transmembrane proteins. In addition, they are thought 
to play a role in signal transduction (Bazzoni and Dejana, 2004). 
Using Western blot analysis, ZO-1 was detected in brain homogenate, capillary lysate 
and capillary membrane fraction at 220 kDa (Figure 3.6). This molecular weight is in ac-
cordance with the molecular weight reported in the literature (Stevenson et al., 1986). 
The strong signal for ZO-1 from brain lysate correlates with previous findings showing 
that ZO-1 is abundantly expressed in the brain (Dermietzel and Krause, 1991; Howarth 
et al., 1992). Due to the association of ZO-1 with the membrane, capillary crude mem-
branes also show a strong signal (Bazzoni and Dejana, 2004; Stevenson et al., 1986). 
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Figure 3.6 
Western blot for ZO-1 
 
ZO-1 is expressed in capillary membranes, cap-
illary lysate as well as brain lysate, indicating 
expression also in other brain cells. 
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Figures 3.7A and B show isolated brain capillaries immunostained for ZO-1 (ZO-1 is 
green; nuclei are red). The staining displays bright and well-defined lines along cell-cell 
contacts. The negative control (incubation with secondary antibody only) shows no sig-
nal (Figure 3.7C).  
 
 
5 µm
10 µm 
C
A B
Figure 3.7 
Immunostaining of capillaries for ZO-1 
 
A and B: ZO-1 staining (green) along cell-cell contacts of brain capillaries, nuclei (red) are counter-
stained with propidium iodide 
 
C: Negative control (green and red channel) 
 
 
 
 
 
 Results and Discussion 33 
  
 
3.1.4.1.2 Occludin (OCLN) 
Occludin (Latin: occludere = occlude) is a tight junctional transmembrane protein that 
consists of 4 membrane-spanning regions and 2 extracellular loops. Both amino and 
carboxy termini are localized in the cytoplasm; the carboxy terminal has a ZO-1 binding 
domain (Balda and Matter, 2000; Furuse et al., 1993; Kniesel and Wolburg, 2000). In the 
brain, occludin is expressed in neurons and astrocytes and at high levels in brain capil-
lary endothelial cells. In other tissues occludin is expressed at much lower levels 
(Vorbrodt and Dobrogowska, 2003). Although it is not required for the formation of tight 
junctions, occludin is considered to regulate barrier properties by sealing the junctions 
and contributing to intercellular adhesion (Wolburg and Lippoldt, 2002). In addition, there 
is evidence that occludin regulates size-selective paracellular diffusion of hydrophilic 
molecules  and facilitates transepithelial migration of leukocytes at the blood-brain bar-
rier (Balda and Matter, 2000; Huber et al., 2000). 
Figure 3.8 shows a Western blot for occludin. The protein was detected at 65 kDa, which 
is consistent with the molecular weight reported in the literature (Furuse et al., 1993). 
Due to low levels of occludin in the brain, no signal was found in total brain lysate 
(Vorbrodt and Dobrogowska, 2003). There is a weak signal for occludin in the capillary 
fraction and a strong signal in the membrane fraction. This enrichment confirms previ-
ously published data on the localization of occludin in brain capillaries (Furuse et al., 
1993; Kniesel and Wolburg, 2000). 
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Figure 3.8 
Western blot for occludin 
Occludin is highly enriched in capillary mem-
branes compared to capillary lysate. Brain lysate 
does not express occludin.  
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Figure 3.9 shows occludin immunostaining (green) in isolated rat brain capillaries (Fig-
ures 3.9A and B). Nuclei are counterstained with propidium iodide (red). The staining 
suggests localization of occludin along cell-cell contacts. This has previously been re-
ported by Furuse et al. (Furuse et al., 1993). There is no signal in the negative control 
(Figure 3.9C). 
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Figure 3.9 
Immunostaining of capillaries for occludin 
 
A and B: Occludin staining (green) along cell-cell contacts of brain capillaries, nuclei (red) are counter-
stained with propidium iodide 
 
C: Negative control (green and red channel) 
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3.1.4.1.3 Claudin-1 and Claudin-5 (CLDN1 and CLDN5) 
Claudins (Latin: claudere = to close) are transmembrane proteins that are essential for 
the formation of tight junctions. They consist of 4 transmembrane domains,  
2 extracellular loops and 2 cytoplasmic terminals (Furuse et al., 1998; Turksen and Troy, 
2004). Claudins form dimers and bind to claudins on adjacent cells to produce the pri-
mary seal of tight junctions. They constitute the backbone of the tight junctional strands 
and are the major structural element of the actin-myosin fibrils. Thus, claudins create a 
tight junctional barrier and determine barrier properties (Anderson, 2001). 
Currently, 24 claudin isoforms are known in humans. However, at the blood-brain barrier 
only claudin-1 and claudin-5 have been detected, where they regulate and maintain 
blood-brain barrier function (Morita et al., 1999). Nitta et al. showed that claudin-5 selec-
tively increased permeability of molecules smaller than 800 Da (Nitta et al., 2003). 
Therefore, claudin-5 is believed to be a critical regulator of blood-brain barrier permeabil-
ity (Matter and Balda, 2003a). 
The Western blot for Claudin-1 (Figure 3.10) shows weak bands for brain and capillary 
lysate and a strong band for capillary membranes. This indicates enrichment of  
claudin-1 in the membrane fraction. In accordance with the literature, the claudin-1 
bands appear at 22 kDa (Furuse et al., 1998). 
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Figure 3.10 
Western blot for claudin-1 
 
Claudin-1 is highly enriched in capillary membranes. 
Brain and capillary lysate show only weak bands. 
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Images of capillaries immunostained for claudin-1 (green) display staining along cell-cell 
contacts of capillary endothelial cells (Figures 3.11A and B). The negative control shows 
no signal (Figure 3.11C). 
 
10 µm 
C
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10 µm 
Figure 3.11 
Immunostaining of capillaries for claudin-1 
 
A and B: Claudin-1 staining (green) along cell-cell contracts; nuclei (red) are counterstained with 
propidium iodide  
 
C: Negative control (green and red channel) 
 
The Western blot for claudin-5 shows bands with capillary lysate and capillary mem-
branes at 22 kDa (Figure 3.12). The signal for capillary lysate is slightly higher than the 
signal for the capillary membranes. Brain lysate shows no signal for claudin-5. 
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Figure 3.12 
Western blot for claudin-5 
 
Capillary lysate and capillary membranes show 
intense bands for claudin-5; brain lysate shows 
no signal. 
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3.1.4.1.4 JAM-A (F11R) 
The 3 homologous junctional adhesion molecule proteins (JAM-A, -B, -C) are members 
of the immunoglobulin superfamily. They are single-span proteins with 2 immuno-
globulin-like domains and a short cytoplasmic tail with a PDZ-binding motif (Bazzoni and 
Dejana, 2004; Martin-Padura et al., 1998). JAM proteins associate laterally with tight 
junctional strands and mediate homophilic and heterophilic interactions in the tight junc-
tional region (Nitta et al., 2003). Besides facilitating the assembly of tight junctions, they 
are also involved in the transmigration of leukocytes (Anderson, 2001; Bazzoni and De-
jana, 2004). JAM-A contributes to the organization of tight junctions by interfering with 
other junctional proteins like ZO-1 via the PDZ binding motif (Wolburg and Lippoldt, 
2002). 
The Western blot in Figure 3.13 shows no JAM-A signal for brain lysate, a moderate 
band for capillary lysate and a strong band for capillary membranes. This indicates that 
JAM-A is associated with the membrane. The bands for JAM-A come at 32 kDa, which is 
consistent with previous reports (Bazzoni and Dejana, 2004; Martin-Padura et al., 1998). 
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Figure 3.13 
Western blot for JAM-A 
 
JAM-A was detected in capillary lysate and cap-
illary membranes, but not in brain lysate. 
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3.1.4.2 Transport Proteins 
3.1.4.2.1 GLUT-1 (SLC2A1) 
GLUT-1 (Glucose Transport Facilitator 1) is a uniporter facilitating glucose transport into 
the brain along a concentration gradient. Within the brain, GLUT-1 is predominantly ex-
pressed in brain capillaries (Boado and Pardridge, 1990; Pardridge et al., 1990a). There-
fore, GLUT-1 is considered to be a blood-brain-barrier-specific protein (Nag, 2003; Orte 
et al., 1999). Although the brain corresponds to only 2% of the body weight, it metabo-
lizes 20% of the total energy of the body (75 mg glucose/minute). This demand for en-
ergy of the brain is served by GLUT-1, which is expressed at the abluminal and luminal 
membranes of the capillaries in a ratio of 4:1 (Farrell and Pardridge, 1991). The capacity 
of the brain to store energy is very limited. Therefore, it is almost exclusively dependent 
on GLUT-1-mediated glucose transport, demonstrating the importance of GLUT-1 for 
proper brain function (Peters et al., 2004). 
Figure 3.14 shows a Western blot for GLUT-1. The transporter was detected at  
42 kDa in rat brain capillary lysate and capillary membrane fraction. 10 µg of total protein 
from capillary lysate gave a weak signal, while 0.1 µg of total membrane protein was suf-
ficient for the detection of GLUT-1 in the membrane fraction. A stronger band was ob-
tained for 1 µg of capillary membranes than for 10 µg of total capillary lysate, indicating 
that GLUT-1 is highly enriched in the capillary membrane. In brain homogenate, GLUT-1 
was not detectable. Similar observations have been made before by several other 
groups (Bolz et al., 1996; Farrell and Pardridge, 1991; Pardridge et al., 1990a; Stewart 
et al., 1994).  
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Figure 3.14 
Western blot for GLUT-1 
 
Capillary lysate and capillary membranes 
show bands for GLUT-1. 0.1-1 µg of total 
membrane protein display strong signals for 
GLUT-1. In brain lysate, GLUT-1 was unde-
tectable. 
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3.1.4.2.2 Na+/K+-ATPase (ATP1A1-4, ATP1B1-4) 
The Na+/K+ transporting ATPase (Na+/K+-ATPase) is a membrane transporter that main-
tains a high sodium and potassium gradient across the cell membrane. This electro-
chemical gradient is important for vital functions of every cell in the body. The Na+/K+-
ATPase builds up this gradient by actively transporting 3 Na+ ions out of the cell and  
2 K+ ions into the cell using the energy of ATP hydrolysis. In polarized cells such as 
brain capillary endothelial cells, Na+/K+-ATPase is located at the abluminal membrane 
transporting Na+ ions from the cytoplasm of the endothelial cell into the brain interstitial 
fluid in exchange for K+ ions (Betz et al., 1980). All its isoforms (α1-4 and β1-4) are ex-
pressed at the blood-brain barrier, where they are involved in K+ regulation, fluid secre-
tion and in maintaining a Na+ gradient for facilitated nutrient transport (Betz, 1986; Betz 
and Goldstein, 1986; Zlokovic et al., 1993). 
Figure 3.15 shows a Western blot for Na+/K+-ATPase α-1 (ATP1A1). At 110 kDa, intense 
bands were detected for brain lysate as well as for capillary membranes. Na+/K+-ATPase 
is slightly enriched in the capillary membrane when compared to brain lysate. 
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Figure 3.15 
Western blot for Na+/K+-ATPase α-1 
 
Brain lysate and capillary membranes show bands for Na+/K+-ATPase α-1 
at 110 kDa. The signal for capillary membranes is slightly stronger, indi-
cating an enrichment of Na+/K+-ATPase α-1 in capillary membranes. 
 
Figure 3.16A shows a rat brain capillary immunostained for Na+/K+-ATPase α-1 (green). 
Nuclei were counterstained with propidium iodide (red). The negative control (incubation 
with secondary antibody only) shows no staining (Figures 16.B-E).  
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Figure 3.16 
Immunostaining of capillaries for Na+/K+-ATPase α-1 
 
A: Capillary immunostained for Na+/K+-ATPase α-1 (green) and counterstained for nuclei (red) 
B: Negative control (green channel) 
C: Negative control (red channel) 
D: Transmitted light image 
E: Overlay of images B, C and D 
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3.1.4.3 ABC Transporter Proteins 
3.1.4.3.1 BCRP (ABCG2) 
The breast cancer resistance protein (BCRP, MXR (mitoxantrone resistance protein) or 
ABCP1) is an ABC half transporter that functions as a homodimer or possibly het-
erodimerizes with other ABCG isoforms (Hori et al., 2004). In addition to the endoge-
nous substrate estrone-3-sulfate, exogenous compounds like daunorubicin, etoposide, 
methotrexate, rhodamine-123 and mitoxantrone as well as sulfated conjugates of sterols 
and drugs are transported by BCRP. Since there is an overlap in substrate specificity 
with P-gp, BCRP is considered to play a similar role in drug absorption and disposition. 
Like P-gp, BCRP can cause multidrug resistance (Sarkadi et al., 2004). BCRP is ex-
pressed at high levels in the placenta and lower levels in breast, ovary, small intestine, 
colon, liver and brain (Allikmets et al., 1998; Maliepaard et al., 2001; Sarkadi et al., 
2004). Immunohistocemical studies demonstrated luminal localization of BCRP in rat 
and human brain capillaries (Cooray et al., 2002; Hori et al., 2004). At the blood-brain 
barrier, BCRP might be involved in brain-to-blood efflux transport of xenobiotics thereby 
restricting their penetration into the brain. However, so far there is no evidence for active 
BCRP-mediated drug efflux at the blood-brain barrier yet (Lee et al., 2005). 
The Western blot for BCRP in Figure 3.17 shows a weak band for capillary lysate and a 
more intense band for capillary membranes (50 µg protein). Whole brain lysate shows 
no signal, whereas renal brush border membranes (positive control) showed a very 
strong signal with 5 µg of total protein. No signal was detected for brain lysate, but en-
richment of BCRP in capillary membranes suggests that in the CNS BCRP is predomi-
nantly expressed in capillary membranes. 
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Figure 3.17 
Western blot for BCRP 
 
BCRP is highly enriched in capillary membranes com-
pared to capillary lysate. Brain lysate does not show a 
BCRP signal, indicating expression restricted to brain 
capillaries. Renal brush border membranes (BBM) were 
used as positive control and showed strong BCRP ex-
pression with 5 µg of protein. 
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Capillaries immunostained for BCRP show distinct staining along the capillary mem-
brane (Figure 3.18A). The images in Figure 3.18B and C indicate luminal localization of 
BCRP, which confirms the findings of Hori et al. and Zhang et al. (Hori et al., 2004; 
Zhang et al., 2003a). The negative control displays no staining (Figure 3.18D-G). 
 
 
 
 
 
 
 
Figure 3.18 
Immunostaining of brain capillaries for BCRP 
 
A: Capillary immunostained for BCRP (green) and counterstained for nuclei (red) 
B: Capillary immunostained for BCRP indicating luminal localization of BCRP 
C: Overlay of transmitted light image and image B 
D: Negative control (green channel) 
E: Negative control (red channel) 
F: Transmitted light image 
G: Overlay of images D, E and F 
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3.1.4.3.2 Mrp1 (ABCC1) 
Multidrug resistance-associated proteins (MRPs) are efflux transporters that are also 
members of the ABC superfamily. They mainly transport organic anions, glutathione, 
glucuronide or sulfate conjugated compounds and various nucleoside analogues. To 
date, 9 MRPs are known (http://www.gene.ucl.ac.uk/nomenclature/genefamily/abc.html). 
All MRPs contain 2 transmembrane domains connected by a cytoplasmic linker region 
that is necessary for proper transport function. As with P-glycoprotein, the MRPs can 
confer multidrug resistance (Lee et al., 2001a; Renes et al., 2000). Mrp1 is both glycosy-
lated and phosphorylated. It is ubiquitously expressed in the body, with high levels in 
lung and kidney. Physiologically, Mrp1 seems to play a role in the regulation of intracel-
lular redox potential, flux of organic anions, inflammatory mediation, and elimination of 
potentially toxic endo- and xenobiotics. Although it has been implicated in resistance to a 
number of anticancer agents (e.g. etoposide, doxorubicin, vincristine), its role in drug re-
sistance is not yet fully understood (Cole et al., 1992; Lee et al., 2001a; Wijnholds, 2002). 
Within the brain, Mrp1 is expressed in astrocytes, microglia, capillary endothelial cells 
and choroid plexus (Dallas et al., 2003; Lee et al., 2001a; Schinkel, 2001). Recent stud-
ies localize Mrp1 to the luminal membrane in brain microvessel endothelial cells 
(Sugiyama et al., 2003a; Zhang et al., 2004a). However, localization and contribution of 
Mrp1 at the blood-brain barrier is controversial. Other groups have found Mrp1 in the 
abluminal membrane (Cisternino et al., 2003). 
The Western blot for Mrp1 shows weak bands for brain and capillary lysate and a strong 
band for capillary membranes (Figure 3.19). This indicates enrichment of Mrp1 in capil-
lary membranes, which is in accordance with previous findings (Schinkel, 2001). 
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Figure 3.19 
Western blot for Mrp1 
Brain and capillary lysate show weak Mrp1 ex-
pression, whereas capillary membranes show 
strong Mrp1 expression. 
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Figure 3.20 shows Mrp1 immunostaining in rat brain capillaries. Mrp1 staining is located 
on the luminal rather than on the abluminal membrane (Figures 3.20A and B). The nega-
tive control shows no staining (Figures 3.20D-E). 
 
 
 
 
 
 
igure 3.20 
munostaining of capillaries for Mrp1 
: Image of a capillary immunostained for Mrp1 (green) and counterstained for nuclei (red) 
: Overlay of transmitted light image and image A 
: Transmitted light image 
: Negative control (green channel) 
: Negative control (red channel) 
F: Transmitted light image 
G: Overlay of images D, E and F 
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3.1.4.3.3 Mrp2 (ABCC2) 
The multidrug resistance-associated protein isoform 2 (Mrp2), also known as canalicular 
multispecific organic anion transporter (cMOAT), is mainly expressed in liver, intestine, 
and kidney tubules (Chan et al., 2004). Most of its substrates are glutathione, glucuron-
ide or sulfate conjugates. Mrp2 plays an important role in the biliary excretion of glu-
curonated bilirubin: A mutation in the Mrp2 gene leads to a defect in Mrp2 protein caus-
ing accumulation of bilirubin and hepatic inflammation, a disease known as Dubin-
Johnson Syndrome (Lee et al., 2001a). There are conflicting reports about the expres-
sion of Mrp2 at the blood-brain barrier. Using RT-PCR and Western blot analysis, Zhang 
et al. showed mRNA expression of Mrp1, 4, 5 and 6, but Mrp2 mRNA expression was 
undetectable in bovine brain microvessel endothelial cells as well as in capillary-
enriched fractions (Zhang et al., 2000; Zhang et al., 2004a). However, Miller et al. de-
tected Mrp2 protein expression and function in isolated rat and porcine brain capillaries 
(Fricker et al., 2002; Miller et al., 2002a; Miller et al., 2000). Furthermore, Potschka et al. 
demonstrated that Mrp2 contributes to barrier function by preventing entry of analeptic 
drugs into the CNS of rats (Potschka et al., 2003). 
Using RT-PCR, no signal for Mrp2 was detected in brain (Figure 3.21, lane 1) and brain 
capillaries (lane 2), whereas kidney (lane 3) and liver (lane 4) displayed strong bands for 
Mrp2. This is in accordance with previous reports (Zhang et al., 2000; Zhang et al., 
2004a). 
409 bp
1       2          3         4         5      300 bp
500 bp
Figure 3.21 
RT-PCR for Mrp2 
 
No signal was detected for brain (lane 1) and brain capillaries (lane 2), 
but strong signals were found for kidney (lane 3) and liver (lane 4). 
 
 
Although no Mrp2 mRNA could be detected in brain and brain capillaries, Mrp2 protein 
was found to be expressed in these tissues. The Western blot in Figure 3.22 shows 
Mrp2 expression in renal brush border membranes (BBM, positive control), brain lysate, 
capillary lysate and capillary membranes. In comparison to brain and capillary lysate, 
Mrp2 is slightly enriched in capillary membranes. 
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Figure 3.22 
Western blot for Mrp2 
 
Mrp2 expression was detected in renal brush border membranes (BBM), brain lysate, capillary lysate and 
capillary membranes. 
 
 Results and Discussion 45 
  
 
Rat brain capillaries immunostained for Mrp2 (Figure 3.23) display distinct staining and 
suggest localization in the luminal membrane. The findings from Western blot and im-
munostaining confirm reports from Miller et al. (Miller et al., 2000). Based on these data, 
there is strong evidence for luminal expression of Mrp2 at the blood-brain barrier in the 
rat. 
 
A B
ED
luminal abluminal
C
10 µm 10 µm
Figure 3.23 
Immunostaining of capillaries for Mrp2 
 
A: The image shows a capillary immunostained for Mrp2 (green) and counterstained for nuclei (red). The 
staining suggests luminal localization of Mrp2. 
B: Negative control (green channel) 
C: Negative control (red channel) 
D: Transmitted light image 
E: Overlay of images B, C and D 
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3.1.4.3.4 Mrp4 (ABCC4) 
Another member of the multidrug resistance-associated protein family is Mrp4 (also 
MOAT-B), which is structurally closer to P-glycoprotein than any other Mrp transporter 
(Belinsky et al., 1998). Mrp4 is expressed in jejunum, kidney, lung, gallbladder and brain 
(Kool et al., 1997; Taipalensuu et al., 2001; van Aubel et al., 2002; Zhang et al., 2000). 
Leggas et al. were the first ones to show Mrp4 protein expression in brain capillaries and 
they localized it to the luminal membrane (Leggas et al., 2004). This was confirmed by 
Nies et al. in human brain capillaries (Nies et al., 2004). However, Zhang et al. reported 
Mrp4 protein in both luminal and abluminal membrane from bovine brain capillary endo-
thelial cells (Zhang et al., 2003a; Zhang et al., 2000; Zhang et al., 2004a). 
Originally, Mrp4 was considered to be a nucleotide analogue pump, transporting cyclic 
nucleotides such as cAMP and cGMP (Chen et al., 2001; Jedlitschky et al., 2004). How-
ever, Mrp4 also transports substrates like methotrexate, folic acid, estradiol-17-β-
glucuronide, bile acids, and prostaglandins as well as antiviral and antiretroviral com-
pounds (Adachi et al., 2002; Chan et al., 2004; Chen and Klaassen, 2004; Leggas et al., 
2004). Recent studies have demonstrated that Mrp4 mediates resistance to purine ana-
logues like nucleoside-based antiviral drugs and anticancer drugs like topotecan and 
thiopurines that are used for the treatment of acute lymphoblastic leukemia (Adachi et al., 
2002; Leggas et al., 2004). These findings suggest that Mrp4 may contribute to blood-
brain barrier function by protecting the brain from cytotoxic agents and that it may cause 
resistance to certain therapeutic drugs. However, the importance of Mrp4 in drug trans-
port at the blood-brain barrier is not clear yet. 
Mrp4 expression in rat brain capillaries was examined by Western blot and immunohis-
tochemistry. The Western blot in Figure 3.24 shows bands for Mrp4 from renal brush 
border membranes, brain lysate, and capillary membranes. Capillary lysate shows no 
Mrp4 signal, indicating that Mrp4 is exclusively expressed in the membrane of brain cap-
illaries. The band for Mrp4 from whole brain lysate suggests Mrp4 expression in other 
brain cells like astrocytes, neurons or microglia (Dallas et al., 2004; Nies et al., 2004). 
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Figure 3.24 
Western blot for Mrp4 
 
Mrp4 expression in capillary membranes, but not capillary lysate. The Mrp4 signal for brain lysate is to be 
caused by Mrp4 expressed in other brain cells. Renal brush border membranes (BBM) served as positive 
control. 
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Images of capillaries immunostained for Mrp4 exhibit strong luminal staining (Figure 
3.25A-B). Moreover, high magnification images show luminal and abluminal Mrp4 stain-
ing, suggesting expression in both membranes (Figure 3.25C). In addition to capillaries, 
blood cells in capillary lumens and other brain cells present in the preparation (indicated 
with white triangles in image A) display staining for Mrp4 as well. No staining was ob-
served in the negative control (Figure 3.25D-G). 
 
Figure 3.25 
Immunostaining of capillaries for Mrp4 
 
A-B: Capillaries immunostained for Mrp4 (green) and counterstained for nuclei (red). 
 Strong luminal and weak abluminal staining for Mrp4. Blood cells as well as brain cells present in 
the preparation also express Mrp4 (white triangles in A). 
C:  Magnification of an immunostained brain capillary showing luminal and abluminal staining for Mrp4 
D:  Negative control (green channel) 
E:  Negative control (red channel) 
F:  Transmitted light image 
G:  Overlay of D, E and F 
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3.1.4.3.5 P-glycoprotein (ABCB1) 
P-glycoprotein (P-gp) is a phosphorylated and glycosylated transmembrane protein that 
belongs to the ATP-binding cassette (ABC) superfamily (Lin and Yamazaki, 2003; 
Schinkel, 1999). P-gp functions as an efflux transporter that protects the body from toxic 
endogenous and exogenous compounds by pumping them out of cells. Since P-gp is 
expressed in barrier and excretory tissues, it is a key determinant for the absorption, dis-
tribution and elimination of a large number of xenobiotics including therapeutic drugs. 
Overexpression of P-gp, e.g. in tumor cells, leads to the phenomenon of multi-drug re-
sistance. Therefore, the gene encoding P-gp protein is known as ‘multidrug resistance 
gene’ (MDR1). In rodents, P-gp is encoded by two genes, mdr1a and mdr1b, which have 
the same function as MDR1 in humans (Fromm, 2004; Schinkel, 1999; Schinkel, 2001). 
In the brain, multiple cell types such as astrocytes, microglia and choroid plexus epithe-
lial cells express P-gp. However, the highest expression is found in capillary endothelial 
cells. In the luminal membrane of the capillary endothelium, P-gp contributes to the 
blood-brain barrier by protecting the CNS from potential toxins. The downside of this de-
fense mechanism is restricted brain penetration of therapeutics, which complicates the 
therapy of many CNS disorders (Begley, 2004a; Jette et al., 1993; Lee et al., 2001b; 
Schinkel, 2001). 
To detect P-gp expression in isolated capillaries, RT-PCR, Western blot and immunohis-
tochemistry were performed. For RT-PCR, total RNA was isolated from capillaries, brain, 
choroid plexus, kidney and liver. After RT-PCR, amplification products were electropho-
resed on an agarose gel. Signals for mdr1a (668 bp) and mdr1b (420 bp) were detected 
in all samples (Figure 3.26A and B). Negative controls (no RT product) showed no signal 
(lanes 6). Since the isolated capillary fraction contains other brain cells (see also 3.1.1 
The Ex Vivo Blood-Brain Barrier Model), it cannot be ruled out that the signal for P-gp in 
the capillary fraction comes in part from contaminating cells. However, the signal for 
mdr1a is higher for capillaries (Figure 3.26A, lane 1) than for brain (Figure 3.17A, lane 2); 
therefore, it is likely that the mdr1a signal derives from the capillaries rather than other 
brain cells. 
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Figure 3.26 
RT-PCR for mdr1a and mdr1b 
 
A: mdr1a 
 capillaries (lane 1), brain (lane 2), choroid plexus (lane 3), kidney (lane 4), liver (lane 5), 
negative control (lane 6) 
 
B: mdr1b 
 capillaries (lane 1), brain (lane 2), choroid plexus (lane 3), kidney (lane 4), liver (lane 5), 
negative control (lane 6) 
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In order to detect P-gp protein expression, two different antibodies were used, C219 and 
mdr Ab-1. C219 is a monoclonal antibody that recognizes a highly conserved cytoplas-
mic amino acid sequence; mdr Ab-1 is a polyclonal antibody that recognizes a cyto-
plasmic C-terminal epitope of P-gp. Rat brain lysate was used for comparison and rat 
kidney brush border membranes were used as positive control (Jette and Beliveau, 1993; 
Thiebaut et al., 1987). 
Figure 3.27A shows a Western blot for P-gp detected with C219. In Figure 3.27B,  
mdr Ab-1 was used to detect P-gp. All bands for P-gp come at about 180 kDa. Both 
blots exhibit very low background signal. The blot developed with C219 (Figure 3.27A) 
shows no signal for brain lysate and a weak band for P-gp with brush border mem-
branes (15 µg of total protein each). For capillary membranes, P-gp was detected with 
total protein as low as 0.1 µg. 15 µg total membrane protein showed a very strong signal. 
Using mdr Ab-1 antibody (Figure 3.27B), P-gp was detected in brain lysate  
(10 µg protein) and brush border membranes (5 µg protein). 0.01 µg protein were suffi-
cient to detect P-gp in capillary membranes; 1 µg protein shows an intense band. 
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Figure 3.27 
Western blot for P-glycoprotein using C219 and mdr Ab-1 antibody 
 
A: P-gp detected with C219 antibody 
The blot developed with C219 shows no signal for brain lysate, a weak signal 
for renal brush border membranes (BBM) and strong bands for capillary 
membranes. Band intensities increase with increasing protein amount. 
 
B: P-gp detected with mdr Ab-1 antibody 
Using the polyclonal mdr Ab-1 antibody, P-gp was detected in brain lysate, 
renal brush border membranes (BBM) and capillary membranes. 0.01 µg pro-
tein were sufficient for the detection of P-gp in capillary membranes. 
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Using the slot blot technique, 0.01 µg of total capillary membrane protein were sufficient 
to detect P-gp with C219 antibody (Figure 3.28). The signal for P-gp increased with in-
creasing protein amounts of capillary membranes. 
 
ries show luminal staining for P-gp (green). Images A1-4 show the negative control 
minal staining for P-gp (green). Images B1-4 show the negative control 
  0.01         0.02          0.03         0.04          0.05         0.06         0.07         0.08          0.09          0.1 Protein [µg] 
Figure 3.29 shows isolated capillaries immunostained for P-gp using C219 (Figure 3.29A) 
or mdr Ab-1 (Figure 3.29B), respectively. Nuclei were counterstained with propidium io-
dide. Luminal staining for P-gp was obtained with both antibodies. The negative controls 
for both antibodies showed no signal (Figures 3.29A1-4 and B1-4). 
 
Figure 3.28 
Slot blot for P-glycoprotein using C219 
Detection of P-gp in capillary membranes on a slot blot using C219 antibody. 0.01 µg protein were suffi-
cient to obtain a signal for P-gp with C219. 
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igure 3.29 
mmunostaining of capillaries for P-glycoprotein 
: C219 antibody 
Rat brain capilla
(A1 green channel, A2 red channel, A3 transmitted light image, A4 overlay of images A1-3). 
mdr Ab-1 antibody 
 
B: 
 Capillaries exhibit lu
(B1 green channel, B2 red channel, B3 transmitted light image, B4 overlay of images B1-3). 
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The capillary in Figure 3.30A was immunostained for P-gp (green) using C219 as pri-
mary antibody; nuclei were counterstained with propidium iodide (red). Figures 3.30B 
and C show a cross-section of the capillary. Both cross-sections demonstrate retained 
tubular structure of this capillary. 
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Figure 3.30 
Cross-section of a capillary immunostained for P-gp 
 
A: Immunostaining for P-gp with C219 (green); 
 nuclei  are counterstained with propidium iodide (red) 
 X-Y Projection 
 
B: X-Z Projection 
C: Y-Z Projection 
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3.1.5 Discussion of Part 3.1: 
 The Ex Vivo Blood-Brain Barrier Model 
For the work presented in this thesis, isolated rat brain capillaries were used as an  
ex vivo blood-brain barrier model. Brain capillaries have been isolated since 1969, when 
Siakatos et al. reported for the first time the isolation of capillaries from human and bo-
vine brain (Saikotos, 1969). Today, several techniques are used for isolating brain capil-
laries, each of which yields intact and metabolically active microvessels (Dallaire et al., 
1991; Goldstein et al., 1975; Miller et al., 2000). In this thesis, a protocol based on me-
chanical homogenization and density gradient centrifugation was followed to isolate 
brain capillaries from rat (Bauer et al., 2004; Hartz et al., 2004). Using this method, a 
fraction highly enriched in capillaries was obtained (Figure 3.1). 
Brain capillaries can be isolated from a variety of species such as killifish, shark, mouse, 
rat, pig, cow and human (Choi and Pardridge, 1986; Dallaire et al., 1991; Goldstein et al., 
1975; Lee et al., 2005; Miller et al., 2002a; Miller et al., 2000; Nobmann et al., 2001; 
Pardridge et al., 1985). Although brain capillaries have now been isolated for more than 
35 years, they have so far mainly been used for the culture of endothelial cells and have 
only been characterized on a functional level, e.g. by enzyme assays (Bauer et al., 2003; 
Choi and Pardridge, 1986; Goldstein et al., 1984; Goldstein et al., 1975; Pardridge et al., 
1985). Recently, Miller et al. used freshly isolated brain capillaries from pig, rat and fish 
to study transport function of efflux transport proteins (Miller, 2003; Miller et al., 2002a; 
Miller et al., 2000). However, there is no comprehensive study showing thorough charac-
terization (morphology, mRNA, protein expression, localization and function) of brain 
capillaries for any single species. Therefore, the first part of the Results and Discussion 
part describes the characterization of isolated rat brain capillaries with regard to struc-
ture, morphology, viability, expression of marker proteins and their localization. 
Diameter, size and morphology of isolated rat brain capillaries were similar to those pre-
viously reported (Figures 3.1-2) (Dallaire et al., 1991; Goldstein et al., 1975; Miller et al., 
2000). At the ultra-structural level, intact mitochondria and intact tight junctions were 
identified, indicating structural integrity, as shown before by Goldstein et al. (Goldstein et 
al., 1975; Shivers et al., 1984). Importantly, capillaries were viable for at least 6 hours 
after isolation (Figure 3.5). However, viability seems to vary between species. Capillaries 
from killifish were shown to be viable for up to 24 hours, whereas a viability of 4-8 hours 
was reported for capillaries from pig and rat (Fricker et al., 2002; Miller et al., 2002a; Mil-
ler et al., 2000). Interestingly, Choi and Pardridge found that some biochemical functions 
of human capillaries remained intact for up to 42 hours after isolation (Choi and 
Pardridge, 1986). 
Since tight junctions are an important element of blood-brain barrier function, several 
junctional proteins were additionally studied on a molecular level. Expression of the tight 
junction proteins ZO-1, occludin, claudin-1, claudin-5 and JAM-A was detected by West-
ern blotting (Figures 3.6, 3.8, 3.10, 3.12 and 3.13) (Kniesel and Wolburg, 2000; Nitta et 
al., 2003; Wolburg and Lippoldt, 2002). In accordance with previously published findings, 
immunostaining showed localization of ZO-1, occludin and claudin-1 along cell-cell con-
tacts (Figures 3.7, 3.9, 3.11) (Gao and Shivers, 2004; Lippoldt et al., 2000; Virgintino et 
al., 2004). 
More than 90% of glucose transport to the brain is mediated by GLUT-1, a transporter 
protein highly expressed in the brain capillary endothelium (Farrell and Pardridge, 1991; 
Pardridge et al., 1990a). Consistent with reports from Pardridge and Boado, GLUT-1  
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was found in capillary lysate; expression was highly enriched in capillary membranes 
(Figure 3.14) (Boado and Pardridge, 1990). Expression of Na+/K+-ATPase was also de-
tected (Figure 3.15). Betz et al. localized Na+/K+-ATPase to the abluminal membrane of 
rat brain capillaries (Betz et al., 1980; Goldstein et al., 1984). However, from the immu-
nostaining shown in Figure 3.16, a clear statement with regard to the localization of 
Na+/K+-ATPase cannot be made.  
In addition, isolated rat brain capillaries also express ABC-transporters such as BCRP, 
Mrp1, 2, 4 and P-glycoprotein. The breast cancer resistance protein, BCRP, was found 
to be enriched in isolated capillary membranes (Figure 3.17) and was localized to the 
luminal membrane (Figure 3.18). This is in accordance with recently found evidence for 
BCRP expression at the blood-brain barrier of humans, pigs, rats and mice (Cisternino et 
al., 2004; Cooray et al., 2002; Eisenblatter and Galla, 2002; Hori et al., 2004; Zhang et 
al., 2003a). Lee et al. studied BCRP-mediated brain efflux of dehydroepiandrosterone 
sulfate and mitoxantrone in mice and demonstrated a minor role for BCRP in active ef-
flux (Lee et al., 2005). In contrast, Cisternino et al. showed that BCRP limits brain uptake 
of mitoxantrone and prazosin in mice (Cisternino et al., 2004). In conclusion, the exact 
role of BCRP at the blood-brain barrier remains to be elucidated. 
Mrp1 expression in isolated rat brain capillaries was demonstrated by Western blot ex-
periments confirming the findings of Regina et al. and Kusuhara et al. (Kusuhara et al., 
1998; Regina et al., 1998). Immunostaining suggested luminal localization of Mrp1, 
which supports the findings of Zhang et al. and Sugiyama et al. (Sugiyama et al., 2003a; 
Zhang et al., 2004a). However, it is controversial, to which membrane Mrp1 is localized. 
Other groups found Mrp1 in the abluminal membrane of polarized cells (Flens et al., 
1996; Schinkel, 2001). Cisternino et al. demonstrated lack of Mrp1-mediated efflux at the 
luminal side of mouse brain endothelial cells and concluded that Mrp1 is not present in 
the luminal membrane, but instead expressed in the abluminal membrane (Cisternino et 
al., 2003). 
Conflicting reports also exist on the expression of Mrp2 at the blood-brain barrier (Miller 
et al., 2000; Nies et al., 2004; Zhang et al., 2000). RT-PCR data showed no signal for 
Mrp2 in brain and capillaries (Figure 3.21), which is in accordance with reports from 
Zhang et al. (Zhang et al., 2000; Zhang et al., 2004a). However, Western blot analysis 
and immunostaining clearly demonstrated Mrp2 expression in isolated rat brain capillar-
ies (Figures 3.22-23). This supports studies from Miller et al., who detected Mrp2 protein 
expression and function in isolated capillaries from pig and rat (Fricker et al., 2002; Miller 
et al., 2002a; Miller et al., 2000). Furthermore, studies by Miller et al. and Potschka et al. 
demonstrated Mrp2 function at the blood-brain barrier of rats (Miller et al., 2002a; 
Potschka et al., 2003). 
Recently, Mrp4 was reported to be expressed in brain capillaries from human, bovine, 
and mouse (Leggas et al., 2004; Nies et al., 2004; Zhang et al., 2000). In the rat, Mrp4 
was shown to be localized in the membranes of capillaries (Figure 3.25), which is con-
sistent with findings by others (Leggas et al., 2004; Nies et al., 2004). Furthermore, high 
magnification images showed both abluminal and luminal Mrp4 expression, as previ-
ously demonstrated by Zhang et al. (Zhang et al., 2004a). Western blot analysis re-
vealed expression of Mrp4 in capillary membranes (Figure 3.24). Both Western blot and 
immunostaining indicate that Mrp4 is also expressed in other brain cells as well as blood 
cells. This is in accordance with reports of Mrp4 expression in astrocytes, neurons, mi-
croglia as well as platelets and macrophages (Jedlitschky et al., 2004; Jorajuria et al., 
2004). Additionally, Leggas et al. provided first evidence that Mrp4 confers drug  
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resistance at the blood-brain barrier (Leggas et al., 2004), which is consistent with lu-
minal localization. 
Using RT-PCR, mdr1a and mdr1b mRNA expression was detected in isolated rat brain 
capillaries. Western blot of capillary membranes showed P-gp protein expression (Fig-
ures 3.27-28) and immunostaining localized P-gp to the luminal membrane of capillaries 
(Figures 3.29-30). Previous studies employing immunohistochemistry and luminal mem-
brane isolation also demonstrated luminal localization of P-gp at the capillary endothe-
lium (Cordon-Cardo et al., 1989; Matsuoka et al., 1999; Pardridge, 1998; Schinkel, 1999; 
Stewart et al., 1996; Thiebaut et al., 1987; Thiebaut et al., 1989). In addition, P-gp was 
localized in the luminal membrane of capillary endothelial cells by immunoelectronmicro-
scopy (Biegel et al., 1995; Sugawara, 1990; Tanaka et al., 1994). 
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3.1.6 Summary of Part 3.1: 
 The Ex Vivo Blood-Brain Barrier Model 
Rat brain capillaries were isolated following a standard protocol based on mechanical 
homogenization and density gradient centrifugation (Bauer et al., 2004; Hartz et al., 
2004). Isolations yielded a fraction enriched in brain capillaries (Figure 3.1) with very 
small amounts of larger vessels, red blood cells, other brain cells and cell debris. Using 
confocal microscopy, isolated brain capillaries revealed intact structure and morphology 
(Figure 3.2). On an ultra-structural level, endothelial cell nuclei, cytoplasm, abluminal 
and luminal membranes, intracellular vesicles, intact mitochondria and tight junctions 
were identified by transmission electron microscopy (Figures 3.3-4). Capillaries were vi-
able for at least 6 hours after isolation, as determined by transport experiments (Figure 
3.5). Figure 3.31 summarizes proteins detected in isolated rat brain capillaries. 
Tight junction proteins (ZO-1, occludin, claudin-1, claudin-5 and JAM-A) were localized 
to endothelial cell-cell contacts (Figures 3.6-13). In addition, GLUT-1 and  
Na+/K+-ATPase were found to be expressed in capillaries and isolated capillary mem-
branes (Figures 3.14-16). 
Moreover, several drug efflux transporters were also found to be expressed in isolated 
rat brain capillaries. Western blots showed expression of Mrp1, 2 and 4 as well as BCRP 
in capillary membranes (Figures 3.17, 3.19, 3.22 and 3.24), which was confirmed by 
immunostaining (Figures 3.18, 3.20, 3.23 and 3.25). Importantly, P-gp protein expres-
sion was detected in capillary membranes using two different antibodies (C219 and mdr 
Ab-1) (Figures 3.27-28). Immunostaining localized P-gp to the luminal membrane of rat 
brain capillaries (Figures 3.29). Using RT-PCR, expression of mdr1a and mdr1b mRNA 
was also detected in capillaries as well as in brain, choroid plexus, kidney and liver (Fig-
ure 3.26). 
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Isolated rat brain capillaries express tight junction proteins (ZO-1, occludin, claudin-1, claudin-5 and 
JAM-A) and transport proteins (GLUT-1, Na+/K+-ATPase, P-gp, BCRP, Mrp1, 2 and 4). 
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3.2 Rapid Regulation of P-glycoprotein at the 
 Blood-Brain Barrier by Endothelin-1 
3.2.1 P-gp-mediated NBD-CSA Transport in Isolated Rat Brain Capillaries 
3.2.1.1 Auto-Fluorescence of Isolated Rat Brain Capillaries 
The combination of confocal microscopy and image analysis is a powerful tool to  
assess P-glycoprotein function in isolated brain capillaries. Capillaries are incubated  
with the fluorescent P-gp-specific substrate NBD-cyclosporin A (NBD-CSA:  
[N-ε(4-nitrobenzofurazan-7-yl)-D-Lys8]-cyclosporine A) and then imaged with a confocal 
microscope. Using image analysis software, images are quantitated by measuring lu-
minal accumulation of NBD-CSA (Hartz et al., 2004; Miller, 2003; Miller et al., 2000).  
Isolated rat brain capillaries were examined for auto-fluorescence with the settings used 
for experiments and exhibited no auto-fluorescence (Figure 3.32). 
 
10 µm
C B A 
 
Figure 3.32 
Isolated rat brain capillaries exhibit no auto-fluorescence 
 
A: Transmitted light image of isolated rat brain capillaries 
 
B: Confocal fluorescent image of capillaries 
 The image displays no fluorescence indicating that capillaries exhibit no auto-fluorescence under 
these experimental conditions. 
 
C: Overlay of A and B 
3.2.1.2 Effect of Temperature on P-gp-mediated NBD-CSA Transport 
To optimize experimental conditions, P-gp-mediated transport of NBD-CSA into the lu-
men of isolated rat brain capillaries was measured at different temperatures (4°C, 22°C 
and 37°C). Figure 3.33 shows how temperature affects accumulation of NBD-CSA in 
capillary lumens. At 4°C, luminal NBD-CSA fluorescence was 47% lower than at room 
temperature (22°C). This might be caused by a slow down of metabolic activity resulting 
in lower ATP synthesis, which is required for energy-dependent transport by P-gp. Sur-
prisingly, NBD-CSA accumulation was about 23% higher at room temperature than at 
37°C. At 37°C, a higher enzymatic degradation leading to a loss of viability could be re-
sponsible for decreased luminal fluorescence. A higher metabolic activity than at 4˚C 
and a higher viability than at 37˚C could add up to a higher P-gp-mediated NBD-CSA 
transport at 22˚C. Therefore, all further experiments were conducted at room tempera-
ture. 
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.2.1.3 Effect of DMSO on P-gp-mediated NBD-CSA Transport 
 be solubilized in 
Figure 3.33 
Effect of temperature on luminal NBD-CSA fluorescence 
 
Accumulation of NBD-CSA was highest at 22°C, lower at 37°C and 
lowest at 4°C (mean ± SEM, n=10, ∗ p < 0.05 and ∗∗∗ p < 0.001 com-
pared to 22˚C). 
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3
Some chemicals and compounds used in the experiments first had to
dimethyl sulfoxide (DMSO). To exclude an effect of DMSO on P-gp-mediated NBD-CSA 
transport, capillaries were exposed to 0.1% of the solvent (highest concentration of 
DMSO capillaries were exposed to in experiments) and NBD-CSA transport was fol-
lowed using a confocal microscope. 0.1% DMSO did not have an effect on P-gp-
mediated luminal NBD-CSA fluorescence (Figure 3.34). 
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Figure 3.34 
No effect of 
 
0.1% DMSO on luminal NBD-CSA fluorescence 
ort 0.1% DMSO did not alter P-gp-mediated NBD-CSA transp
(mean ± SEM, n=10). 
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3.2.1.4 Time-course of P-gp-mediated NBD-CSA Transport 
NBD-CSA rapidly accumulated in the lumens of isolated rat brain capillaries. Figure 
3.35A shows a representative image of a capillary after 60 min of incubation with  
2 µM NBD-CSA at room temperature. Fluorescence intensity is low in the bath, moder-
ate in the endothelium, and highest in the capillary lumen. To inhibit P-gp-mediated 
NBD-CSA transport, the specific P-glycoprotein inhibitor, PSC833 ((3’-keto-Bmt’)- 
[Val (2)]-cyclosporin A, valspodar), was used (Fellner et al., 2002; Kemper et al., 2003).  
5 µM PSC833 blocked luminal NBD-CSA accumulation completely (Figure 3.35B). 
 
A B
10 µm 10 µm
bath containing 
2 µM NBD-CSA
luminal NBD-CSA 
fluorescence capillary lumen
bath containing 2 µM NBD-CSA 
and 5 µM PSC833
Figure 3.35 
NBD-CSA accumulation in brain capillaries with and without PSC833 
 
A: Accumulation of NBD-CSA in capillary lumen after 60 min of incubation 
with 2 µM NBD-CSA. 
 
B: 5 µM PSC833 significantly reduced luminal NBD-CSA fluorescence. 
 
Over a period of 60 min, capillaries for each time point were randomly chosen to follow 
NBD-CSA accumulation. In control capillaries, luminal NBD-CSA fluorescence increased 
rapidly and reached steady-state levels after approximately 30 min (Figure 3.36). Expos-
ing capillaries to 5 µM PSC833 decreased luminal NBD-CSA fluorescence significantly 
for each time point to about 45% of the corresponding control value. 
 
Figure 3.36 
Time course of luminal NBD-CSA fluorescence
with and without the P-gp inhibitor, PSC833 
 
NBD-CSA rapidly accumulated in the lumens of 
control capillaries. Luminal NBD-CSA fluores-
cence reached steady state levels after 30 min. 
5 µM PSC833 prevented luminal NBD-CSA accu-
mulation (mean ± SEM, n=7). 
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At steady state about 45-50% of fluorescence remained in the lumen when capillaries 
were treated with PSC833. This component of fluorescence was insensitive to the P-gp 
inhibitor, PSC833 (Figures 3.33 and 3.34), and to the metabolic inhibitor, NaCN (Figure 
3.29). It likely reflects non-specific NBD-CSA 
Hartz et al., 2004). 
 
 
 
3.2.1.5 P-gp-Specific Transport of NBD-C
P-glycoprotein-mediated NBD-CSA transport w
ies to PSC833. Figure 3.37 shows the PSC833 effect on P-gp-mediated NBD-CSA 
transport into the lumens of isolated rat brain capillaries. PSC833 decreased luminal 
BD-CSA fluorescence in a concentration-dependent manner. 5 µM PSC833 gave 
ycoprotein and decreased NBD-CSA fluorescence to 30-40% 
of the control. The PSC833-sensitive component reflects active P-gp-mediated NBD-
CSA transport. Again, the component insensitive to PSC833 likely represents non-
specific binding of NBD-CSA. Since 5 µM PSC833 gave maximal inhibition, this concen-
tration was used for all further experiments. 
 
 
 
Figure 3.37 
Concentration-dependence of PSC833 on P-gp-
mediated NBD-CSA transport into capillary lumens 
 
Concentration-dependent decrease of luminal NBD-CSA 
fluorescence with 0.1-10 µM PSC833. 5 µM PSC833 
had a maximal inhibitory effect on P-gp transport func-
tion (mean ± SEM, n=10, ∗ p < 0.05, ∗∗∗ p < 0.001). 
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Inhibition studies were also done using well-known P-gp substrates (verapamil, ivermec-
tin and cyclosporin A), as well as compounds mainly transported by Mrp1 and Mrp2 
(MK571, leukotriene C4 (LTC4), probenecid) (Ford and Hait, 1990; Nobmann et al., 2001; 
Saeki et al., 1993). 
Verapamil and ivermectin reduced luminal NBD-CSA fluorescence to about 60% of con-
ols, which is comparable to the effect of PSC833 (Figure 3.38A). Non-fluorescent cyc-
sporin A (CSA) decreased luminal NBD-CSA fluorescence in a concentration-
ependent manner (Figure 3.38B): with 1 µM CSA luminal fluorescence was reduced by 
 ± 8.1%. The 
 
Figure 3.38 
Effects of  on luminal NBD-CSA 
fluorescence in isolated 
 
A: Verapamil and ive nal NBD-CSA fluorescence to the same extent as PSC833 
(mean ± SEM, n=10, 
 
B: Concentration-depen -gp-mediated NBD-CSA 
transport into capillar
 
C: Mrp substrates and in minal accumulation of 
NBD-CSA (mean ± S
tr
lo
d
20.7 ± 9.4%, with 5 µM CSA by 29.5 ± 8.1% and with 10 µM CSA by 39.1
Mrp-inhibiting compounds, LTC4, MK571 and probenecid did not alter luminal NBD-CSA 
accumulation (Figure 3.38C), indicating as expected that Mrps (likely Mrp1 and Mrp2) 
are not involved in NBD-CSA transport into capillary lumens. 
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3.2.1.6 Summary of Part 3.2.1: 
 P-gp-mediated NBD-CSA Transport in Isolated Rat Brain Capillaries 
Bath-to-lumen transport of the fluorescent cyclosporin A derivative, NBD-CSA, into the 
res 3.35A and 3.36). The  
-gp inhibitor, PSC833, reduced luminal accumulation in a concentration-dependent 
anner to about 40-50% of control values (Figure 3.37). The P-gp substrates verapamil, 
 
ct (Figure 3.38C). These findings indicate 
that concentrative, specific and energy-dependent transport of NBD-CSA in isolated rat 
brain capillaries is mediated by P-glycoprotein. 
 
lumens of freshly isolated rat brain capillaries was followed using a confocal microscope. 
Luminal accumulation of NBD-CSA was imaged and fluorescence intensity was ana-
lyzed with imaging software. 
Brain capillaries did not exhibit any auto-fluorescence under experimental conditions 
(Figure 3.32). Transport of NBD-CSA was maximal at room temperature (Figure 3.33); 
concentrations of up to 0.1% DMSO did not affect luminal NBD-CSA accumulation (Fig-
ure 3.34). Over a period of 60 min, capillaries rapidly accumulated NBD-CSA; luminal 
fluorescence reached steady state levels after 30 min (Figu
P
m
ive
Mrp substrates and inhibitors were without effe
rmectin and cyclosporin A reduced NBD-CSA transport (Figures 3.38A and B); 
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3.2.2 Effects of Endothelin-1 on P-gp Transport 
produces and releases ET-1, 
). Removing ET-1 from the medium re-
tored luminal NBD-CSA fluorescence (time point 150 min). Luminal fluorescence in 
control capillaries remained constant over the entire time course of the experiment. 
 
 
Figure 3.39 
Effect of endothelin-1 on luminal NBD-CSA fluorescence 
 
A: Concentration-dependent effect of ET-1 on P-gp-mediated transport of NBD-CSA in capillary lumens 
 ET-1 decreased luminal NBD-CSA fluorescence in a concentration-dependent manner. 1 nM ET-1 
had a maximal effect on luminal NBD-CSA fluorescence (mean ± SEM, n=10, ∗∗∗ p < 0.001). 
 
B: Time course of the ET-1 effect on luminal NBD-CSA fluorescence 
 When ET-1 was added to capillaries preloaded with NBD-CSA (time point 0 min), luminal fluorescence 
rapidly decreased (maximal effect after 60 min). Upon removal of ET-1 (time point 90 min), fluores-
cence increased and steady state levels were reached after 60 min (time point 150 min) (mean ± 
SEM, n=7). 
A B 
3.2.2.1 Effects of Endothelin-1 on Luminal NBD-CSA Accumulation 
Previous work with renal proximal tubules from killifish demonstrated rapid reduction of 
P-glycoprotein and Mrp2 function by endothelin-1 (ET-1) (Masereeuw et al., 2000; Miller, 
2002; Terlouw et al., 2001). Considering that endothelin receptors are also expressed in 
brain capillaries and that the cerebral capillary endothelium 
this hormone could also play a role in regulating P-gp transport function at the blood-
brain barrier (Durieu-Trautmann et al., 1993; Yoshimoto et al., 1990). 
In the following experiments, isolated rat brain capillaries were exposed to subnanomo-
lar to nanomolar concentrations of ET-1, and then, P-gp-mediated NBD-CSA transport 
was measured after 60 min incubation with 2 µM NBD-CSA. ET-1 decreased steady 
state luminal NBD-CSA fluorescence in a concentration-dependent manner (Figure 
3.39A). ET-1 at 0.1 nM reduced luminal fluorescence by 32.5 ± 3.8%. The maximal ef-
fect was found with 1 nM ET-1 (decrease to 49.4 ± 3.8% of the control value). 
When capillaries were first loaded to steady state with NBD-CSA and ET-1 was then 
added (at zero time-point), luminal fluorescence declined rapidly to less than 50% of 
control levels (time point 60 min) (Figure 3.39B
s
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3.2.2.2 Effects of PSC833 and Mannitol on Lumina l NBD-CSA Accumulation 
ave resulted 
 
 
 
igure 3.40 
C833 and mannitol on luminal NBD-CSA fluorescence 
orescence 
f 
 mannitol was removed, the effect 
A B 
The decrease in luminal NBD-CSA accumulation caused by ET-1 could h
from 1) reduced P-gp transport function or from 2) an opening of tight junctions and 
leakage of pumped dye out of the lumen. The effects of PSC833 and mannitol on lu-
minal NBD-CSA accumulation were examined and compared to the time-dependent ef-
fect of ET-1 shown in Figure 3.39B. 
PSC833 inhibits P-gp transport function by direct interaction; mannitol osmotically opens 
tight junctions at the blood-brain barrier (Kroll and Neuwelt, 1998; Tan et al., 2000). 
PSC833 reduced luminal fluorescence within 45 min (Figure 3.40A) to 52.7 ± 2.8% of 
the control value. 30 min after PSC833 removal (time point 75 min), luminal fluorescence 
was back to control levels. Mannitol showed the same pattern as ET-1 and PSC833: a 
rapid decrease in luminal fluorescence after adding to capillaries and an increase to con-
trol levels after removal from the medium (Figure 3.40B). 
These results demonstrate rapid and reversible effects for ET-1, PSC833 and mannitol 
on luminal NBD-CSA fluorescence. However, the data do not allow any conclusions on 
whether the decrease of luminal NBD-CSA fluorescence caused by ET-1 results from 
reduced P-gp function, from open tight junctions or an overlapping effect of both. 
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A: Time course of the PSC833 effect on luminal NBD-CSA flu
 After adding PSC833 to preloaded capillaries, luminal fluorescence decreased. Upon removal o
PSC833, fluorescence returned to control levels (mean ± SEM, n=7). 
 
Time course of the mannitol effect on luminal NBD-CSA fluorescence B: 
 Mannitol rapidly decreased luminal NBD-CSA fluorescence. When
was completely restored within 30 min (mean ± SEM, n=7). 
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3.2.2.3 Kinetic Efflux Assay to Examine the Effect of ET-1 
In order to experimentally distinguish between P-gp inhibition and opening of tight junc-
tions, a kinetic assay based on the efflux of a preloaded fluorescent test compound from 
the lumens of capillaries was developed. This assay had to be independent from P-gp 
transport function, therefore, the compound used was Texas Red (sulforhodamine 101, 
free acid, MW 625 Da). Texas Red is a rhodamine-based, fluorescent organic anion that 
 brain capillaries (Figure 3.41). 
mal re-
uction in NBD-CSA accumulation in capillary lumens (Figure 3.39). 
sul ared to the control. Since 
orescence, it is likely that 
Tex loped.  
Figure 3.41 
Effects of LTC4, PSC833 and ET-1 on Texas Red transport 
 
The Mrp2 inhibitor LTC4 significantly decreased Texas Red transport; 
PSC833 and ET-1 had no effect (mean ± SEM, n=10, ∗∗∗ p < 0.001). 
is a substrate for the multidrug resistance-associated protein isoform 2 (Mrp2), another 
ABC-transporter located at the luminal membrane of brain capillaries (part 3.1.3.3, Fig-
ures 3.21-23). In the same manner as P-gp transports NBD-CSA, Mrp2 pumps Texas 
Red into the capillary lumen (Hartz et al., 2004; Miller et al., 2002a; Miller et al., 2002b; 
Miller et al., 2000). Luminal Texas Red fluorescence can then be quantitated accordingly 
as described above. 
First, Texas Red was tested for its Mrp2 specificity in rat
The P-gp inhibitor PSC833 did not affect steady-state luminal accumulation of Texas 
Red. The Mrp2 inhibitor LTC4, however, significantly reduced luminal Texas Red accu-
mulation to 52.4 ± 2.9% of the control. Importantly, Texas Red accumulation was not af-
fected by 100 nM ET-1, a concentration 100 times higher than that causing maxi
d
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Figure 3.41 shows that ET-1 does not affect Texas Red transport: If ET-1 had opened 
tight junctions; Texas Red would have leaked out of the lumens, which would have re-
ted in a decreased luminal Texas Red fluorescence comp
ET-1 did not cause such a decrease in luminal Texas Red flu
ET-1 has no effect on tight junctions. To prove this point, a kinetic assay based on 
as Red efflux from brain capillary lumens was deve
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For the kinetic efflux assay, capillaries were preloaded with Texas Red, washed with 
Figure 3.42 
fflux of Tex
: Transmitted light image of an isolated rat brain capillary 
buffer, and then dye efflux was followed over a period of 60 min using confocal micros-
copy. Mannitol, sucrose and 1-O-pentylglycerol, compounds known to open tight junc-
tions, were used as positive controls. At high concentrations, mannitol and sucrose both 
increase permeability by osmotically opening tight junctions, whereas 1-O-pentylglycerol 
opens tight junctions by a so far unknown, non-osmotic mechanism (Erdlenbruch et al., 
2003; Kroll and Neuwelt, 1998). 
Figure 3.42 shows representative images for rapid efflux of Texas Red after adding  
30 mM 1-O-pentlylglycerol. After 10-15 min, luminal fluorescence was substantially re-
duced (Figures 3.42C and D); after 60 min, fluorescence was essentially undetectable 
(Figure 3.42F). 
 
 
 
 
 
 
A B C
FED
E
 
as Red with 30 mM 1-O-pentylglycerol over time 
A
B: Capillary loaded with 2 µM Texas Red after washing with buffer (start) 
C: Capillary after 10 min 
D: Capillary after 15 min 
E: Capillary after 30 min 
F: Capillary after 60 min 
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Figure 3.43 shows the time course of Texas Red efflux from preloaded capillaries 
treated with mannitol, sucrose, 1-O-pentylglycerol and ET-1. In control capillaries (Figure 
3.43A), loss of dye from the lumen was slow, but significant (14.8 ± 4.5% lost after 
15 min, 50.1 ± 3.2% lost after 30 min; 64.7 ± 3.2% lost after 60 min). Mannitol, sucrose 
and 1-O-pentylglycerol, however, showed significantly increased Texas Red efflux com-
pared to control capillaries: after 5 min, luminal fluorescence was reduced to about 50% 
(50% efflux) and to about 30% (70% efflux) after 
 
30 min. In contrast, 100 nM ET-1 did 
nd 1-O-pentylglycerol-treated capillaries. The mean efflux rate constant for 
in-1 (Table 3.1). This value is not 
3 ± 0.004 min-1). Mannitol and  
ose increased Texas Red 
 
 
 
 
 
 
 
k [min-1]  ± SEM 
not alter Texas Red efflux (Figure 3.43B).  
 
A B 
 
 
By modeling Texas Red efflux as a first-order process and calculating rate constants us-
ing nonlinear regression, k-values were obtained for control capillaries, ET-1-, mannitol-, 
sucrose- a
capillaries exposed to 100 nM ET-1 was 0.53 ± 0.003 m
different from that of control capillaries (0.5
1-O-pentylglycerol increased efflux rate about 4-fold and sucr
efflux about 6-fold. 
 
Treatment 
Control 0.053  ± 0.004 
100 nM ET-1 0.053  ± 0.003 
100 mM Mannitol 0.192  ± 0.009 
100 mM Sucrose 0.293  ± 0.011 
30 mM 1-O-Pentylglycerol 0.183  ± 0.005 
Table 3.1 
Texas Red mean efflux rate constants 
 
k-values for Texas Red efflux from capillar-
ies exposed to ET-1, mannitol, sucrose and 
1-O-pentylglycerol (mean ± SEM min-1, 
control n=42, ET-1 n=21, mannitol n=42, 
sucrose n=7, 1-O-pentylglycerol n=7). 
Figure 3.43 
Texas Red efflux from capillaries 
 
A: Effects of mannitol, sucrose and 1-0-pentylglycerol on Texas Red efflux 
 Osmotic agents (mannitol, sucrose) as well as 1-0-pentylglycerol enhanced efflux of Texas Red sub-
stantially (mean ± SEM, n=7). 
 
B: Effect of ET-1 on Texas Red efflux 
 ET-1 did not alter efflux of Texas Red (mean ± SEM, n=7). 
0 15 30 45 60
0
50
100
150
200
Control
100 mM Mannitol
30 mM 1-O-Pentylglycerol
100 mM Sucrose
Time [min]L
um
in
al
 T
ex
as
 R
ed
 F
lu
or
es
ce
nc
e 
[a
u]
0 15 30 45 60
0
50
100
150
200
Control
100 nM ET-1
Time [min]L
um
in
al
 T
ex
as
 R
ed
 F
lu
or
es
ce
nc
e 
[a
u]
Lu
m
in
al
 T
ex
as
 R
ed
 F
lu
or
es
ce
nc
e 
[a
u]
Lu
m
in
al
 T
ex
as
 R
ed
 F
lu
or
es
ce
nc
e 
[a
u]
 
 Results and Discussion 67 
  
 
3.2.2.4 Summary of Part 3.2.2: 
 Effects of Endothelin-1 on P-gp Transport 
Exposing capillaries to nanomolar concentrations of ET-1 rapidly diminished luminal 
NBD-CSA fluorescence (Figure 3.39). This effect was concentration-dependent and re-
versible: removing ET-1 restored luminal NBD-CSA fluorescence to control levels. 
PSC833, a P-gp inhibitor and mannitol, which osmotically opens tight junctions, had 
comparable effects on luminal NBD-CSA fluorescence (Figure 3.40). Mrp2-mediated 
exas Red transport was unchanged with PSC833 and ET-1 (Figure 3.41). Compounds 
gure 3.43A). However, ET-1 had no effect on Texas Red efflux (Figure 3.43B and Ta-
ble 3.1). Thus, ET-1 decreased luminal NBD-CSA fluorescence by decreasing P-gp 
function and not by opening tight junctions. 
 
 
 
 
 
 
 
 
T
that open tight junctions highly increased Texas Red efflux from preloaded capillaries 
(Fi
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3.2.3 Regulation of P-glycoprotein by Endothelin-1 
.2.3.1 
TA and ETB receptors are expressed by endothelial cells, glial cells and neurons 
edzierski and Yanagisawa, 2001; Levin, 1995; Willette, 1995). At the blood-brain bar-
er, ET-1 seems to stimulate Na+/K+-ATPase, Na+/H+ exchanger and Na+/K+/Cl- co-
ansporter through ETA receptors (Kawai et al., 1995a; Kawai et al., 1995b). Kobari et al. 
emonstrated ETB receptor-mediated dilatation in cerebral microvessels in cats (Kobari 
t al., 1994). 
xpression of ETA and ETB receptors in isolated rat brain capillaries was examined by 
estern blot analysis and immunohistochemistry. The Western blot for the ETA receptor 
in Figure 3.44 shows bands at 40 kDa for capillary lysate but not for capillary mem-
branes. 
 
 
 
 
 
 
 
Figure 3.44 
Western blot for the ETA receptor 
 
The ETA receptor was detected at 40 kDa in capil-
lary lysate, but not in capillary membranes. 
    10         15         20         10         15           20 Protein [µg] 
3 ET-1 Signals through the ETB Receptor 
3.2.3.1.1 Expression of ETA and ETB Receptors in Rat Brain Capillaries 
In mammals, endothelins (ET-1, ET-2 and ET-3) act through two receptors: the endo-
thelin A (ETA) and the endothelin B (ETB) receptor. Both receptors are classical  
G-protein-coupled membrane proteins with seven transmembrane domains. ET-1 and 
ET-2 have subnanomolar affinity for the ETA receptor, whereas ET-3 has a 100-fold 
lower affinity (Kedzierski and Yanagisawa, 2001). The A-type receptor is mainly ex-
pressed on smooth muscle cells where its stimulation leads to an increase in intracellular 
calcium. All three endothelin isoforms have subnanomolar affinities for the ETB receptor. 
The B-type receptor is predominantly expressed on endothelial cells, where it stimulates 
he release of NO and prostacyclin (Highsmith, 1998; Offermanns, 2004). In the CNS, t
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The immunostaining of the ETA receptor in brain capillaries shows weak and diffuse fluo-
). This suggests intracellular rather 
nd supports the Western blot data 
 high laser 
 
 
The Weste a for the ETB receptor in 
capillary lys essed receptor in capillary 
lysate is significantly higher than in capillary membranes. This suggests intracellular  
ETB receptor pools. 
 
 
igure 3.45 
munostaining of capillaries for the ETA receptor 
: Weak and diffuse immunostaining of the ETA receptor 
 
B: Negative control (green and red channel) 
rescence extending over the cytoplasm (Figure 3.45A
than membranous localization of the A-type receptor a
(Figure 3.44). To obtain a weak signal for the ETA receptor in image A, a very
power had to be used. This strong laser intensity also caused a faint signal for the nega-
tive control (Figure 3.45B). 
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Figure 3.46 
Western blot for the ETB receptor 
 
Capillary lysate and capillary membranes show 
intense bands for the ETB receptor at 40 kDa. 
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Images of capillaries immunostained for the ETB receptor show a distinct staining along 
both, the luminal and abluminal capillary membranes (Figure 3.47A). The negative con-
trol shows no staining (Figure 3.47B-E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.47 
Immunostaining of capillaries for the ETB receptor 
 
10 µm
luminal
abluminal
A: Luminal and abluminal staining for the ETB receptor 
B: Negative control (red channel) 
C: Negative control (green channel) 
D: Transmitted light image 
E: Overlay of images B, C and D 
A
10 µm
D E
B C
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3.2.3.1.2 ETB Receptor Mediates ET-1 Signaling  
To determine through which receptor ET-1 signals the decrease in P-gp function (Figure 
.39), experiments were done with spec3 ific antagonists for both receptors. To block the 
-type receptor, JKC-301 was used (Figure 3.48A). This ETA receptor antagonist had no 
T-1 signaling. In contrast, the ETB receptor antagonist RES-701-1, which also had no 
ffect on P-gp transport function by itself, completely abolished the ET-1-mediated de-
rease in luminal NBD-CSA fluorescence (Figure 3.48B). 
 
Sarafotoxin S6c, the venom of the snake Atractapsis Engaddensis, is a potent and se-
lective agonist for the ETB receptor. Like ET-1, subnanomolar to nanomolar concentra-
tions of sarafotoxin S6c significantly reduced P-gp-mediated transport. Figure 3.49 
shows the concentration-dependent effect of sarafotoxin S6c on NBD-CSA fluorescence 
in capillary lumens. 
ntagonists on ET-1 signaling 
A ntagonist, did not reverse the ET-1 effect (mean ± SEM, n=10,∗∗∗ p < 0.001). 
 
B: The ETB receptor antagonist RES-701-1 completely abolished the ET-1 effect (mean ± SEM, n=10, ∗∗∗ p < 0.001). 
A
effect on P-gp-mediated NBD-CSA transport itself. Importantly, JKC-301 did not affect 
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Figure 3.49 
Concentration-dependent effect of 
sarafotoxin S6c on NBD-CSA fluores-
cence in capillary lumens 
 
The ETB receptor agonist sarafotoxin S6c 
reduces luminal NBD-CSA accumulation 
in a concentration-dependent manner 
(mean ± SEM, n=10, ∗∗∗ p < 0.001). 
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The ETA antagonist JKC-301 did not reverse the effect of sarafotoxin S6c (Figure 3.50A). 
In contrast, RES-701-1 completely blocked the sarafotoxin-caused decrease in luminal 
NBD-CSA fluorescence (Figure 3.50B). 
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-1-mediated decrease in luminal NBD-CSA fluorescence (Figures 
3.48A and 3.50A). These results indicate that ET-1 decreased P-gp function by acting 
through an ETB receptor. 
 
 
toxin S6c effect (mean ± SEM, n=10, 
∗∗∗
 
ET-1 and sarafotoxin S6c, both significantly reduced P-gp-mediated NBD-CSA transport 
in isolated rat brain capillaries in a concentration-dependent manner (Figures 3.39A and 
3.49). This decrease was fully abolished by the ETB receptor antagonist RES-701-1 
(Figures 3.48B and 3.50B), whereas blocking of the A-type receptor with JKC-301 did 
not reverse the ET
Figure 3.50 
Effects of ETA and ETB receptor antagonists on sarafotoxin S6c response 
 
A: The ETA receptor antagonist JKC-301 did not reverse the sarafo∗∗∗ p < 0.001). 
 
B: The ETB receptor antagonist RES-701-1 completely abolished the sarafotoxin S6c effect
ean ± SEM, (m n=10,  p < 0.001). 
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3.2.3.2 NO Synthase is Involved in ET-1 Signaling 
Previous studies demonstrated modulation of P-gp function by nitric oxide (Miller, 2002; 
otenboom et al., 2002). In order to exaN
s
mine whether NO and NO synthase (NOS), re-
pectively, are involved in the signaling pathway, sodium nitroprusside (SNP), a NO do-
D-CSA transport into capillary lumens is shown in Figure 3.51. Like ET-1, SNP 
caused a concentration-dependent reduction of luminal NBD-CSA fluorescence. A con-
centration as low as 10 nM SNP gave a maximal decrease to about 60% of the control. 
 
 
L-NMMA (NG-monomethyl-L-arginine) is a non-selective NOS inhibitor that inhibits all 
NOS isoforms: endothelial (eNOS), neuronal (nNOS) and inducible (iNOS) NO syn-
MMA did not affect luminal NBD-CSA accumulation or the SNP-mediated 
bolished the effect of 
pat
 
Figure 3.51 
Concentration-dependent effect of SNP on 
NBD-CSA fluorescence in capillary lumens
 
Concentration-dependent reduction of luminal 
NBD-CSA fluorescence with SNP 
(mean ± SEM, n=10, ∗∗∗ p < 0.001). 
nor
NB
, was used to mimic NOS activation. The dose-response for SNP on P-gp-mediated 
thases. L-N
decrease of luminal fluorescence (Figure 3.52A). Blocking NOS a
ET-1 (Figure 3.52B) indicating that NOS activation is involved in the ET-1 signaling 
hway. 
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Figure 3.52 
Inhibition of NO synthase with L-NMMA 
 
A: L-NMMA did not reverse the SNP effect (mean ± SEM, n=10, ∗∗∗ p < 0.001). 
 
B: L-NMMA abolished the ET-1 effect by NOS inhibition (mean ± SEM, n=10, ∗∗∗ p < 0.001). 
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3.2.3.3 Protein Kinase C is Involved in ET-1 Signaling 
 signaling. Figures 3.54A and B show that BIM completely blocked the de-
KC signaling followed both, ET-1 binding and NOS activation. Thus, ET-1, 
acting through an ETB receptor, activated NOS and PKC, and this chain of events rap-
idly decreased P-glycoprotein transport function. 
To examine whether protein kinase C (PKC) is part of the ET-1 signaling pathway, capil-
laries were exposed to PKC agonists and antagonists. The phorbol ester, phorbol-12-
myristate-13-acetate (PMA), which activates PKC, decreased P-gp-mediated NBD-CSA 
transport (Figure 3.53A). This decrease was concentration-dependent; 10 nM PMA 
caused a maximal decrease. Bisindolylmaleimide I (BIM) is a potent inhibitor for all PKC 
isoforms. BIM had no effect on luminal NBD-CSA accumulation by itself, but it blocked 
completely the effect of PMA (Figure 3.53B). 
 
To determine whether PKC is involved in the ET-1 signaling pathway, BIM was used to 
block ET-1
Effect of the PKC agonist PMA on luminal NBD-CSA fluorescence 
 
A: Concentration-dependent effect of PMA. The PKC agonist PMA decreased luminal NBD-CSA fluores-
cence in a concentration-dependent manner (mean ± SEM, n=10, 
Figure 3.53 
∗∗∗ p < 0.001). 
 
B: Reversal of the PMA effect by the PKC antagonist BIM (mean ± SEM, n=10, ∗∗∗ p < 0.001). 
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Figure 3.54 
PKC inhibition reversed the effects of SNP and ET-1 
 
A: Reversal of the SNP effect by PKC inhibition with BIM (mean ± SEM, n=10, ∗∗∗ p < 0.001). 
 
B: Reversal of the ET-1 effect by BIM (mean ± SEM, n=10, ∗∗∗ p < 0.001). 
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3.2.3.4 Effects of ET-1, SNP, PMA and Mannitol on P-gp Expression 
as from either reduced trans-
id 
no change in P-gp expression (mean ± SEM, n=15). 
A decre e in P-gp-mediated transport could have resulted 
port function or decreased P-gp expression. Capillaries were incubated for 1h with ET-1, 
SNP, PMA or mannitol and immunostained for P-gp. In addition, membranes were iso-
lated and Western blots for P-gp were performed. 
Figure 3.55 shows the result from a quantitative immunostaining of P-gp from capillaries 
treated with ET-1, SNP, PMA or mannitol over 1 hour. P-gp protein expression remained 
unchanged, indicated by no change in P-gp immunofluorescence.  
 
The Western blot for P-gp in Figure 3.56 shows that P-gp protein expression remained 
unchanged after 1-hour exposure to ET-1, SNP, PMA and mannitol, confirming the find-
ing from the immunostaining. These findings strongly indicate that the decrease in lu-
minal NBD-CSA accumulation caused by these compounds is due to reduced P-gp 
transport function without downregulation of P-gp protein expression. 
Figure 3.55 
Effects of ET-1, SNP, PMA and mannitol on P-gp expression 
 
Exposing capillaries for 1h to ET-1, SNP, PMA or mannitol d
not alter luminal membrane P-gp immunofluorescence indicating 
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Figure 3.56 
Western blot for P-glycoprotein 
 
No change in capillary membrane P-glycoprotein exposi
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3.2.3.5 Summary of Part 3.2.3: 
 Regulation of P-glycoprotein by Endothelin-1 
Western blot and immunostaining demonstrated expression of both, ETA and ETB recep-
tor in isolated rat brain capillaries (Figures 3.44-47). However, only the ETB receptor was 
detected in capillary membranes. 
Like ET-1, the ETB receptor agonist sarafotoxin S6c reduced P-gp-mediated NBD-CSA 
transport in a concentration-dependent manner (Figure 3.49). Only the ETB receptor an-
tagonist reversed the effects of ET-1 and sarafotoxin S6c (Figures 3.48 
tes that ET-1 decreased P-gp-mediated NBD-CSA transport by signaling through
 receptor. The NO donor SNP also decreased luminal fluorescence in a concen-
tration-dependent manner (Figure 3.51). A NO synthase inhibitor completely reversed 
the effect of ET-1 suggesting that NOS is involved in the signaling pathway (Figur
3.52B). Experiments with PKC activators and PKC inhibitors implicate that P
hway, with PKC activation following NOS activation (Figures 3.53-
ession remained unchanged in capillaries expos
PMA or mannitol for 1 hour (Figures 3.55-56). 
 support the hypothesis that ET-1 decreased P-gp transport func-
tion by signaling through an ETB receptor, NOS and PKC. 
and 3.50). This 
indica  
the ETB
e 
KC is part of 
the ET-1 signaling pat
54). P-gp protein expr ed to ET-1, SNP, 
Together, the findings
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3.2.4 Discussion of Part 3.2: 
Rapid Regulation of P-glycoprotein at the Blood-Brain Barrier by Endothelin-1 
ansport function at the blood-brain barrier. This model 
. For this purpose, inhibition experiments 
n inhibitor PSC833 (Achira et 
l., 1999; Kusunoki et al., 1998; Mayer et al., 1997; Watanabe et al., 1995). In addition, 
capillaries were incubated with compounds mainly transported by Mrp1 and Mrp2, in or-
der to exclude any contribution to NBD-CSA transport by Mrps. All experiments clearly 
indicated that NBD-CSA is specifically transported by P-glycoprotein: PSC833 prevented 
luminal accumulation (Figures 3.35B and 3.36) and reduced fluorescence in a concen-
tration-dependent manner to about 40-50% of control values (Figure 3.37). In previous 
studies with isolated brain capillaries from rat, pig and fish, concentrative, energy-
dependent and PSC833-sensitive bath-to-lumen transport of NBD-CSA was also dem-
onstrated (Fellner et al., 2002; Miller, 2003; Miller et al., 2002a; Schramm et al., 1995). A 
combined in vitro/in vivo study by Fellner et al. showed that co-administration of the anti-
cancer drug paclitaxel and PSC833 enhanced paclitaxel levels in brains leading to sig-
nificant reduction of brain tumor size in mice (Fellner et al., 2002). Preclinical and clinical 
studies also showed that PSC833 inhibits P-glycoprotein in humans resulting in higher 
paclitaxel plasma levels (Advani et al., 2001; Fracasso et al., 2000; Mayer et al., 1997). 
The P-gp substrates verapamil, ivermectin and cyclosporin A also reduced transport of 
NBD-CSA (Figures 3.38A and B), whereas Mrp substrates and inhibitors were without 
effect (Figure 3.38C). These results confirm the studies by Miller et al. and Nobmann et 
al., who clearly established that NBD-CSA is specifically transported by P-glycoprotein 
into lumens of isolated brain capillaries of rat and pig (Fellner et al., 2002; Miller et al., 
2000; Nobmann et al., 2001). However, another multispecific efflux pump, BCRP, is also 
expressed at the luminal membrane of rat brain capillaries (Figures 3.17-18) (Cooray et 
al., 2002; Hori et al., 2004). Although BCRP and P-gp share substrates, PSC833 is at 
best a low-affinity inhibitor of BCRP, and does not affect BCRP-mediated transport 
(Sarkadi et al., 2004; Tan et al., 2000; Zhang et al., 2003a). Although the participation of 
yet-unidentified transporters cannot be excluded, these data strongly suggest that the 
concentrative, specific and energy-dependent transport of NBD-CSA in isolated rat brain 
capillaries is mediated by P-glycoprotein. To date, the brain capillary ex vivo blood-brain 
barrier model has been used to look at transport of fluorescent P-glycoprotein and Mrp2  
 
For the work in the second part of the Results and Discussion, isolated rat brain capillar-
ies were used in combination with fluorescent dyes and confocal laser scanning micros-
copy to measure P-glycoprotein tr
system has previously been shown by Miller et al. to be a powerful tool to study trans-
port at the blood-brain barrier (Miller, 2003; Miller et al., 2002a; Miller et al., 2000). It en-
ables one to visualize and follow bath to lumen transport of fluorescent dyes that are 
substrates for efflux pumps present in the brain capillary endothelium (Fricker et al., 
2002; Miller et al., 2000; Nobmann et al., 2001). 
First, the ex vivo model system was optimized with regard to microscopy settings, incu-
bation temperature and incubation time (Figures 3.32, 3.33 and 3.36). In addition,  
0.1% DMSO in the incubation buffer was found to have no effect on capillary function 
(Figure 3.34). 
With the basic experimental settings optimized, rat brain capillary P-glycoprotein was 
studied for its specificity to transport NBD-CSA
were conducted using well-known P-glycoprotein substrates such as verapamil, ivermec-
tin and cyclosporin A as well as the specific P-glycoprotei
a
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substrates and to test compounds for their potential to inhibit transport (Fellner et al., 
ann 
say based on efflux of preloaded Texas 
s was unaffected by 100 nM ET-1 (Figure 3.41), a concentration 100 
uced in the brain in vivo could affect P-gp-mediated transport at the blood-brain barrier. 
2002; Fricker et al., 2002; Miller, 2003; Miller et al., 2002a; Miller et al., 2000; Nobm
et al., 2001). 
In this thesis, for the first time, this model system was used to unravel signaling at the 
blood-brain barrier. More specifically, the short-term regulation of P-glycoprotein at the 
blood-brain barrier by the peptide hormone endothelin-1 (ET-1) was studied. Subnano-
molar to nanomolar concentrations of ET-1 rapidly and reversibly reduced 
P-glycoprotein-mediated transport of NBD-CSA into capillary lumens (Figure 3.39). It 
should be stressed that decreased luminal accumulation of NBD-CSA caused by ET-1 
was not accompanied by increased capillary permeability (caused by opening of tight 
junctions). This was shown by using a kinetic as
Red from the lumens of capillaries. ET-1 did not increase Texas Red efflux compared to 
efflux from control capillaries (Figure 3.43, Table 3.1), suggesting that tight junctions 
were not affected. It is also noteworthy that Mrp2-mediated Texas Red transport into 
capillary lumen
times higher than that causing maximal reduction of P-glycoprotein mediated NBD-CSA 
transport. This is further proof that ET-1 did not open tight junctions. Moreover, this ob-
servation is interesting since it is different from renal proximal tubules, where ET-1 was 
shown to reduce Mrp2 transport function (Masereeuw et al., 2000; Miller, 2002; Noten-
boom et al., 2002; Terlouw et al., 2001). 
The literature contains conflicting reports as to the effects of ET-1 on brain capillary 
permeability. For example, injection of ET-1 into the brain has been reported to increase 
permeability (Miller et al., 1996; Narushima et al., 2003; Narushima et al., 1999) or to 
have no significant effect (Hughes et al., 2003). In these in vivo studies, permeability 
measurements were made after many hours to days of ET-1 treatment. In the present 
experiments, capillaries were exposed to ET-1 for only 1 to 2 hours. Thus, it is possible 
that ET-1 does increase brain capillary permeability over longer time periods whereas 
decreased P-glycoprotein transport function with no change in capillary permeability is 
an early effect of ET-1 exposure (Hartz et al., 2004). 
Taken together, from these data, it was concluded that ET-1-mediated reduction of P-gp 
transport function rather than an opening of tight junctions caused the decrease in lu-
minal NBD-CSA fluorescence. 
Further experiments were conducted to reveal the signaling pathway through which  
ET-1 changes P-glycoprotein function. NBD-CSA transport was reduced by ET-1 activa-
tion of ETB receptor and subsequent activation of two intracellular enzymes, NO syn-
thase (NOS) and protein kinase C (PKC). ET-1 actions were mimicked by the ETB recep-
tor agonist sarafotoxin S6c; both ET-1 and sarafotoxin S6c effects were blocked by an 
ETB receptor antagonist but not by an ETA receptor antagonist (Figures 3.48-3.50). Con-
sistent with previous findings, both the ETA and ETB receptor were found to be ex-
pressed in isolated rat brain capillaries (Kedzierski and Yanagisawa, 2001; Levin, 1995; 
Willette, 1995). The A-type receptor was expressed in capillary lysate, but not in capillary 
membranes (Figures 3.44 and 3.45). The ETB receptor was highly expressed in capillary 
lysate as well as in capillary membranes (Figures 3.46 and 3.47). The signal for ETB in 
capillary membranes was lower than the one for capillary lysate, which might reflect in-
tracellular pools as previously reported (Bremnes et al., 2000). In addition, the B-type 
receptor was immunolocalized to both, the luminal and abluminal membranes of the 
capillary endothelium (Figure 3.47, inlet). Thus, ET-1 released into the blood or pro-
d
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SNP, which generates NO, also reduced P-glycoprotein-mediated transport, presumably 
mimicking the effects of NOS activation (Figure 3.51). The NOS inhibitor, L-NMMA, did 
not reverse the SNP-mediated decrease of luminal NBD-CSA fluorescence but abol-
 
ies that fits the data is linear, going 
ished the ET-1 effect (Figure 3.52). Since L-NMMA inhibits all NOS isoforms, further 
studies are needed to clarify which isoform is activated by ET-1. 
However, at present, there are no NOS isoform-specific inhibitors commercially available.
Activation of PKC with nanomolar concentrations of phorbol-12-myristate-13-acetate 
(PMA) also reduced P-glycoprotein-mediated NBD-CSA transport into capillary lumens 
(Figure 3.53A). A PKC inhibitor, BIM, could block this effect (Figure 3.53B). Inhibition of 
PKC also blocked the effects of ET-1 and SNP (Figure 3.54). However, at present it is 
not clear how PKC modifies P-glycoprotein function. Given the rapid time course of ac-
tion seen with isolated brain capillaries, three types of mechanism seem possible: 
1) PKC directly phosphorylates the transporter changing turnover number or substrate 
affinity. 
However, this hypothesis is contradictory to Chambers et al., who found that P-gp 
phosphorylation by PKC stimulated P-gp transport in KB-V1 cells (Chambers et al., 
1990a; Chambers et al., 1990b; Chambers et al., 1992). On the other hand, Ger-
mann et al. suggested that phosphorylation of P-glycoprotein has no effect on its 
transport function at all (Germann et al., 1995). 
2) PKC phosphorylates an accessory protein that modifies P-glycoprotein activity. 
3) PKC influences P-glycoprotein trafficking, stimulating retrieval from the plasma mem-
brane into a vesicular compartment. 
This has been demonstrated for P-glycoprotein and other ABC transporters in hepa-
tocytes (Kipp and Arias, 2002; Kipp et al., 2001).  
At present, however, it cannot be distinguished between the three possibilities. 
 
Taken together, the minimal signaling pathway of ET-1-mediated reduction in P-glyco-
protein transport function in isolated rat brain capillar
from the ETB receptor over NOS to PKC (Hartz et al., 2004). 
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3.2.5 Summary of Part 3.2: 
Rapid Regulation of P-glycoprotein at the Blood-Brain Barrier by Endothelin-1 
(Hartz et al., 2004) 
Freshly isolated rat brain capillaries were used to study short-term regulation of  
mula-
Over a period of 60 min, capillaries rapidly accumulated NBD-CSA; luminal fluorescence 
rea
hib
(Fig
los
hib
minal 
jun
Mrp
3.4 however, was highly increased by 
effect on 
exas Red efflux, suggesting that ET-1 does not affect tight junctional permeability (Fig-
B receptor was detected in 
apillary membranes (Figures 3.44-47). Like ET-1, the ETB receptor agonist sara- 
fotoxin S6c reduced P-gp-mediated NBD-CSA transport in a concentration-dependent 
manner (Figure 3.49). Only an ETB receptor antagonist reversed the effects of ET-1 and 
sarafotoxin S6c, but not an ETA receptor antagonist (Figures 3.48 and 3.50). The NO 
donor SNP also decreased luminal fluorescence in a concentration-dependent manner 
(Figure 3.51). A NO synthase inhibitor completely reversed the effect of ET-1 suggesting 
that NOS is involved in the signaling pathway (Figure 3.52B). Experiments with PKC ac-
tivators and inhibitors implicate that PKC is part of the ET-1 signaling pathway (Figures 
3.53-54). P-gp protein expression remained unchanged in capillaries exposed to ET-1, 
SNP, PMA or mannitol for 1 hour (Figures 3.55-56). 
Altogether, these findings indicate that concentrative, specific and energy-dependent 
transport of NBD-CSA in isolated rat brain capillaries is mediated by P-glycoprotein. Fur-
thermore, they show that ET-1 decreased P-gp transport function by acting through an 
ETB receptor followed by activation of NOS and PKC. Figure 3.57 summarizes the find-
ings on rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1. 
P-glycoprotein transport function at the blood-brain barrier. Accumulation of  
P-glycoprotein-specific, fluorescent NBD-cyclosporin A (NBD-CSA) in capillary lumens 
was followed using confocal microscopy. Confocal images were analyzed and quanti-
tated using imaging software. 
Preliminary experiments revealed that brain capillaries did not exhibit auto-fluorescence 
(Figure 3.32), that NBD-CSA transport was maximal at room temperature (Figure 3.33) 
and that concentrations of up to 0.1% DMSO did not affect luminal NBD-CSA accu
tion (Figure 3.34). 
ched steady state levels after 30 min (Figures 3.35A and 3.36). The P-gp-specific in-
itor PSC833 reduced luminal fluorescence in a concentration-dependent manner 
ures 3.35B, 3.36 and 3.37). The P-gp substrates verapamil, ivermectin and cyc-
porin A reduced NBD-CSA transport (Figures 3.38A and B); Mrp substrates and in-
itors were without effect (Figure 3.38C). 
Exposing capillaries to nanomolar concentrations of ET-1 rapidly diminished lu
NBD-CSA fluorescent in a concentration-dependent manner (Figure 3.39A); this effect 
was reversible (Figure 3.39B). PSC833 and mannitol, which osmotically opens tight 
ctions, had comparable effects on luminal NBD-CSA fluorescence (Figure 3.40). 
2-mediated Texas Red transport was unchanged with PSC833 and ET-1 (Figure 
1). Texas Red efflux from preloaded capillaries, 
compounds that open tight junctions (Figure 3.43A). Importantly, ET-1 had no 
T
ure 3.43B and Table 3.1). 
Western blot and immunostaining demonstrated that both, ETA and ETB receptor are ex-
pressed in isolated rat brain capillaries. However, only the ET
c
 
 Results and Discussion 81 
  
 
 
Figure 3.57 
Rapid regulation of P-glycoprotein at the blood-brain barrier by endothelin-1 
 
ET-1 rapidly decreased P-gp transport function in isolated rat brain capillaries by signaling through an
ETB receptor, NOS and PKC. 
ET-1 PKC P-gp
NBD-CSA
ETB
Tight Junction
Brain Blood
NOS
Tight Junction
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Figure 3.58 
RT-PCR for rat PXR 
 
Capillaries, brain, kidney and liver show bands of a 353 bp rat PXR-specific amplicon. 
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3.3 Pregnane X Receptor Upregulation of P-glycoprotein 
 Expression and Transport Function at the Blood-Brain Barrier 
3.3.1 Detection of Pregnane X Receptor in Isolated Rat Brain Capillaries 
The pregnane X receptor (PXR, NR1I2) is a ligand-activated, nuclear transcription factor. 
In liver, PXR regulates a network of multiple target genes, mainly those encoding drug 
metabolizing enzymes and drug transporters (Kliewer et al., 1998). PXR activation oc-
curs upon binding by its ligands, which include endogenous compounds (e.g. steroids, 
bile acids, metabolites) as well as xenobiotics (e.g. large number of drugs, dietary com-
pounds, pollutants) (Jacobs et al., 2003). PXR is abundantly expressed in liver and in-
testine, and was also detected in other tissues. It is the only nuclear receptor known to 
regulate P-glycoprotein expression (Geick et al., 2001) 
The objective of this part was to examine whether PXR is expressed at the blood-brain 
barrier and whether it regulates P-gp in brain capillaries. PXR expression in isolated rat 
brain capillaries was analyzed by RT-PCR, Western blot analysis and immunohisto-
chemistry. Figure 3.58 shows RT-PCR for PXR mRNA. A 353 bp product was obtained 
for the control tissues liver and kidney, and more importantly for brain homogenate and 
brain capillaries. To confirm the identity of the band, the PCR product was sequenced 
and found to be 100 % identical only to a portion of the rat PXR gene (GenBank acces-
sion no. AF151377). 
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Figure 3.59 shows a Western blot for PXR from capillary nuclear protein. In the left lane, 
the membrane was incubated with PXR antibody only; in the right lane, the membrane 
d 
. An-
 
 
e: Membrane incubated with PXR antibody. The capillary nu-
senting PXR and a strong band at 105 kDa likely repre-
senting PXR-RXRα. 
 
Right lane: Membrane incubated with antigen-blocked PXR antibody. 
The band at 60 kDa is due to unspecific binding of either 
primary or secondary antibody. 
PXR  ~  50 kDa
was incubated with antigen-blocked antibody. Therefore, bands that appear in the left 
lane are specific for PXR. The weak band at about 50 kDa is likely to be PXR. The ban
at about 105 kDa might be a heterodimer of PXR and the nuclear receptor RXRα
other band at about 100 kDa might be PXR homodimer, the formation of which has been 
reported in the literature before (Watkins et al., 2003a). The bands between 105 kDa 
and 160 kDa might be PXR-RXRα heterodimer in complex with coactivators or corep-
ressors (Glass, 1994; Mangelsdorf et al., 1995; Watkins et al., 2003a). However, none of 
the bands has been sequenced and therefore, cannot clearly be identified. 
 
 
 
Figure 3.59 
Western blot for PXR from capillary nuclear proteins 
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Figure 3.60 shows capillaries immunostained for PXR. Immunofluorescence (Figure 
3.60A) is extending over endothelial cell cytoplasm and nucleus. The strong staining 
supports the findings of the RT-PCR and the Western blot. 
A
 
3.3.2 
 Detection of PXR in Isolated Rat Brain Capillaries 
PXR mRNA expressio igure 3.58); the 
PCR product was con g to be 100% identical only to the rat 
XR gene. Western blot analysis showed PXR protein expression in the nuclear fraction 
f capillaries (Figure 3.59). Immunostaining PXR in isolated brain capillaries showed ex-
nding immunofluorescence over cytoplasm and nucleus (Figure 3.60). This is the first 
vidence of PXR expression in brain and rat brain capillaries (Bauer et al., 2004). 
Figure 3.60 
Immunostaining of capillaries for PXR 
 
A: Rat brain capillaries immunostained for PXR (green) and counterstained for nuclei (red) 
 PXR immunofluorescence extends over endothelial cell cytoplasm and nucleus. 
B: Negative control (green channel) 
C: Negative control (red channel) 
D: Transmitte
E: Overlay of
D EB C
10 µm
PXR staining
Summary of Part 3.3.1: 
n in brain capillaries was detected by RT-PCR (F
firmed by direct sequencin
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e
d light image 
 images B, C and D 
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3.3.3 In Vitro Induction of P-gp Expression and Transport Function by PXR 
3.3.3.1 In Vitro Experiments with PCN 
3.3.3.1.1 Effects of PCN, Hyperforin and Paclitaxel on P-gp Expression 
In order to examine PXR regulation of P-glycoprotein expression at the blood-brain bar-
rier, isolated rat brain capillaries were exposed to the PXR ligands, pregnenolone-16α-
carbonitrile (PCN), the St. John’s wort constituent, hyperforin, and the anti-cancer thera-
peutic, paclitaxel. Since PXR shows remarkable species differences in ligand specificity, 
PCN activates rodent PXR but not human PXR (hPXR) (Kliewer et al., 1998; Xie et al., 
2004). In contrast, hyperforin and paclitaxel are potent activators of hPXR but do not ac-
tivate rodent PXR (Moore et al., 2000a; Synold et al., 2001; Wentworth et al., 2000). 
Isolated rat brain capillaries were treated for 6 hours with 10 µM PCN, hyperforin or pa-
clitaxel, respectively. Then, capillary membranes were isolated and analyzed for P-gp 
expression by Western blotting (Figure 3.61). Membranes from capillaries treated with 
10 µM PCN showed a significant stronger signal for P-gp in comparison to membranes 
from control capillaries. Importantly, hyperforin and paclitaxel had no effect on P-gp ex-
pression levels in rat brain capillaries. 
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hyperforin or paclitaxel. 
Figure 3.61 
Western blot for P-gp with membranes from capillaries treated with 
rforin or paclitaxel 
pillaries treated with 10 µM PCN show strong P-gp in-
 to membranes from control capillaries. There is no 
change in band intensity with membranes from capillaries treated with 
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3.3.3.1 Time-Dependent Induction of P-gp Expression by PCN .2 
P-gp expression by PXR activation, isolated 
d 
. 
 
 
 
Ca
 
Exposing capillar d P-gp immunofluorescence in a time-dependent 
manner (bottom p nel). 
To examine the time-dependent increase in 
capillaries were exposed to 5 µM PCN. After 0, 1, 3 and 6 hours, capillaries were fixe
and immunostained for P-gp; images were taken using a confocal microscope
Figure 3.62 shows representative images of capillaries immunostained for P-gp (green), 
nuclei were counterstained with propidium iodide (red). The top panel shows that in con-
trol capillaries P-gp immunofluorescence remained unchanged over the period of the 
6-hour time course. In contrast, capillaries treated with PCN showed significantly in-
creased P-gp immunofluorescence after 3 hours (Figure 3.62 bottom panel). After  
6 hours, the fluorescent signal for immunostained P-gp had increased even more. 
 
 
PCN Exposure Time [h]
 
 
 
Figure 3.62 
pillaries immunostained for P-gp after 0, 1, 3 and 6 hours of exposure to 5 µM PCN 
ies to 5 µM PCN significantly increase
anel) compared to the corresponding control at the same time point (top pa
10 µm10 µ
trol
5 µM PCN
0 1 3 6
Con
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Confocal images of untreated control capillaries and 5 µM PCN-treate
Figure 3.63 
Time course of P-gp immunofluorescence 
from capillaries exposed to 5 µM PCN 
 
P-gp immunofluorescence of control capillar-
ies was unchanged over a period of 6 hours.
Capillaries treated with 5 µM PCN showed a 
significant increase in P-gp immunofluores-
cence in the same period of time (pooled 
tissue from 10 rats, mean ± SEM, n=15,
∗∗∗ p < 0.001). 
d capillaries were 
 
 
analyzed and P-gp immunofluorescence in the luminal membrane of capillaries was 
quantitated using imaging software. P-gp immunofluorescence data is presented in Fig-
ure 3.63 as a function of time. In accordance with the immunostainings in Figure 3.62, 
luminal membrane immunofluorescence in PCN-treated capillaries increased signifi-
cantly after 3 hours and increased further after 6 hours. Over this period, luminal mem-
brane immunofluorescence in control capillaries did not change. 
These results demonstrate that PXR activation increases P-gp expression in the luminal 
membrane of isolated rat brain capillaries. P-glycoprotein induction in this model occurs 
over a period of 6 hours. 
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3.3.3.1.3 Concentration-Dependent Induction of P-gp Expression by PCN 
Isolated capillaries were exposed to 1, 5 and 10 µM PCN for 6 hours. Then, capillaries 
were immunostained for P-gp. Figure 3.64 shows representative images for control and 
PCN-treated capillaries. Capillaries treated with 1 and 5 µM PCN displayed a signifi-
cantly stronger staining than control capillaries. However, immunofluorescence of capil-
laries exposed to 10 µM PCN was only slightly higher than immunofluorescence of con-
trol capillaries. This is possibly due to toxic effects of PCN at higher concentrations. 
Control 1 µM PCN 5 µM PCN 10 µM PCN
10 µm
 
Figure 3.65 summarizes immuno
cence is presented as a function of PCN 
staining data from 5 experiments. P-gp immunofluores-
concentration. P-gp induction was concentra-
on-dependent: 1 µM PCN increased P-gp immunofluorescence on average to  
35 ± 5.4% of the control value, 3 µM PCN to 149 ± 4.9% and a maximal increase to 
186 ± 17% of the control was observed with 5 µM PCN. Capillaries treated with  
10 µM PCN showed about 25% lower P-gp immunofluorescence than capillaries ex-
posed to 5 µM PCN, again suggesting PCN toxicity at higher concentrations. 
 
 
 
ti
1
Figure 3.64 
Immunostaining for P-gp of capillaries treated with 0, 1, 
 
PCN caused an increase in P-gp immunofluorescence (gree
the strongest P-gp immunofluorescence. Nuclei were counte
Figure 3.65 
Concentration-dependent increase of P-gp immunofluorescence by PCN 
 
PCN increased P-gp immunofluorescence in luminal membranes of capillaries in a concentration-
dependent manner (mean ± SEM, summarized data from 5 experiments, each point represents the aver-
age luminal membrane P-gp immunofluorescence from 15-20 capillaries of pooled tissue from 3-10 rats 
per single preparation). 
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After 6-hour exposure of capillaries to 0, 1, 3 and 5 µM PCN, capillary membranes were 
 
ere also probed for GAPDH (glycerylaldehyde-phosphate dehydrogenase), a cyto-
tern blot is 
representative for all /K -ATPase and GAPDH 
are not shown for the following experiments. 
Figure 3.66 
Western blot for P-gp with membranes from capillaries exposed to 0, 1, 3 and 5 µM PCN 
 
PCN increased P-gp band intensity in a concentration-dependent manner. The increase was weak with 
oderate with 3 µM PCN and strongest with 5 µM PCN. 
Protein [µg]    10       10          1          1          1           1 
isolated and Western blot analysis for P-gp was performed. Membranes from capillaries 
treated with 1, 3 and 5 µM PCN displayed increased band intensities when compared to 
the control (Figure 3.66). The increase caused by PCN was concentration-dependent:  
1 µM PCN had the weakest effect, 3 µM PCN had a moderate effect and 5 µM PCN 
caused the highest increase in P-gp expression.  
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In order to guarantee equal protein-loading of the gels, expression of Na+/K+-ATPase, 
used as housekeeping gene and plasma membrane marker, was examined. Samples
w
plasmic protein, to evaluate purity of crude membrane preparations. 
Figure 3.67 shows a Western blot for Na+/K+-ATPase and GAPDH from the same brain 
capillary crude membrane preparation as shown in Figure 3.66. It shows membranous 
expression of Na+/K+-ATPase in capillaries. Importantly, Na+/K+-ATPase expression lev-
els were not changed in PCN-treated rats. In addition, only faint GAPDH bands were 
observed for isolated membranes (renal as well as capillary crude membranes), 
whereas the signal for total brain homogenate was strong. Since this Wes
+ +in vitro experiments, Western blots for Na
    10       10        1         1         1        1 Protein [µg] 
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P
igure 3.67 
estern blot for Na+/K+-ATPase and GAPDH with capillary membranes from PCN-treated rats 
CN did not change expression of Na+/K+-ATPase, indicating equal gel-protein-loading. The capillary 
membrane fraction shows only faint GAPDH bands indicating a pure membrane preparation. 
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3.3.3.1.4 Concentration-Dependent Induction of P-glycoprotein Transport  
Function by PCN 
To determine whether PCN also increased P-glycoprotein transport function at the 
blood-brain barrier, isolated rat brain capillaries were exposed to 0-5 µM PCN for  
6 hours, and NBD-CSA transport was measured. In order to assess P-gp-specific trans-
port, some capillaries were also incubated with the metabolic inhibitor NaCN and the  
P-gp inhibito
cence in a concentra-
 
l. With 5 µM PCN, 
specific NBD-CSA transport e intensity to NaCN or 
 
 
 
Figure 3.68 
Concentration-de
 
P-gp-mediated NB 3 and 5 µM PCN. 
1 µM PCN had no si nsitive to 1 mM NaCN and 
5 µM PSC833 (mea
r PSC833. 
Figure 3.68 shows that PCN increased luminal NBD-CSA fluores
tion-dependent manner: 1 µM PCN increased P-gp-specific transport to 119 ± 5%, 
3 µM PCN to 163.5 ± 4.8% and 5 µM PCN to 202 ± 4.7% of the contro
had more than doubled. Fluorescenc
PSC833 was not changed by PCN. 
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Figure 3.69 summarizes data from 5 transport experiments. It shows P-gp-mediated 
NBD-CSA transport as a function of PCN concentration. P-gp transport increased with  
 
1 - 5 µM PCN to about 164-269 % of the control, respectively. NBD-CSA fluorescence in 
capillaries exposed to 10 µM PCN showed a decline in NBD-CSA transport, which is 
likely to be PCN toxicity.  
 
 
 
 
 
Figure 3.69 
P-gp-mediated NBD-CSA transport as a function of PCN concentration 
 
Concentration-dependent increase of P-gp-mediated NBD-CSA transport into capillary lumens after 
a 6-h exposure to PCN. Transport was maximal for 5 µM PCN-treated capillaries. 10 µM PCN had a toxic 
effect, shown as a decline in luminal NBD-CSA fluorescence (mean ± SEM, summarized data from 5 ex-
periments, each point represents the average luminal membrane P-gp immunofluorescence from 15-20
capillaries of pooled tissue from 3-10 rats per single preparation). 
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3.3.3.2 In Vitro Experiments with Dexamethasone 
3.3.3.2.1 Time-Dependent Induction of P-gp Expression by Dexamethasone 
The glucocorticoid dexamethasone is a widely prescribed anti-inflammatory drug that is 
being used for the treatment of diseases with an inflammatory component, e.g. meningi-
s, arthritis or severe allergic reactions (Offermanns, 2004; Rang, 1999). Dexa-
ethasone induces metabolizing enzymes and transporters in the liver (Hartley et al., 
004; Lehma  
f this phenomenon remained unclear for a long time. Recently, it has been reported 
at dexamethasone is a potent PXR activator. But unlike PCN, dexamethasone acti-
vates both rodent and human PXR (Kliewer et al., 2002; Lehmann et al., 1998). 
Exposing capillaries to 0.5 µM dexamethasone increased P-gp immunofluorescence in a 
time-dependent manner (Figure 3.70). After 3-hour exposure, P-gp immunofluorescence 
was significantly increased. A further increase was measured after 6 hours. P-gp im-
munofluorescence of control capillaries remained the same over the entire time course. 
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 igure 3.70 
ime-dependent increase of P-gp immunofluorescence by dexamethasone 
nduction of P-glycoprotein expression in brain capillaries measured as P-gp immunofluorescence. 
.5 µM dexamethasone caused a significant, time-dependent increase in luminal membrane P-gp im-
∗∗∗unofluorescence (mean ± SEM, n=15,  p < 0.001). 
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3.3.3.2.2 Concentration-Dependent Induction of P-gl ycoprotein Expression 
 
 
Figure 3.72 summari ts. Isolated capillaries 
were exposed to 0.01-0.5 With 0.1 to 0.5 µM dexa-
methasone, P-gp immunofluores eased on average to 176 ± 9%  
(p < 0.01) of the control. There 
 
 
 
 
 
 
 
by Dexamethasone 
The effects of dexamethasone on P-gp expression were further examined by exposing 
isolated capillaries to different concentrations of dexamethasone for 6 hours. Capillaries 
incubated with 0.1 and 0.5 µM dexamethasone displayed higher P-gp immunofluores-
cence than control capillaries (Figure 3.71). 0.01 µM dexamethasone had no effect. 
 
Control 0.01 µM Dexamethasone 0.1 µM Dexamethasone 0.5 µM Dexamethasone
10 µm
zes data from 5 immunostaining experimen
µM dexamethasone for 6 hours. 
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was no change with 0.01 µM dexamethasone. 
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Figure 3.72 
P-gp immunofluorescence as a function of dexamethasone concentration 
 
Increase of P-gp immunofluorescence in capillaries exposed for 6 hours to 0.1-0.5 µM dexamethasone 
in vitro. P-gp immunofluorescence of control capillaries and capillaries exposed to 0.01 µM dexametha-
sone was unchanged (mean ± SEM, summarized data from 5 experiments, each point represents the av-
erage luminal membrane P-gp immunofluorescence from 15-20 capillaries of pooled tissue from 3-10 rats 
per single preparation). 
Figure 3.71 
P-gp immunostaining with capillaries exposed to dexamethasone 
 
Increased luminal membrane P-gp immunofluorescence in capillaries treated with 0.1 µM and 0.5 µM 
dexamethasone for 6 hours in comparison to the control capillaries (no dexamethasone). P-gp im-
munofluorescence was not increased in capillaries exposed to 0.01 µM dexamethasone. 
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Figure 3.73 shows a Western blot for P-gp with membranes from capillaries expo
dexamethasone for 6
sed to 
0.1-5 µM  hours. Capillaries treated with 0.1, 1 and 5 µM de-
 
 
 
 
 
embranes from capillaries treated with 0.1-5 µM dexamethasone show stronger band intensities for P-gp 
an control capillaries. The highest induction of P-gp expression levels was observed with 1 µM dexa-
samethasone display stronger bands for P-gp compared to the control, indicating in-
creased P-gp expression. Highest induction levels were observed when capillaries were 
exposed to 1 µM dexamethasone. 
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Figure 3.73 
Western blot for P-gp with membranes from capillaries exposed to dexamethasone 
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3.3.3.2.3 Concentration-Dependent Induction of P-gp Transport Function 
 by Dexamethasone 
P-gp transport activity also increased when isolated rat brain capillaries were exposed to 
dexamethasone. Figure 3.74 shows P-gp-specific transport (NaCN- and PSC833 sensi-
ive) from 5 experiments with dexat methasone-incubated capillaries. Treating capillaries 
ith 0.01-0.5 µM dexamethasone for 6 hours markedly increased accumulated luminal 
BD-CSA. function to 173.5 ± 8.2% 
e control. A more than  
2-fold increase (214.3 ± 6.1% was observed with 0.5 µM dex-
amethasone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
igure 3.74 
-gp-mediated NBD-CSA transport as a function of dexamethasone concentration 
apillaries treated with 0.01-0.5 µM dexamethasone for 6 hours showed an increase in P-gp-mediated 
ansport (mean ± SEM, summarized data from 5 experiments, each point represents the average luminal 
BD-CSA fluorescence from 10-15 capillaries of pooled tissue from 3-10 rats per single preparation). 
w
N  0.01 µM dexamethasone increased P-gp transport 
and 0.1 µM dexamethasone to 193.9 ± 6.3%, respectively, of th
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3.3.3.3 Summary of Part 3.3.3: 
 In Vitro Induction of P-gp Expression and Transport Function by PXR 
n in rat brain capillaries (Figure 3.61) (Jones et al., 2000; Watkins et al., 
001). Dexamethasone, another PXR ligand, also increased P-gp expression and trans-
ort function. Like PCN, the increase of P-gp expression caused by dexamethasone was 
oth time- and concentration-dependent (Figures 3.70-73). With 5 µM PCN or 0.1- 
.5 µM dexame than doubled (Figures 3.68-
9 and 3.74). 
The rodent-specific PXR activator PCN increased P-gp expression in isolated rat brain 
capillaries in a time- and concentration-dependent manner (Figures 3.62-66). After  
3 hours, P-gp immunofluorescence was significantly increased and was even higher af-
ter 6 hours. Over this period of time, 5 µM PCN had the strongest effect on P-gp induc-
tion. The increase in P-gp expression was accompanied by a parallel increase in P-gp 
transport function (Figures 3.68-69). In accordance with the literature, hyperforin and 
paclitaxel, both of which only activate human PXR but not rodent PXR, had no effect on 
-gp expressioP
2
p
b
0 thasone, P-gp transport function had more 
6
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3.3.4 PXR Induction of P-gp Expression and Transport Function In Vivo 
.3.4.1 
 
 
Confocal images of capillaries immunostained for P-gp were analyzed and P-gp im-
munofluorescence was quantitated. The data are presented in Figure 3.76. PCN in-
creased P-gp immunofluorescence in a dose-dependent manner: 10 mg/kg PCN in-
creased P-gp immunofluorescence to 130.7 ± 2.6 % (1.3-fold) of the control value;  
25 mg/kg PCN increased P-gp immunofluorescence to 169.1 ± 5.4 % (1.7 fold). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.75 
P-gp immunostaining of capillaries from rats dosed with 10 or 25 mg/kg PCN  
 
Isolated capillaries from rats treated with 10 or 25 mg/kg PCN display stronger P-gp immunofluorescence 
in the luminal membrane than capillaries from control rats. 
3 In Vivo Dosing Experiments with PCN 
3.3.4.1.1 Dose-Dependent Induction of P-gp Expression by PCN 
For in vivo experiments, five rats per group were dosed daily for 3 days by i.p. injection 
with 10-50 mg/kg PCN in corn oil. Control animals received corn oil alone. 24 hours after 
the last injection, animals were euthanized, decapitated, and brains were taken immedi-
ately for capillary isolation. Capillaries were used for NBD-CSA transport experiments 
and P-gp immunostaining. Capillary membranes were isolated for further analysis by 
Western blotting. In addition, livers and kidneys were removed and snap-frozen in liquid 
nitrogen until use. 
Figure 3.75 shows representative confocal images of isolated capillaries immunostained 
for P-gp from PCN-treated and untreated animals. Capillaries from animals treated with 
10 or 25 mg/kg PCN show markedly stronger P-gp immunofluorescence in the luminal 
membrane than capillaries from control animals. 
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Figure 3.76 
P-gp immunofluorescence of capillaries 
from PCN-treated rats 
 
Luminal membranes of capillaries from rats 
treated with 10 or 25 mg/kg PCN show signifi-
cantly higher immunofluorescence for P-gp than 
control capillaries: 10 mg/kg PCN increased 
P-gp immunofluorescence to about 130 %;
25 mg/kg PCN to about 170 % of control values 
(mean ± SEM, n=15, ∗∗ p < 0.01). 
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Brain capillaries, kidneys and livers from animals dosed for 3 days with 10 and 25 mg/kg 
 further analysis by Western blotting. 
ysate and renal brush border mem-
espectively. Mem-
igure 3.78 shows a Western blot for Na /K -ATPase and GAPDH from the same brain 
apillary crude membrane preparation to demonstrate equal protein loading (Na+/K+-
Figure 3.77 
Western blot for P-gp r from PCN-treated rats 
 
Dosing animals for crude membranes 
isolated from brain capilla ). 10 µg protein/lane 
or brain lysate and renal BBM, respectively. 
PCN were also used to isolate crude membranes for
Figure 3.77 shows P-gp Western blots; total brain l
branes (BBM) were used as negative and positive controls for P-gp, r
branes isolated from brain capillaries, kidneys and livers from PCN-treated animals, 
showed markedly increased P-gp expression to controls. P-glycoprotein expression in 
liver and kidney membranes increased with increasing PCN dose, whereas P-gp ex-
pression levels in capillary membranes looked the same for both, 10 and 25 mg/kg PCN. 
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Figure 3.78 
+Western blot for Na /K+-ATPase 
and GAPDH with capillary mem-
nes from PCN-treated rats 
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PCN did not change expression of 
Na+/K+- ATPase, indicatin
protein-loading. The capillary mem-
brane fraction shows only faint 
GAPDH bands indicating a pure 
membrane preparation. 
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3.3.4.1.2 Dose-Dependent Induction of P-gp Transport Function by PCN 
The in vivo effect of PCN on P-gp function at the blood-brain barrier was determined by 
NBD-CSA transport into the lumens of isolated brain capillaries from treated and un-
treated animals. Figure 3.79 presents P-glycoprotein-specific (PSC833-sensitive) trans-
port of NBD-CSA into capillary lumens of 10 or 25 mg/kg PCN-dosed rats. In comparison 
to control capillaries, PCN-treated animals exhibited significantly higher luminal accumu-
lation of NBD-CSA. This increase was dose-dependent: 10 mg/kg PCN increased lu-
minal NBD-CSA fluorescence from 41 to 76 fluorescence units (increase to 185.4 ± 5 % 
of the control) and 25 mg/kg increased luminal NBD-CSA fluorescence to 90 fluores-
cence units (increase to 219.5 ± 5.5 % of the control). 
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Figure 3.79 
-gp-mediated transport in capillaries from PCN-treated animals P
 
PCN increased P-glycoprotein-mediated luminal NBD-CSA accumulation in a dose-dependent manner 
(mean ± SEM, n=15, ∗∗∗ p < 0.001). 
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3.3.4.2 In Vivo Dosing Experiments with Dexamethasone 
3.3.4.2.1 Dose-Dependent Induction of P-gp Expression by Dexamethasone 
The in vitro experiments presented above (Part 3.3.2.2) demonstrated induction of P-gp 
expression and transport function by the PXR ligand dexamethasone. Since dexa-
methasone is a widely prescribed drug, it was important to study its effects on P-gp ex-
pression and function at the blood-brain barrier in vivo. Thus, rats were dosed daily i.p. 
with dexamethasone for 3 days (1-50 mg/kg in corn oil). Control animals received vehi-
cle only. 
The images in Figure 3.80 show capillaries immunostained for P-glycoprotein. 
-glycoprotein is shown in green, nuclei are in re
 
d. Luminal membrane P-gp im-
unofluorescence was markedly higher in capillaries from animals treated with  
examethasone when apillaries. The effect was higher with  
 mg/kg dexamethasone than with 1 mg/kg dexamethasone. 
 
 
Figure 3.81 shows the corresponding, quantitated P-gp immunofluorescence data. Dex-
creased P-gp immunofluorescence in a dose-dependent 
47.7 ± 3.4 % (1.5-fold) and  
increase of P-gp immunofluorescence (increase to 196.4 ± 3.8 % of the control). 
Figure 3.80 
Capillaries from dexamethasone-
treated rats immunostained for P-gp
 
P-gp immunofluorescence (green) in 
luminal membranes is markedly in-
creased in capillaries from dexa-
methasone-treated animals in com-
parison to capillaries from untreated 
animals. 
P
m
d  compared to control c
5
 
amethasone significantly in
manner: 1 mg/kg dexamethasone increased P-gp to 1
5 mg/kg dexamethasone increased P-gp immunofluorescence to 199.2 ± 3.1 % (2-fold) 
of the control. Dosing animals with 50 mg/kg dexamethasone did not cause any further 
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Figure 3.81 
P-gp immunofluorescence of capillaries from 
dexamethasone-treated animals 
 
Dosing rats with 1 and 5 mg/kg dexamethasone 
caused a dose-dependent increase of P-gp im-
munofluorescence in the luminal membrane of brain 
capillaries. 50 mg/kg dexamethasone caused no fur-
ther increase (mean ± SEM, n=20, ∗∗ p < 0.05, 
∗∗∗ p < 0.01). 
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In addition to immunostaining, the change of P-gp protein expression was confirmed by 
. The 
gp in 
ive
treated animals 
 
Dosing animals for 3 days with 1 and 5 mg/kg dexamethasone increased P-gp p
embranes isolated from brain capillaries (1 µg protein/lane), d liver (10 µg protein/lane). 
0 µg protein/lane were loaded for brain lysate and renal BBM, respectively. 
Western blotting of membranes from brain capillaries, kidney and liver (Figure 3.82)
increase of P-gp was dose-dependent. As PCN, dexamethasone also induced P-
kidney and liver. 
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Figure 3.82 
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3.3.4.2.2 Dose-Dependent Induction of P-glycoprotein Transport Function 
by Dexamethasone 
To examine whether dexamethasone also increased P-glycoprotein function, P-gp-
ediated NBD-Cm
a
SA transport was determined in capillaries isolated from control rats 
nd dexamethasone-dosed rats. Figure 3.83 shows luminal NBD-CSA fluorescence as a 
llaries from untreated rats 
and rats dosed with 1 or 
 in a dose-
dependent manner. A e 
to 176.3 ± 5.2 % ( ed it to 252.3 ± 4.9 %  
(p 
 
 
 
 
 
 
 
Figure 3.83 
Increase of P-gp-mediated NBD-CSA transport by dexamethasone 
 
Dexamethasone increased P-glycoprotein transport function in a dose-dependent manner. 
(mean ± SEM, ∗∗ p < 0.01, ∗∗∗ p < 0.001) 
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3.3.4.3 Correlation of P-gp Transport Function and P-gp Protein Expressi
Isolated Brain Capill
on in 
aries from PCN- and Dexamethasone-Dosed Rats 
 
lycoprotein expression in the luminal 
more than doubled (increase to 234 ± 6%). 
 addition, NBD-CSA transport experiments revealed a dose-dependent increase of  
-gp function in brain capillaries from dosed animals (Figure 3.84B). Luminal NBD-CSA 
ccumulation increa control values in capillaries from  
5 mg/kg PCN- or 5 mg/kg dexamethasone-treated rats, respectively. As was observed 
r the in vitro experiments (part 3.3.2), dexamethasone was a 5-10-fold more potent in-
ucer of P-gp immunofluorescence and luminal NBD-CSA fluorescence than PCN. 
 
 
 
 
 
Figure 3.84 
PCN and dexamethasone induce P-glycoprotein immunofluorescence and  
luminal NBD-CSA fluorescence in vivo 
 
A: Dose-dependent increase of P-gp immunofluorescence in the luminal capillary membrane of PCN-
or dexamethasone-dosed rats (mean ± SEM, n=20, ∗∗∗ p < 0.001). 
 
B: Dose-dependent increase of luminal NBD-CSA fluorescence in capillaries isolated from PCN- or 
dexamethasone-treated rats (mean ± SEM, n=10, ∗∗∗ p < 0.001). 
A B
Brain capillaries from PCN- and dexamethasone-dosed rats (10-25 mg/kg PCN or 
1-5 mg/kg dexamethasone daily i.p. for 3 days) were isolated for NBD-CSA transport 
experiments and quantitative P-gp immunostaining. Figure 3.84 shows P-gp transport 
and protein expression as a function of PCN and dexamethasone dose. Quantitative  
P-gp immunostaining of capillaries showed that P-g
membrane increased as dose levels of PCN and dexamethasone were raised (Figure 
3.84A). With 25 mg/kg PCN, P-glycoprotein immunofluorescence increased by about 
1.7-fold compared to the control (increase to 169 ± 5%). With 5 mg/kg dexamethasone, 
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Quantitative P-gp immunostaining and NBD-CSA transport data from 5 independen
eriments with PCN- and dexamethasone-dosed rats were correlated. Eac
t  
in vivo exp h 
 
 
 
Figure 3.85 
In vivo correlation of P-gp transport function and P-gp protein expression 
 
Summary of data from 5 in vivo experiments of PCN- or dexamethasone-dosed rats: (A) control values, 
(B) values for animals given low doses of PCN or dexamethasone, (C) values for animals given high 
 or dexamethasone. Luminal NBD-CSA fluorescence and P-gp immunofluorescence in lu-
nd, indicating that newly 
l (mean ± SEM, summarized data from 5 experiments, each 
data point represents the mean value of 15-20 capillaries from pooled tissue of  
3-10 rats per single preparation. Figure 3.85 shows specific luminal NBD-CSA fluores-
cence (P-gp transport function) plotted against P-gp immunofluorescence (P-gp protein 
expression in luminal capillary membrane). Control values cluster at the bottom left (A), 
values for animals given low doses of PXR ligand cluster in the middle (B), and values 
for animals given high doses of PXR ligand cluster in the upper right (C). Importantly, 
both P-gp immunofluorescence and luminal NBD-CSA fluorescence increased in parallel 
as PXR was activated by increasing doses of ligand. This indicates that newly synthe-
sized P-gp protein was also functional. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
doses of PCN
minal capillary membranes increased in parallel with increasing doses of PXR liga
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point represents the average luminal NBD-CSA fluorescence from 10-15 capillaries of pooled tissue from 
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3.3.4.4 Summary for Part 3.3.4: 
In Vivo Induction of P-glycoprotein Expression and Transport Function by PXR 
Dosing rats with PCN and dexamethasone increased P-gp protein expression and 
transport function in brain capillaries. This increase ranged between 1.3-fold for low PCN 
concentrations (10mg/kg) and about 2-fold for 25 mg/kg PCN (Figures 75-79). Dexa-
methasone doses of 1-5 mg/kg caused doubling of P-gp expression and transport func-
tion (Figures 3.80-83). Both PXR ligands also induced P-gp expression in liver and kid-
ney (Figures 3.77 and 3.82). 
These in vivo data demonstrated for the first time that P-glycoprotein expression and 
transport function at the blood-brain barrier both increased in parallel when rats were 
eated with PXR ligands (Bauer et al., 2004). tr
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3.3.5 Discussion of Part 3.3: 
Pregnane X Receptor Upregulation of P-glycoprotein Expression and Transport 
ecker, 2003; Synold et al., 2001). Although PXR is highly 
). However, capillaries comprise less than 
.1% of brain volume. If PXR expression were restricted primarily to brain capillaries, 
RNA levels in whole brain might be below the detection limits of the technique used in 
ose studies (Northern blotting). Using RT-PCR, PXR mRNA was detected in whole 
rain homogenates and in isolated brain capillaries (Figure 3.58). The PCR product was 
onfirmed by direct sequencing to be identical only to the rat PXR gene. Consistent with 
is, Western blot analysis from capillary nuclear protein showed a weak band at the 
ght molecular weight for PXR (~ 50 kDa) and a much stronger band at about 105 kDa, 
hich might represent PXR-RXRα heterodimer (Figure 3.59). These bands should be 
pecific, since in parallel Western blot experiments, PXR-antibody was blocked with an-
gen so that specific and unspecific bands, respectively, could be distinguished from 
each other. The bands between 105 and 160 kDa might be PXR-RXRα heterodimer with 
coactivator and/or corepressor (Glass, 1994; Mangelsdorf et al., 1995; Watkins et al., 
2003a). However, none of the bands has been sequenced yet and therefore, cannot 
clearly be identified. Additionally, immunostaining of isolated brain capillaries showed 
PXR immunofluorescence extending over endothelial cell cytoplasm and nucleus (Figure 
3.60), which confirms the previous findings. 
PCN is the prototypical ligand for rodent PXR but a poor ligand for the human ortholog. 
In contrast, paclitaxel and hyperforin are high-affinity ligands for human PXR but not for 
rodent PXR (Jones et al., 2000; Moore et al., 2000b; Watkins et al., 2001). In accor-
dance with this, PXR activation with PCN increased P-gp protein expression in isolated 
rat brain capillaries, whereas hyperforin and paclitaxel had no effect (Figure 3.61). 
These data validate the model as a useful tool to study long-term effects on  
P-glycoprotein expression at the blood-brain barrier. 
In initial time course experiments, P-glycoprotein immunofluorescence in the luminal 
membrane of capillaries increased significantly after 3-hour exposure to PCN and in-
creased further after 6 hours (Figures 3.62-63). Exposing capillaries to increasing con-
centrations of PCN caused concentration-dependent increases in immunoreactive  
P-glycoprotein in the luminal membrane of capillaries as shown by quantitative immu-
nostaining and Western blotting (Figures 3.64-66). Importantly, PCN also increased  
P-glycoprotein transport function in isolated capillaries (Figures 3.68-69). 
The widely prescribed anti-inflammatory glucocorticoid dexamethasone is also a ligand 
for rodent PXR (Kliewer et al., 2002). Exposing capillaries to this drug also increased  
P-gp protein expression in capillary membranes (quantitative immunostaining, Western 
blot) and increased P-gp transport function in a time- and concentration-dependent 
manner (Figures 3.70-74). Interestingly, dexamethasone induction occurred at concen-
trations (0.01-0.5 µM) that were at least an order of magnitude lower than those for  
Function at the Blood-Brain Barrier 
(Bauer et al., 2004) 
The third part of this thesis describes the long-term regulation of P-glycoprotein by the 
pregnane X receptor (PXR) in isolated rat brain capillaries. PXR is a ligand-activated 
transcription factor that controls P-gp mRNA expression in liver and intestine (Geick et 
al., 2001; Kullak-Ublick and B
expressed in liver, kidney and certain regions of the gut, previous experiments did not 
detect any evidence of PXR mRNA expression in whole brain homogenates (Jones et al., 
2000; Kliewer et al., 1998; Zhang et al., 1999
0
m
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c
th
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PCN, suggesting that dexamethasone is a more potent P-gp inducer. However, it cannot 
er in vivo exposure to PXR ligands altered P-glycoprotein expres-
f receptor activation in rats dosed with PXR 
ed at the barrier itself or more dis-
ion and conju-
be excluded that dexamethasone also activated the glucocorticoid receptor, which syn-
ergistically might have affected P-gp induction, as reported previously (Pascussi et al., 
2001). 
To determine wheth
sion at the blood-brain barrier, rats were injected i.p. with PCN or dexamethasone daily 
for 3 days. Capillaries were isolated 24 hours after the last dosing and P-glycoprotein 
expression and transport function were measured. Livers and kidneys were also re-
moved; crude membrane fractions were isolated and analyzed by Western blotting. P-gp 
protein expression was increased by both PCN and dexamethasone in Western blots of 
brain capillary plasma membranes (Figures 3.77 and 3.82). In agreement with previously 
published studies (Demeule et al., 1999; Salphati and Benet, 1998), immunoreactive  
P-glycoprotein in liver and kidney crude membranes was also increased (Figures 3.77 
and 3.82). Quantitative immunostaining of capillaries showed that luminal P-glycoprotein 
immunofluorescence increased as dose levels were raised; at the highest doses used, 
immunofluorescence about doubled (Figures 3.75-76 and Figures 3.80-81). When  
P-glycoprotein-specific transport was measured, significant dose-dependent increases 
were found (Figures 3.79 and 3.83). Importantly, P-glycoprotein-mediated NBD-CSA 
transport and immunofluorescence correlated (Figure 3. 85), suggesting that both im-
munofluorescence and specific transport increased in parallel as PXR was activated by 
increasing dose of ligand. 
The present results identify one underlying mechanism by which drug export pump activ-
ity at the blood-brain barrier is modulated. They show that PXR is expressed in brain 
capillaries and that P-glycoprotein expression and transport function at the blood-brain 
barrier increase after in vitro or in vivo exposure to the PXR ligands, PCN and dexa-
methasone. Thus, one consequence of exposure to PXR ligands is selective tightening 
of the blood-brain barrier to those chemicals that are P-glycoprotein substrates. 
The results, which show the consequences o
ligands, provide a “proof of principle” with regard to PXR expression and action in the 
blood-brain barrier. The extent, to which other PXR ligands will alter blood-brain barrier 
function in vivo in rats or in other species, will depend on several interrelated factors. For 
example, the nature of the ligand, its pharmacokinetics and the exposure (dosing proto-
col) will determine whether ligand accumulates in brain capillary endothelial cells at suf-
ficient levels to affect gene expression. Certainly, for PXR ligands that are also  
P-glycoprotein substrates, accumulation may be limit
tally at the intestine or liver. So far, PXR is the only nuclear receptor known to regulate 
P-glycoprotein and to be expressed at the blood-brain barrier. However, the blood-brain 
barrier does express other multi-specific drug metabolizing enzymes and transporters 
that are regulated by PXR in other tissues, e.g., cytochrome P450s, glutathione trans-
ferases, Mrps, and organic anion transport polypeptides (Chen et al., 2003; Guo et al., 
2002; Kast et al., 2002). In liver and gut, ligand-activated nuclear receptors regulate a 
network of genes that encode enzymes responsible for xenobiotic oxidat
gation as well as excretory transport of xenobiotics and products of xenobiotic metabo-
lism (Rosenfeld et al., 2003). To what extent such a regulatory network is also present at 
the blood-brain barrier is unclear. 
Taken together, upregulation of P-glycoprotein has important clinical implications. On 
the one hand, P-glycoprotein is responsible for the efflux of neurotoxic chemicals and 
metabolites from the CNS and increased pump expression should provide increased  
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neuroprotection. On the other hand, many P-glycoprotein substrates are used therapeu-
tically, e.g., to treat brain tumors, viral and bacterial infections and epileptic seizures, 
and increased pump expression also implies reduced access of those drugs to sites of 
action within the CNS. Thus, a better understanding of the mechanisms that regulate the 
selective barrier to drug entry also holds the promise of treatments, e.g., drugs or dietary 
modifications that could downregulate pump expression. For example, transient  
P-glycoprotein downregulation could provide a window in time during which normally im-
permeant drugs would be able to access sites within the CNS. Whether this can be done 
effectively through manipulation of PXR or through other faster acting regulatory mecha-
nisms remains to be demonstrated. 
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3.3.6 Summary of Part 3.3: 
Pregnane X Receptor Upregulation of P-glycoprotein Expression and  
Transport Function at the Blood-Brain Barrier 
(Bauer et al., 2004) 
PXR mRNA expression in brain capillaries was detected by RT-PCR (Figure 3.58); the 
PCR product was confirmed by direct sequencing to be 100% identical only to the rat 
PXR gene. Western blot analysis showed PXR protein expression in the nuclear fraction 
of capillaries (Figure 3.59). Immunostaining PXR in isolated brain capillaries showed 
immunofluorescence extending over cytoplasm and nucleus (Figure 3.60). The rodent-
pecific PXR activator, PCN, induced P-gp expression in isolated rat brain capillaries in 
a time- and concentration-dependent manner (Figures 3.62-66). After 3 hours, P-gp im-
munofluorescence was significantly increased and was even higher after 6 hours. Dose-
response experiments showed that 5 µM PCN had the strongest effect on P-gp induction. 
The increase in P-gp expression was accompanied by a parallel increase in P-gp trans-
port function (Figures 3.68-69). Activators of human PXR (hyperforin and paclitaxel) had 
no effect on P-gp expression in rat brain capillaries (Figure 3.61). Dexamethasone, an-
other PXR ligand, also increased P-gp expression and transport function. The increase 
of P-gp expression was both time- and dose-dependent as seen before with PCN (Fig-
ures 3.70-73). With 5 µM PCN or 0.1-0.5 µM dexamethasone, P-gp transport activity had 
more than doubled (Figures 3.68-69 and 3.74). Dosing rats with PCN or dexamethasone 
increased P-gp protein expression and transport function in brain capillaries (Figures 
3.75-83). Protein expression and transport more than doubled with the highest doses 
used. P-gp expression in liver and kidney was also induced (Figures 3.77 and 3.82). Im-
portantly, both P-gp protein expression and transport function in brain capillaries in-
creased in parallel when rats were given increasing doses of PXR ligand (Figure 3.85). 
The present in vitro and in vivo data provide a “proof of principle” with regard to PXR ex-
pression and action in brain capillaries. For the first time, these results demonstrate a 
molecular basis for regulation of the xenobiotic transporter P-glycoprotein at the blood-
brain barrier (Figure 3.86) (Bauer et al., 2004). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.86 
Pregnane X Receptor upregulation of P-gp expression and activity at the blood-brain barrier 
 
The scheme illustrates upregulation of P-gp expression by PXR. Binding of PXR ligands (blue) like PCN or 
dexamethasone activates the pregnane X receptor (PXR). PXR translocates into the nucleus, binds to the 
xenobiotic response element (XRE) and induces transcription of its target gene, Mdr1. This leads to an 
increase of P-gp protein expression in the luminal membrane of brain capillaries and causes higher P-gp-
mediated drug efflux. 
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4 Summary and Outlook 
4.1 Summary 
The objective of this thesis was to study regulation of P-glycoprotein using isolated rat 
brain capillaries as an ex vivo model of the blood-brain barrier. The studies addressed 
the following hypotheses: 
1. Endothelin-1 regulates P-gp transport function at the blood-brain barrier 
2. PXR regulates P-gp expression and transport function at the blood-brain barrier 
 
Characterization of isolated rat brain capillaries showed that this ex vivo model is a suit-
able and powerful tool to study blood-brain barrier function. Confocal microscopy and 
transmission electron microscopy revealed intact morphology and ultra-structure of 
freshly isolated capillaries. P-glycoprotein transport function was assessed by measuring 
accumulation of the fluorescent, P-gp-specific substrate, NBD-cyclosporine A (NBD-CSA) 
in the lumens of isolated rat brain capillaries using confocal microscopy and quantitated 
by image analysis. Importantly, transport experiments showed that capillaries were vi-
able for at least 6 hours. P-glycoprotein expression was detected in capillary mem-
branes and immunostaining localized P-gp to the luminal membrane. In addition to P-gp, 
expression of other drug efflux transporters and tight junction proteins was also found. In 
essence, these findings demonstrate that freshly isolated rat brain capillaries can be 
used as an ex vivo blood-brain barrier model to study P-glycoprotein expression and 
transport function. 
 
 
 
1. Rapid Regulation of P-glycoprotein at the Blood-Brain Barrier by Endothelin-1 
 
Exposing capillaries to 0.1-100 nM ET-1 rapidly (within 1 hour) and reversibly reduced 
luminal NBD-CSA accumulation. Importantly, a kinetic dye efflux assay showed that tight 
junctions were not affected by ET-1. Sarafotoxin S6c, an ETB receptor agonist, also re-
duced P-gp-mediated transport; the effects of ET-1 and sarafotoxin S6c were blocked by 
an ETB receptor antagonist, but not by an ETA receptor antagonist. Immunostaining lo-
calized the ETB receptor to the luminal and abluminal membranes of brain capillaries. 
NBD-CSA transport was also reduced by the NO donor, sodium nitroprusside (SNP), 
and by the protein kinase C (PKC) activator, PMA. Inhibition of NO synthase (NOS) or 
PKC blocked the effects of ET-1; PKC inhibition blocked the effects of SNP and PMA. 
Thus, P-glycoprotein at the blood-brain barrier is regulated in the short-term by ET-1 act-
ing through an ETB receptor, NOS, NO and PKC (Hartz et al., 2004). 
Taken together, this is the first evidence for hormonal signaling causing rapid and re-
versible changes of P-gp-mediated transport at the blood-brain barrier (Figure 4.1:  
1. Functional Modulation by Endothelin-1). ET-1 regulation of P-glycoprotein may be of 
clinical importance, since this hormone has been implicated in many CNS disorders. 
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2. Pregnane X Receptor Upregulation of P-glycoprotein Expression and Transport 
Function at the Blood-Brain Barrier 
 
Expression of the nuclear receptor, PXR, was detected in isolated rat brain capillaries by 
RT-PCR, Western blot analysis and immunostaining. Six hour exposure of isolated capil-
laries to the PXR ligands, PCN (1-10 µM) or dexamethasone (0.1-0.5 µM), significantly 
increased expression of P-gp in the plasma membrane; maximal stimulation was about 
2-fold. Consistent with this, P-gp immunostaining demonstrated significantly increased 
immunoreactivity at the luminal membrane of capillaries. Increased (2-fold) P-gp-
mediated NBD-CSA transport into capillary lumens was also detected. No such in-
creases in P-gp expression were found when capillaries were exposed to ligands that 
activate human PXR (hyperforin, paclitaxel), but do not activate rodent PXR. Importantly, 
2-3-fold increases in P-glycoprotein expression and transport function were also found in 
capillaries isolated from rats dosed with PCN and dexamethasone (Bauer et al., 2004). 
In this thesis for the first time it is shown that the nuclear receptor PXR is expressed at 
the blood-brain barrier, where it regulates expression and function of P-glycoprotein 
(Figure 4.1: 2. Transcriptional Regulation by PXR). Since P-gp is a major determinant for 
CNS entry of drugs and since a large number of drugs activate PXR, these findings 
might have important clinical implications for patients receiving multiple drugs over 
longer periods of time. 
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odulation of P-gp transport function and expression 
. Functional modulation of P-glycoprotein by endothelin-1: 
T-1 modulates P-glycoprotein transport function at the blood-brain barrier over the short-term by acting 
hrough the ETB receptor, NO synthase (NOS) and protein kinase C (PKC) (Hartz et al., 2004). 
. Transcriptional regulation of P-glycoprotein by PXR:  
ctivation of PXR by ligands regulates transcription of Mdr1 resulting in increased P-glycoprotein expres-
ion and transport function (Bauer et al., 2004).
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4.2 Outlook 
Effect of inflammatory mediators on P-glycoprotein at the blood-brain barrier 
At present, little is known about the physiological role of endothelin-1 at the blood-brain 
barrier. However, it is clear that many CNS disorders are accompanied by inflammation, 
that endothelin-1 is involved in many inflammatory CNS diseases and that endothelin-1 
is released in the brain’s innate immune response (Nie and Olsson, 1996; Willette, 1995). 
Therefore, inflammatory mediators present in the brain during CNS disorders could act 
through ET-1 to affect P-glycoprotein at the blood-brain barrier. In addition, inflammation 
in the periphery could also affect the brain and modulate P-glycoprotein at the blood-
brain barrier. 
 
Nuclear receptor regulation of efflux transporters at the blood-brain barrier 
In liver and gut, nuclear receptors regulate a network of genes encoding xenobiotic ef-
flux pumps that are involved in excretory transport (Rosenfeld et al., 2003). Although 
PXR is the only nuclear receptor that is known to regulate P-glycoprotein, brain capillar-
ies express other efflux transporters (Geick et al., 2001; Labialle et al., 2002). Thus, it is 
likely that PXR controls transcription of multiple transporters at the blood-brain barrier. 
For example, preliminary data indicate PXR regulation of Mrp2 in rat brain capillaries 
(Bauer et al., 2004). Moreover, recent molecular findings show also expression of other 
nuclear receptors in brain capillaries. However, it is not known if these receptors are in-
volved in efflux transporter regulation. Therefore, it remains to be determined, (1) which 
nuclear receptors are actually expressed at the blood-brain barrier, (2) if they are in-
volved in transporter regulation and (3) if nuclear receptors and efflux transporters are 
part of a regulatory network at the blood-brain barrier. 
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5 Materials and Methods 
5.1 Materials 
5.1.1 Chemicals 
Albumin bovine serum, Fraction V Sigma-Aldrich, St. Louis, MO, USA 
Ampicillin Sigma-Aldrich, St. Louis, MO, USA 
Bacto™ Agar BD Diagnostic Systems, Sparks, MD, USA 
Bacto™ Tryptone BD Diagnostic Systems, Sparks, MD, USA 
Bacto™ Yeast Extract BD Diagnostic Systems, Sparks, MD, USA 
BD Advantage™ UltraPure, 
PCR Deoxynucleotide Mix 
BD Biosciences Clontech, Palo Alto, CA, USA 
 
BenchTop PCR Markers Promega Corporation, Madison, WI, USA 
Bio-Rad Protein Assay, Dye Reagent Concentrate Bio-Rad Laboratories, Hercules, CA, USA 
Bisindolylmaleimide I EMD Biosciences/Calbiochem®, San Diego, CA, USA 
Boric Acid Sigma-Aldrich, St. Louis, MO, USA 
BupH™ Tris Buffered Saline Packs Pierce Biotechnology, Rockford, IL, USA 
Cacodylic Acid, Sodium Salt, Trihydrate Electron Microscopy Sciences, Fort Washington, USA 
Calcium Chloride (anhydrous, CaCl2) Sigma-Aldrich, St. Louis, MO, USA 
CelLytic™-MT Mammalian Tissue Lysis / 
Extraction Reagent 
Sigma-Aldrich, St. Louis, MO, USA 
 
Chloroform Mallinckrodt Baker, Phillipsburg, NJ, USA 
Complete®, 
EDTA-free, Protease Inhibitor Cocktail Tablets 
Roche Diagnostics Corporation, 
Roche Applied Science, Hague Road, IN, USA 
Corn Oil Sigma-Aldrich, St. Louis, MO, USA 
Cyclosporin A Sigma-Aldrich, St. Louis, MO, USA 
DEPC-treated Water Research Genetics (Invitrogen), Huntsville, AL, USA 
Dexamethasone 
(9α-Fluoro-16 α-methylprednisolone) 
Sigma-Aldrich, St. Louis, MO, USA 
 
Dimethyl Sulfoxide (DMSO) Sigma-Aldrich, St. Louis, MO, USA 
Dithiothreitol (DTT) Sigma-Aldrich, St. Louis, MO, USA 
DMP-30 [2,4,6-Tri(dimethylaminomethyl) phenol] Electron Microscopy Sciences, Fort Washington, USA 
DyeEx™ 2.0 Spin Kit Qiagen, Valencia, CA, USA 
EDTA (ethylenediamine tetra-acetic acid) Sigma-Aldrich, St. Louis, MO, USA 
Endothelin 1, Human and Porcine EMD Biosciences/Calbiochem®, San Diego, CA, USA 
Ethidium Bromide Sigma-Aldrich, St. Louis, MO, USA 
Ethyl Alcohol 200 Proof ACS/USP Grade Pharmaco™ Products, Brookfield, CT, USA 
Ficoll® 400 Sigma-Aldrich, St. Louis, MO, USA 
Full-Range Rainbow™ Molecular Weight Markers Amersham Biosciences, Piscataway, NJ, USA 
Gel Loading Buffer II Ambion, Austin, TX, USA 
GeneAmp® 10x PCR Buffer II & MgCl2 Applied Biosystems, Foster City, CA, USA 
α-D (+) Glucose Sigma-Aldrich, St. Louis, MO, USA 
Glutaraldehyde, 25% Sigma-Aldrich, St. Louis, MO, USA 
Glutaraldehyde, 50% Electron Microscopy Sciences, Fort Washington, USA 
Hydrochloric Acid (HCl) Sigma-Aldrich, St. Louis, MO, USA 
Hyperforin Sigma-Aldrich, St. Louis, MO, USA 
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Ivermectin Sigma-Aldrich, St. Louis, MO, USA 
JKC-301 EMD Biosciences/Calbiochem®, San Diego, CA, USA 
Lead Nitrate, Reagent, A.C.S. Electron Microscopy Sciences, Fort Washington, USA 
Leukotriene C4 (LTC4) Sigma-Aldrich, St. Louis, MO, USA 
Methanol Caledon Laboratories LTD., Georgetown, Canada 
Magnesium Chloride (MgCl2 ⋅ 6H2O) Sigma-Aldrich, St. Louis, MO, USA 
Magnesium Sulfate (MgSO4 ⋅ 7H2O) Sigma-Aldrich, St. Louis, MO, USA 
D-Mannitol Sigma-Aldrich, St. Louis, MO, USA 
2-Mercaptoethanol Bio-Rad Laboratories, Hercules, CA, USA 
MK 571 (sodium salt) Cayman Chemical, Ann Arbor, MI, USA 
MuLV Reverse Transcriptase Applied Biosystems, Foster City, CA, USA 
NBD-CSA: 
[N-ε(4-nitrobenzofurazan-7-yl)-D-Lys8]-cyclosporine A 
Custom-synthesized by Novartis, Basel, CH 
 
L-NMMA: NG-Monomethyl-L-arginine acetate salt EMD Biosciences/Calbiochem®, San Diego, CA, USA 
NuPAGE® Antioxidant Invitrogen Corporation, Carlsbad, CA, USA 
NuPAGE® LDS Sample Buffer (4x) Invitrogen Corporation, Carlsbad, CA, USA 
NuPAGE® MOPS SDS Running Buffer (20x) Invitrogen Corporation, Carlsbad, CA, USA 
NuPAGE® Reducing Agent (10x) Invitrogen Corporation, Carlsbad, CA, USA 
NuPAGE® Transfer Buffer (20x) Invitrogen Corporation, Carlsbad, CA, USA 
Osmium Tetroxide Electron Microscopy Sciences, Fort Washington, USA 
Paclitaxel Sigma-Aldrich, St. Louis, MO, USA 
Paraformaldehyde Sigma-Aldrich, St. Louis, MO, USA 
Paraformaldehyde, 16% Electron Microscopy Sciences, Fort Washington, USA 
PCR-grade Water BD Biosciences Clontech, Palo Alto, CA, USA 
1-O-Pentylglycerol 
 
Dr. Erdlenbruch, Children’s Clinic, 
University of Göttingen, Germany 
Phosphatase Inhibitor Cocktail 2 Sigma-Aldrich, St. Louis, MO, USA 
Potassium Chloride (KCl) Sigma-Aldrich, St. Louis, MO, USA 
Potassium Phosphate, Monobasic (KH2PO4) Sigma-Aldrich, St. Louis, MO, USA 
5-Pregnen-3β-ol-20-one-16α-carbonitrile (PCN) Sigma-Aldrich, St. Louis, MO, USA 
Phorbol-12-Myristate-13-Acetate (PMA) EMD Biosciences/Calbiochem®, San Diego, CA, USA 
2-Propanol Mallinckrodt Baker, Phillipsburg, NJ, USA 
Probenecid Sigma-Aldrich, St. Louis, MO, USA 
Propidium Iodide Sigma-Aldrich, St. Louis, MO, USA 
Propylene Oxide, EM Grade Electron Microscopy Sciences, Fort Washington, USA 
PSC833 Novartis AG, Basle, Switzerland 
Random Hexamers Applied Biosystems, Foster City, CA, USA 
RES-701-1 EMD Biosciences/Calbiochem®, San Diego, CA, USA 
RNase Inhibitor Applied Biosystems, Foster City, CA, USA 
RNaseZap™ Ambion, Austin, TX, USA 
Sarafotoxin S6c Sigma-Aldrich, St. Louis, MO, USA 
Seakem® GTG® Agarose Cambrex Bio Science Rockland, Rockland, ME, USA 
Sodium Citrate, Dehydrate, Reagent Electron Microscopy Sciences, Fort Washington, USA 
Sodium Nitroprusside Dihydrate Sigma-Aldrich, St. Louis, MO, USA 
Sodium Phosphate, Dibasic (Na2HPO4) Sigma-Aldrich, St. Louis, MO, USA 
Sodium Chloride (anhydrous, NaCl) Sigma-Aldrich, St. Louis, MO, USA 
Sodium Cyanide (NaCN) Sigma-Aldrich, St. Louis, MO, USA 
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Sodium Hydroxide (NaOH 1N) Sigma-Aldrich, St. Louis, MO, USA 
Sodium Pyruvate Sigma-Aldrich, St. Louis, MO, USA 
Sucrose Sigma-Aldrich, St. Louis, MO, USA 
SuperBlock® Blocking Buffer (TBS) Pierce Biotechnology, Rockford, IL, USA 
SuperSignal® West Pico Chemiluminescent Substrate Pierce Biotechnology, Rockford, IL, USA 
Surfact-Amps® 20 Pierce Biotechnology, Rockford, IL, USA 
Surfact-Amps® X-100 Pierce Biotechnology, Rockford, IL, USA 
Texas Red (sulforhodamine 101, free acid) Sigma-Aldrich, St. Louis, MO, USA 
Tris Base Sigma-Aldrich, St. Louis, MO, USA 
Trizol® Reagent Invitrogen Corporation, Carlsbad, CA, USA 
Uranyl Acetate, Reagent, A.C.S. Electron Microscopy Sciences, Fort Washington, USA 
(±)-Verapamil Hydrochloride Sigma-Aldrich, St. Louis, MO, USA 
 
 
 
5.1.2 Equipment and Materials 
ABI Prism 377 DNA Sequencer Applied Biosystems, Foster City, CA, USA 
Beckman Allegra™ 21R Centrifuge, 
S 4180 Swinging Bucket Rotor 
Beckman Coulter, Fullerton, CA, USA 
 
Beckman L8-55M Ultracentrifuge, 
SW 41 Ti Swinging Bucket Rotor 
Beckman Coulter, Fullerton, CA, USA 
 
Beckman TL-100 Tabletop Ultracentrifuge, 
TLS-55 Swinging Bucket Rotor 
Beckman Coulter, Fullerton, CA, USA 
 
Beem™ Capsule Press Electron Microscopy Sciences, Fort Washington, USA 
Beem™ Embedding Capsules Electron Microscopy Sciences, Fort Washington, USA 
Black & Decker, 3/8” Drill The Black & Decker Corporation, Towson, MD, USA 
ChemiDoc™ Gel Documentation Systems Bio-Rad Laboratories, Hercules, CA, USA 
Costar® 96 Well Cell Culture Cluster, Polystyrene Corning Incorporated, Corning, NY, USA 
DNA Speed Vac® DNA 110, RD24 Rotor Savant Instruments, Holbrook, NY, USA 
Dounce Homogenisator, Clearance 130-180 µm Kimble / Kontes, Vineland, NJ, USA 
Dumont Forceps No. 5, Carbon Steel, 0.08 x 0.04 mm Biomedical Research Instruments, Malden, MA, USA 
Eppendorf Centrifuge 5415D,  
Eppendorf F45-24-11 Rotor 
Brinkmann Instruments, Westbury, NY, USA 
 
Eppendorf Centrifuge 5417 R, 
Aerosol-Tight Rotor FA45-30-11 
Brinkmann Instruments, Westbury, NY, USA 
 
Falcon® Cell Strainer, 100 µm Nylon BD Biosciences, Bedford, MA, USA 
Falcon® Ten-twenty-nine™ Petri Dish, 
100x15 mm Style 
BD Biosciences, Bedford, MA, USA 
 
Formvar®/Carbon Coated Copper Grids Electron Microscopy Sciences, Fort Washington, USA 
FEI Tecnai™ G2 12 Electron Microscope FEI Company, Hillsboro, OR, USA 
GeneQuant RNA/DNA Calculator Biochrom Ltd, Cambridge, UK 
Glass Beads, 0.45-0.5 mm B. Braun Biotech International GmbH, Melsungen, D 
Hoefer™ HE 33, Mini Horizontal Submarine Unit Amersham Biosciences, Piscataway, NJ, USA 
Innova™ 2000 Platform Shaker New Brunswick Scientific, Edison, NJ, USA 
Invitrolon™ PVDF Membrane, Pore Size 0.45 µm Invitrogen Corporation, Carlsbad, CA, USA 
IR AutoFlow™ Incubator NuAire, Plymouth, MN, USA 
Leica Ultracut Ultramicrotome Leica, Deerfield, IL, USA 
Market Forge Sterilmatic STME Autoclave Global Medical Instrumentation, Albertville, MN, USA 
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Mettler PM 1200 Balance Mettler-Toledo, Columbus, OH, USA 
Microscope Cover Glass, 40x40, No.1 Thickness A. Daigger & Company, Vernon Hills, IL, USA 
Monoject® 6cc Syringes with Luer Lock Tip Sherwood Medical, St. Louis, MO, USA 
Monoject® Aluminum Hub 
Hypodermic Needles 19 x 1.5” 
Sherwood Medical, St. Louis, MO, USA 
 
Monoject® Sterile Single-Use Syringe, Luer Tip, 50 ml Sherwood Medical, St. Louis, MO, USA 
Nalgene® Small Filter Unit Sterilization, 
0.2 µm Cellulose Nitrate Membrane 
Nalgene Nunc International, Rochester, NY, USA 
 
NuPAGE™ Bis-Tris Gel 4-12%, 1.0 mm x 15 wells Invitrogen Corporation, Carlsbad, CA, USA 
Ohaus® Analytical Plus Balance Ohaus Corporation, Pine Brook, NJ, USA 
PCR Sprint Thermal Cycler Therma Electron Corporation, Waltham, MA, USA 
Pestle Tissue Grinder, Clearance 150-230 µm Thomas Scientific, Swedesboro, NJ, USA 
Pharmaseal K75 3-way Stopcock, Sterile 
 
Scientific Products / Baxter Healthcare, Bedford, MA, 
USA 
PP graduated Micro Tube, RNase/DNase free, 1.7 ml PGC Scientifics, Frederick, MD, USA 
PP Macro Filters, Polypropylene, 300 µm Spectrum Laboratories, Rancho Dominguez, CA, USA 
SafeSeal Microcentrifuge Tubes 1.7ml PGC Scientifics, Frederick, MD, USA 
Sorvall® RC-5B PLUS Superspeed Refrigerated  
Centrifuge, Sorvall® SM-24 Rotor and SS-34 Rotor 
Kendro Laboratory Products, Newtown, CT, USA 
 
Spectra/Mesh® Nylon Filters, 30 µm Spectrum Laboratories, Rancho Dominguez, CA, USA 
Spectrum® Micro Tissue Grinder  Spectrum Laboratories, Rancho Dominguez, CA, USA 
Sponge Pad for XCell II™ Blotting Invitrogen Corporation, Carlsbad, CA, USA 
VersaMax™, Tunable Microplate Reader Molecular Devices, Sunnyvale, CA, USA 
Wild M7 S Microscope Leica Microsystems AG, Heerbrugg, CH 
Xcell II™ Blot Module (Version G) Invitrogen Corporation, Carlsbad, CA, USA 
Xcell SureLock™ Mini-Cell Invitrogen Corporation, Carlsbad, CA, USA 
Zeiss 510 NLO, 
(Zeiss Inverted Axiovert 100M Microscope) 
Carl Zeiss MicroImaging, Thornwood, NY, USA 
 
Zeiss LSM 410, (Axiovert 135 Microscope) Carl Zeiss MicroImaging, Thornwood, NY, USA 
 
 
 
5.1.3 Kits 
BigDye® Terminator Cycle Sequencing Kit Invitrogen Corporation, Carlsbad, CA, USA 
GeneAmp® RNA PCR Kit Applied Biosystems, Foster City, CA, USA 
pcDNA3.1/V5-His© TOPO® TA Expression Kit, 
Version G 
Invitrogen Corporation, Carlsbad, CA, USA 
 
NE-PER®
Nuclear and Cytoplasmic Extraction Reagents 
Pierce Biotechnology, Rockford, IL, USA 
 
Nuclei PURE Prep Nuclei Isolation Kit Sigma-Aldrich, St. Louis, MO, USA 
One Shot® TOP10 Invitrogen Corporation, Carlsbad, CA, USA 
QIAEX II Agarose Gel Extraction Kit Quiagen, Valencia, CA, USA 
RNeasy® Mini Kit Qiagen, Valencia, CA, USA 
Titanium™ Taq PCR Kit BD Biosciences Clontech, Palo Alto, CA, USA 
UltraClean™ 6 Minute Mini Plasmid Prep Kit™ Mo Bio Laboratories, Solana Beach, CA, USA 
Poly/Bed 812 Kit Polysciences, Warrington, PA, USA 
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5.1.4 Antibodies 
Alexa Fluor® 488 Chicken Anti-Rat IgG (H + L) Molecular Probes, Eugene, OR, USA 
Alexa Fluor® 488 Goat Anti-Mouse IgG (H + L) Molecular Probes, Eugene, OR, USA 
Alexa Fluor® 488 Goat Anti-Rabbit IgG (H + L) Molecular Probes, Eugene, OR, USA 
Alexa Fluor® 633 Donkey Anti-Goat IgG (H+L) Molecular Probes, Eugene, OR, USA 
Anti-Endothelin Receptor Type B Alomone Labs, Jerusalem, Israel 
Anti-ETA-Receptor PAb 
(Polyclonal Antibody to Endothelin A Receptor) 
Alexis Axxora, LCC, San Diego, CA, USA 
 
Anti-GAPDH Abcam Limited, Cambridgeshire, UK 
Anti-Glucose Transporter 1 (Rabbit) EMD Biosciences/Calbiochem®, San Diego, CA, USA 
Anti-Mouse JAM-1 Antibody R&D Systems, Minneapolis, MN, USA 
Anti-Na+/K+ ATPase a-1 Upstate Biotechnology, Lake Placid, NY, USA 
Fluorescein-Labeled Affinity Purified Antibody 
To Sheep IgG, (H+L) 
Kirkegaard & Perry Laboratories, Gaithersburg, MD, 
USA 
ImmunoPure® Goat Anti-Mouse IgG, (H+L), 
Peroxidase Conjugated 
Pierce Biotechnology, Rockford, IL, USA 
 
ImmunoPure® Goat Anti-Rabbit IgG, (H+L), 
Peroxidase Conjugated 
Pierce Biotechnology, Rockford, IL, USA 
 
ImmunoPure® Goat Anti-Rat IgG, (H+L), 
Peroxidase Conjugated 
Pierce Biotechnology, Rockford, IL, USA 
 
ImmunoPure® Rabbit Anti-Goat IgG, (H+L), 
Peroxidase Conjugated 
Pierce Biotechnology, Rockford, IL, USA 
 
ImmunoPure® Rabbit Anti-Sheep IgG, (H+L), 
Peroxidase Conjugated 
Pierce Biotechnology, Rockford, IL, USA 
 
mdr Ab-1 Oncogene Research Products, Cambridge, MA, USA 
Monoclonal Antibody to Breast Cancer Resistance Pro-
tein (BXP-53) 
Alexis Axxora, LCC, San Diego, CA, USA 
 
Monoclonal Antibody to MRP2/cMOAT (M2 III-6) Alexis Axxora, LCC, San Diego, CA, USA 
Monoclonal Mouse anti-Claudin-5 Zymed® Laboratories, South San Francisco, CA, USA 
Mouse Monoclonal C219 Signet Laboratories, Dedham, MA, USA 
Polyclonal Antibody to MRP1 (A23) Alexis Axxora, LCC, San Diego, CA, USA 
Polyclonal Antibody to MRP4 (human) Alexis Axxora, LCC, San Diego, CA, USA 
PXR (R-14) Santa Cruz Biotechnology, Santa Cruz, CA, USA 
Rabbit Anti-Claudin-1 Zymed® Laboratories, South San Francisco, CA, USA 
Rabbit Anti-Occludin Zymed® Laboratories, South San Francisco, CA, USA 
Rabbit Anti-ZO-1 Zymed® Laboratories, South San Francisco, CA, USA 
 
 
5.1.5 Enzymes 
Hind III New England Biolabs, Beverly, MA, USA 
RNase-Free DNase Qiagen, Valencia, CA, USA 
Taq DNA Polymerase in Storage Buffer A (5 U/µl) Promega Corporation, Madison, WI, USA 
Xho I New England Biolabs, Beverly, MA, USA 
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5.1.6 Primers 
Mdr1a 
Forward primer (bases 1253-1278): 
5’-CACTTCAGTTACCCGTCTCGAAAAGA-3’ 
Reverse primer (bases 1895-1920): 
5’-CCTTTCTCTCTCATGAGCTCATCATG-3’ 
Qiagen Inc., Valencia, CA, USA 
Mdr1b 
Forward primer (bases 2264-2289): 
5’-GCATACAACCAGTGTTTGCCATAGTG-3’ 
Reverse primer (bases 2658-2683): 
5’-GTAAAAGTGTAAGCTGCCAGCCATAG-3’ 
Qiagen Inc., Valencia, CA, USA 
Mrp2 
Forward primer (bases 2123-2147): 
5’-GTATCAGCCATGCTGGGAGAAATGG-3’ 
Reverse primer (bases 2507-2531): 
5’-AGATTCTCGTCTTGCCAGCCAACAG-3’ 
Qiagen Inc., Valencia, CA, USA 
PXR 
Forward primer (bases 538-560): 
5’-GATGATCATGTCTGATGCCGCTG-3’) 
Reverse primer (bases 890-868): 
5’-AGGTTGGTAGTTCCAGATGCTG-3’ 
Qiagen Inc., Valencia, CA, USA 
T7 Sequencing Primer 
5’-TAATACGACTCACTATAGGG-3’ Invitrogen Corporation, Carlsbad, CA, USA 
BGH Reverse Sequencing Primer 
5’-TAGAAGGCACAGTCGAGG-3’ Invitrogen Corporation, Carlsbad, CA, USA 
 
 
5.1.7 Software 
EndNote, Version 7.0.0 (Bld 98) ISI ResearchSoft, Carlsbad, CA, USA 
GraphPad Prism®, Version 4.00 GraphPad Software Inc., San Diego, CA, USA 
MegaView III Soft Imaging System (SIS) Soft Imaging System Corp., Lakewood, CO, USA 
Microsoft® Excel 2002, SP3 Microsoft Corporation, Redmond, WA, USA 
Microsoft® Office XP Microsoft Corporation, Redmond, WA, USA 
Microsoft® PowerPoint® 2002, SP3 Microsoft Corporation, Redmond, WA, USA 
Microsoft® Word 2002, SP3 Microsoft Corporation, Redmond, WA, USA 
NIH ImageJ, Version 1.31 NIST Laboratories, Gaithersburg, MD, USA 
Primer Express®, Version 8.0 Applied Biosystems, Foster City, CA, USA 
Quantity One, Version 4.3.0 Bio-Rad Laboratories, Hercules, CA, USA 
Scion Image Beta 4.02 Scion Corporation, Frederich, MD, USA 
SoftMax® Pro, Version 3.1.2 Molecular Devices Corp., Sunnyvale, CA, USA 
Zeiss LSM 510 NLO, Version 3.2 SP2 Carl Zeiss MicroImaging, Inc., Thornwood, NY, USA 
Zeiss LSM Version 3.99 Carl Zeiss MicroImaging, Inc., Thornwood, NY, USA 
Zeiss LSM 5 Image Examiner, Version 3.2 Carl Zeiss MicroImaging, Inc., Thornwood, NY, USA 
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5.1.8 Buffers 
  
 Phosphate Buffered Saline (PBS), pH 7.4 
 Final concentration: 
 
NaCl 8.00 g 136.90 mM 
KCl 0.20 g 2.70 mM 
Na2HPO4 1.15 g 8.10 mM 
KH2PO4 0.20 g 1.46 mM 
CaCl2 (anhyd.) 0.10 g 0.90 mM 
MgCl2 ⋅ 6H2O 0.10 g 0.50 mM 
Na-pyruvate 0.11 g 1.00 mM 
Glucose 0.90 g 5.00 mM 
Distilled water ad 1000 ml 
 
NaOH and HCl were used to adjust pH; buffer was filter sterilized (0.2 µm). Na-pyruvate and glucose were 
added prior to experiments.  
  
 
  
 Ca2+ and Mg2+-free PBS, pH 7.4 
 Final concentration: 
 
NaCl 8.00 g 136.90 mM 
KCl 0.20 g 2.70 mM 
Na2HPO4 1.15 g 8.10 mM 
KH2PO4 0.20 g 1.46 mM 
Na-pyruvate 0.11 g 1.00 mM 
Glucose 0.90 g 5.00 mM 
Distilled water ad 1000 ml 
 
NaOH and HCl were used to adjust pH; buffer was filter sterilized (0.2 µm). Na-pyruvate and glucose were 
added prior to experiments. 
  
 
  
 Tris-Borate-EDTA Buffer (TBE Buffer) 
 Final concentration: 
 
Tris base 108 g 0.89 M 
Boric Acid 55 g 0.89 M 
EDTA (pH 8.0), 0.5 M 40 ml 20 mM 
Distilled water ad 1000 ml 
 
TBE buffer was filtered through a 0.2 µm filter-sterilizing unit. 
  
 
 
5.1.9 Solutions for Capillary Isolation 
  
 1% BSA 
 Final concentration: 
 
Albumin bovine serum 1 g 1% 
PBS ad 100 ml 
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30% Ficoll®
 Final concentration: 
 
Ficoll® 30 g 30% 
PBS ad 100 ml 
  
 
 
 
5.1.10 Fixative for Immunohistochemistry 
  
3% Paraformaldehyde/0.25% Glutaraldehyde Fixative 
 Final concentration: 
 
Paraformaldehyde 3 g 3% 
Glutaraldehyde 0.25 g 0.25% 
Ca2+ and Mg2+-free PBS* ad 100 ml 
 
* without glucose and Na-pyruvate 
  
 
 
 
5.1.11 Culture Media 
  
Luria Agar Plates, pH 7.2 
 Final concentration: 
 
Bacto™ Tryptone 10 g 1% 
Bacto-Yeast Extract 5 g 0.5% 
NaCl 10 g 171.1 mM 
Bacto™ Agar 20 g 2% 
Ampicillin 0.1 g 100 µg/ml 
Distilled water ad 1000 ml 
 
1N NaOH was used to adjust pH; mixture was autoclaved at 121˚C for 20 minutes, cooled down and dis-
pensed into sterile petri dishes (30 ml per plate). 
  
 
  
Luria-Bertani Medium, pH 7.5 
 Final concentration: 
 
Bacto™ Tryptone 10 g 1% 
Bacto-Yeast Extract 5 g 0.5% 
NaCl 10 g 171.1 mM 
Ampicillin 0.1 g 100 µg/ml 
Distilled water ad 1000 ml 
 
1N NaOH was used to adjust pH; medium was autoclaved at 121˚C for 25 minutes. 
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SOC Medium, pH 7.0 
 Final concentration: 
 
Bacto™ Tryptone 20 g 2% 
Bacto-Yeast Extract 5 g 0.5% 
NaCl, 1 M 10 ml 10 mM 
KCl, 1 M 2.5 ml 2.5 mM 
MgCl2, 2 M 5 ml 10 mM 
MgSO4, 2 M 5 ml 10 mM 
Glucose, 2 M 10 ml 20 mM 
Distilled H2O ad 1000 ml 
 
SOC medium was filtered through a 0.2 µm filter-sterilizing unit. 
  
 
 
 
5.1.12 RT and PCR Reagent Mixtures 
  
RT Reagent Mix 
 Final concentration: 
 
Sample (RNA in H2O) 9 µl 5 µg 
Random hexamer, 50 µM 1 µl 2.5 µM 
RNase inhibitor, 20 U/µl 1 µl 1 U/µl 
PCR buffer II, 10x 2 µl 1x 
dNTP mix, 10 mM each 2 µl 1 mM each 
MgCl2, 25 mM 4 µl 5 mM 
MuLV RT, 50 U/µl 1 µl 2.5 U/µl 
  
Total volume: 20 µl 
  
 
  
Touch Down-PCR Reagent Mix 
 Final concentration: 
 
Sample (RT product) 1-5 µl  
Forward primer, 10 µM 1 µl 0.2 µM 
Reverse primer, 10 µM 1 µl 0.2 µM 
PCR buffer II, 10x 5 µl 1x 
dNTP mix, 10 mM each 1 µl 0.2 mM each 
MgCl2, 25 mM 4 µl 2 mM 
Taq DNA Polymerase, 5 U/µl 0.5 µl 0.05 U/µl 
PCR-graded H2O 32.5-36.5 µl 
  
Total volume: 50 µl 
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5.1.13 Reagents for Cloning and Sequencing 
  
TOPO® Cloning Reaction Mixture 
 Final concentration: 
 
Sample (PCR product)  4 µl 
Salt solution 1 µl 200 mM NaCl, 10 mM MgCl2
TOPO® vector, 10 ng/µl 1 µl 1.66 ng/µl 
  
Total volume: 6 µl 
  
 
  
Double Restriction Mixture 
 Final concentration: 
 
Sample (plasmid DNA) 10 µl 
NEBuffer 2, 10x 1.5  µl 1x 
BSA, 10x 1.5 µl 0.1% 
Hind III 1 µl 1.3 U/µl 
Xho I 1 µl 1.3 U/µl 
  
Total volume: 15.0 µl 
  
 
  
BigDye® Terminator Sequencing Reaction 
 
 Final concentration: 
 
Sample (DNA) 11 µl 
T7 / BGH primer 1 µl 0.82 / 0.895 µM 
BigDye® Terminator Master Mix 8 µl 
  
Total volume: 20 µl 
  
 
 
 
5.1.14 Reagents for Transmission Electron Microscopy 
  
0.1 M Sodium Cacodylate Buffer 
 Final concentration: 
 
Sodium cacodylate buffer, 0.2 M 50 ml 0.1 M 
Distilled H2O ad 100 ml 
 
Filtered using 0.22 µm Nalgene® disposable filtration unit. 
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1% OsO4
 Final concentration: 
 
OsO4, 2% in H2O 10 ml 1% 
Sodium cacodylate buffer, 0.2 M 10 ml 0.1M 
  
 
  
Fixative for TEM (Modified Karnovsky’s Fixative: 2% Paraformaldehyde/2.5% 
Glutaraldehyde in 0.1M Sodium Cacodylate Buffer, pH 7.4) 
 Final concentration: 
 
Paraformaldehyde, 16% 12.5 ml 2% 
Glutaraldehyde, 70% 3.57 ml 2.5% 
Sodium cacodylate buffer, 0.2 M ad 50 ml 0.1M 
Distilled H2O ad 100 ml  
 
Fitered using 0.22 µm Nalgene® disposable filtration unit. 
  
 
  
5% Uranyl Acetate 
 Final concentration: 
 
Uranyl acetate 5 g 5% 
Distilled H2O ad 100 ml  
  
 
  
Reynold’s Stain 
 Final concentration: 
 
Lead nitrate 1.33 g 80.4 mM 
Sodium citrate 1.76 g 119.6 mM 
Distilled H2O* ad 50 ml 
 
* Distilled water was degassed by boiling and cooling to room temperature in an airtight container. Carbon-
ate-free 1 N NaOH was used to adjust pH to 12. Filtered using 0.22 µm Nalgene® disposable filtration unit. 
  
 
  
Epoxy Resin/Propylene Oxide for Infiltration 
 Final concentration: 
 
Polybed 812 100 ml  
Propylene oxide 100 ml  
DMP-30 2 ml 2% 
  
 
  
Epoxy Resin for Embedment 
 Final concentration: 
 
Polybed 812 100 ml  
DMP-30 2 ml 2% 
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5.2 Methods 
5.2.1 Animal Housing and Handling 
Sprague Dawley outbred rats (male retired breeders, 500-750 g) were purchased from 
Taconic (Germantown, NY, USA) and used for all in vitro and in vivo experiments. Ani-
mals were acclimated to the housing facilities for at least 5 days after delivery and had 
free access to NIH #31M rodent diet (Zeigler Brothers, Gardners, PA, USA) and tap wa-
ter. Rats were kept under controlled external conditions (1 animal/cage, 22 ± 1˚C,  
40-60 % relative humidity, 12-hour light/dark cycle) and were watched at least once a 
day. Animal housing, dosing protocols and in vivo treatments were in accordance with 
NIEHS guidelines and the NIH Guide for the Use and Care of Laboratory Animals (U.S. 
Department of Health, 1985). Rats were euthanized by CO2 inhalation and decapitated; 
tissue was harvested immediately. Tissue was kept at 4˚C in PBS for immediate use or 
snap-frozen in liquid nitrogen for later use. 
 
 
 
5.2.2 Isolation of Rat Brain Capillaries 
(Dallaire et al., 1991; Hartz et al., 2004; Miller et al., 2000) 
 
Capillaries were isolated from fresh rat cerebral cortex using mechanical homogeniza-
tion, density-gradient centrifugation and purification on a glass bead column. 
Ice-cold PBS was used; all materials and tools were kept on ice over the whole proce-
dure. The protocol described is for isolating capillaries from 10 rat brains. Rat brains 
(cerebrum) were purified from meninges and white matter using forceps and a stereo-
microscope. Brain tissue was minced with a scalpel, then suspended 1:1 in PBS and 
homogenized with a pestle tissue grinder (clearance: 150-230 µm) by 10 up-and-down 
strokes using a drill. The suspension was further homogenized by 10 up-and-down 
strokes in a dounce homogenizer (clearance: 130-180 µm). An equal volume of 30% Fi-
coll® was added to a final concentration of 15%. The homogenate was centrifuged at 
5,800 g for 20 min at 4°C in a Sorvall® RC-5B PLUS Superspeed refrigerated centrifuge. 
Floating fat and white matter were discarded; the pellet was resuspended in 1% BSA 
and filtered through a 300 µm mesh. The capillary suspension was passed over a glass 
bead column (30 ml of 0.45 mm glass beads in a 50 ml column, Ø 2.5 cm) and the col-
umn was washed with 400 ml 1% BSA. Capillaries adhering to the glass beads were 
washed off and collected by gentle agitation in 1% BSA followed by filtration through a 
100 µm cell strainer. After centrifugation (300 g, 5 min, 4˚C, Allegra™ 21R centrifuge), 
the capillary pellet was washed twice with PBS and immediately used for transport ex-
periments, immunohistochemistry or capillary membrane isolation. Purity of the prepara-
tion was confirmed under a light microscope. The yield of enriched capillary fraction was 
25-30 mg per 1 g of brain tissue (wet weight). 
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5.2.3 Transport Experiments 
(Bauer et al., 2004; Hartz et al., 2004; Schramm et al., 1995) 
 
Freshly isolated capillaries were transferred to confocal imaging chambers, pre-
incubated for 30 min with the corresponding modulator diluted in PBS, and then incu-
bated in the dark for 1 hour at room temperature in PBS containing a fluorescent dye 
(NBD-CSA or Texas Red). For some experiments, capillaries were first loaded with the 
fluorescent marker to steady state and modulators were added then. Per group of treat-
ment, images were acquired from 10-15 capillaries by confocal microscopy;  
luminal fluorescence intensity was quantitated using Scion Image Beta 4.02 or  
Zeiss LSM 5 Image Examiner 3.2. Specific luminal NBD-CSA fluorescence (P-gp-
specific transport) was calculated by subtracting the PSC833/NaCN-insensitive compo-
nent of fluorescence from the quantitated fluorescence values. 
 
 
 
5.2.4 Kinetic Efflux Assay 
(Hartz et al., 2004) 
 
Capillary lumens were loaded with 2 µM Texas Red in PBS for 1 hour at room tempera-
ture to steady state. After washing the capillaries 3 times with PBS, luminal efflux of 
Texas Red was followed using a confocal microscope. Images of capillaries were taken 
for each time point and luminal Texas Red fluorescence was analyzed using  
Zeiss LSM 5 Image Examiner 3.2. Data were plotted as one phase exponential decay 
using GraphPad Prism® software 4.00. 
 
 
 
5.2.5 Immunostaining 
(Bauer et al., 2004; Hartz et al., 2004) 
 
Ca2+ and Mg2+-free PBS without glucose and Na-pyruvate was used for preparing all  
solutions (fixative, 0.1-0.5% Triton X-100, 1% BSA and propidium iodide nuclei staining 
solution). Rat brain capillaries were transferred to confocal imaging chambers and let 
attach to the bottom for 15-20 min. Fixation was done with 3% para-formaldehyde/0.25% 
glutaraldehyde for 10-15 min at room temperature. After washing 5 times with buffer, 
capillaries were permeabilized for 15-30 min with 0.1-0.5% Triton X-100, washed twice 
with buffer and blocked for 15-30 min with 1% BSA. Capillaries were then incubated for 
either 1-2 hours at 37°C or overnight in the refrigerator with primary antibody diluted in 
1% BSA. After washing 5 times with 1% BSA, capillaries were incubated for 1-2 hours at 
37°C with the corresponding fluorescence-labeled secondary antibody (1:1,000 dilution 
in 1% BSA). Capillaries were washed, nuclei were stained with 1 µg/ml propidium iodide 
for 5-15 min and afterwards, capillaries were washed again. Capillary immunostaining 
was watched using confocal microscopy. For quantitative immunostaining, images of  
20 capillaries per group were acquired. Immunofluorescence was quantitated using NIH 
ImageJ 1.31. 
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5.2.6 Laserscanning Confocal Microscopy 
(Bauer et al., 2004; Hartz et al., 2004; Miller, 2003; Schramm et al., 1995) 
 
For transport studies, efflux experiments and immunostaining, laser scanning confocal 
microscopy was used (Zeiss LSM 410 invert or LSM 510 NLO Laser Scanning Micro-
scope). 
For transport studies with NBD-CSA, the 488 nm line of an argon ion laser provided the 
excitation. Images from experiments using Texas Red (transport and efflux studies) were 
obtained using a HeNe laser (excitation: 543 nm). Low laser intensity was used to avoid 
photobleaching of the dyes. Tissue auto-fluorescence was undetectable with the applied 
settings. To obtain an image, dye-loaded capillaries were viewed under transmitted light 
illumination. A single capillary, at least 50 µm in length with well-defined lumen and un-
damaged endothelium, was selected. The plane of focus was adjusted to cut through the 
center of the capillary lumen and a confocal image (512 x 512 x 8 bits) was acquired by 
averaging four scans. Fluorescence intensities were measured from stored images using 
Scion Image Beta 4.02 or Zeiss LSM 5 Image Examiner 3.2. For fluorescence quantita-
tion, three luminal areas (> 20 µm2 each) were selected from each capillary. Because 
luminal fluorescence intensity cannot be related to the actual concentration of accumu-
lated compound in the lumen, data are reported as average measured pixel intensity. 
Arbitrary fluorescence units [au] range from 0-255. 
Immunofluorescence was visualized by confocal microscopy using an argon ion laser 
(488 nm). To quantitate immunofluorescence, luminal membrane fluorescence was 
measured using NIH ImageJ 1.31. A 10 x 10 grid was superimposed on each image, 
and measurements were taken at every intersection of a grid line with a capillary luminal 
plasma membrane. The fluorescence intensity for each capillary was the mean of all 
measurements. 
 
Confocal microscope 
Zeiss 510 NLO 
mounted on Zeiss Inverted Axiovert 100M 
Zeiss LSM 410 invert 
mounted on Axiovert 135 
Fluorescent marker 
1. NBD-CSA 
2. Texas Red 
3. Alexa Fluor® 488 
4. Propidium iodide 
NBD-CSA 
Objective lens 
Zeiss C-Apochromat 
40x water immersion objective 
(numerical aperture = 1.2) 
Zeiss C-Apochromat 
40x water immersion objective 
(numerical aperture = 1.2) 
Laser type 1. HeNe laser 2. Argon ion laser Argon ion laser 
Laser excitation 1. 543 nm 2. 488 nm 488 nm 
Emission filter 1. Long Pass 560 nm 2. Band Pass 500-530 nm Long Pass 500 nm 
Beam splitters 1. HFT 488/543, NFT 490 2. HFT 488/543 FT 488/647 nm 
Pinhole setting ≤ 1 Airy unit ≤ 1.7 Airy unit 
Zoom 4 4 
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5.2.7 Plasma Membrane Isolation 
(Bauer et al., 2004; Wakayama et al., 2002) 
 
Crude plasma membrane fractions from liver, kidney or brain capillaries were obtained 
by differential centrifugation. Tissue was homogenized in mammalian tissue lysis buffer 
(CelLytic™MT) containing Complete™ protease inhibitor cocktail using a micro-
homogenizer. After 1 hour on ice with occasional vortexing, samples were centrifuged at 
10,000 g for 30 min. Denucleated supernatants were centrifuged at 100,000 g for 90 min 
(TL-100 tabletop ultracentrifuge). Pellets (crude plasma membranes) were resuspended 
in PBS containing protease inhibitor cocktail and phosphatase inhibitor and kept at -80˚C 
until use. 
 
 
 
5.2.8 Isolation of Nuclear Proteins 
Nuclear proteins from capillaries were isolated according to a protocol combining the 
Nuclei PURE Prep Nuclei Isolation Kit and the NE-PER® Nuclear und Cytoplasmic Ex-
traction Reagents Kit. All steps were carried out on ice; all equipment used was pre-
cooled; buffers contained inhibitors for phosphatases and proteases. 
Isolated capillaries were homogenized with 10 ml of ice-cold Nuclei PURE lysis buffer 
using micro-homogenizers. The homogenate was mixed with 15 ml 1.8 M Nuclei PURE 
Sucrose Cushion Buffer and carefully layered on top of 2.5 ml 1.8 M Nuclei PURE Su-
crose Cushion Buffer. Samples were centrifuged at 40,000 g for 2 hours at 4˚C (Beck-
man L8-55M ultracentrifuge). Supernatant was removed; nuclei pellets were resus-
pended in Nuclei PURE Storage Buffer and centrifuged at 500 g for 5 min at 4˚C (Beck-
man Allegra™ 21R centrifuge). After washing with Ca2+ and Mg2+-free PBS, nuclei were 
resuspended in 100 µl nuclear extraction reagent. Samples were placed on ice and 
thoroughly vortexed every 10 min, for a total of 60 min. Samples were centrifuged at 
16,000 g for 10 min at 4˚C. Supernatant (nuclear extract) was transferred to a pre-chilled 
tube and stored at -80˚C until use. 
 
 
 
5.2.9 Bradford Protein Assay 
(Bradford, 1976) 
 
For the standard curve, BSA was diluted in 1N NaOH (0, 1, 2, 3, 4, 5 µg/µl). Samples 
were also diluted in 1N NaOH, vortexed and centrifuged. Per well, 10 µl standard or 
sample were pipetted (3 repeats of each). 200 µl freshly prepared Bradford reagent (1:5 
in H2O) was added and mixed thoroughly. NaOH was used as blank. The plate was read 
at λ = 595 nm in a VersaMax™ tunable micro-plate reader. Sample protein concentra-
tions were calculated from the standard curve and obtained as mean concentration in 
µg/µl by SoftMax® Pro software program. 
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5.2.10 Western Blotting 
(Bauer et al., 2004; Hartz et al., 2004; Laemmli, 1970) 
 
Western blots were performed using the Invitrogen NuPage™ Bis-Tris electrophoresis 
system with pre-cast 4-12% Bis-Tris-gradient gels, NuPage® MOPS SDS running buffer 
and NuPage® transfer buffer under reducing conditions. Samples were prepared using 
NuPAGE® LDS sample buffer, NuPAGE® reducing agent and deionized water and di-
luted to the protein concentration needed (usually 1 µg/µl). Samples were heated (70°C) 
for 10 min, cooled down to room temperature, vortexed and loaded onto the gel. Full-
Range Rainbow™ marker was used as molecular weight standard. The electrophoresis 
was run at 200 V (constant) for about 50-60 min. Gels were subsequently blotted on 
PVDF membranes. Transfer conditions were 30 V (constant) for 2 hours. After protein 
transfer, membranes were blocked with SuperBlock® blocking buffer containing  
0.5% Surfact-Amps® 20 for 8 hours in the refrigerator. Membranes were incubated over-
night with a primary antibody diluted in blocking buffer. Then, membranes were washed 
7 times for 7 min while agitating on a rotary platform shaker with BupH™ Tris Buffered 
Saline containing 0.05% Tween® 20. Membranes were incubated with horseradish per-
oxidase-conjugated ImmunoPure® secondary antibody (1:10,000 - 1:20,000) for 1 hour 
at room temperature while shaking. After washing (7 times 7 min), proteins were de-
tected using SuperSignal® West Pico Chemoluminescent Substrate and visualized with 
a BioRad Chemi Doc 2000™ gel documentation system. 
 
 
 
5.2.11 In Vitro Induction Experiments 
(Bauer et al., 2004) 
 
Freshly isolated capillaries were exposed to modulators (dexamethasone, PCN, hyper-
forin and paclitaxel) in PBS for 6 hours at room temperature. Modulators in DMSO stock 
solutions were prepared in PBS. Control medium contained DMSO; the final DMSO con-
centration did not exceed 0.05%. 
 
 
 
5.2.12 In Vivo Induction Experiments 
(Bauer et al., 2004) 
 
For in vivo induction, five animals per group were injected i.p. daily with PCN  
(10-50 mg/kg in corn oil, 3 days) or dexamethasone (1-50 mg/kg in corn oil, 3 days). 
Control animals were treated with corn oil only. The injection volume was 5 ml/kg.  
24 hours after the last injection, rats were euthanized and decapitated; brains were 
taken immediately to isolate brain capillaries. Livers and kidneys were removed, snap-
frozen in liquid nitrogen and stored at -80°C until use. 
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5.2.13 Total RNA Isolation 
To avoid contamination with RNase, bench surfaces, pipettes and gloves were cleaned 
with RNaseZap™ prior to isolation. All steps were carefully performed and pipettes, re-
served for RNA work only, were used with sterile RNase- and DNase-free pipet tips. 
Total RNA was isolated using Trizol® reagent and further purified using the RNeasy® 
Mini Kit to obtain an optimal yield of high purity total RNA. 20-50 mg of tissue (isolated 
capillaries, brain, liver and kidney) were thoroughly homogenized in 1 ml Trizol® reagent 
using a micro-homogenizer. The homogenate was transferred into an RNase-free tube, 
200 µl chloroform were added, then the samples were vortexed for 15 sec and incubated 
for 10 minutes at room temperature. For phase separation, samples were centrifuged at 
12,000 g for 15 min at 4°C. The mixture separated into a lower red, phenol-chloroform 
phase, an inter-phase containing protein, and a colorless upper aqueous phase contain-
ing total RNA. The aqueous phase was transferred to a fresh tube and RNA was precipi-
tated by adding 0.5 ml of 100% isopropyl alcohol. After 10 min incubation, samples were 
centrifuged at 12,000 g for 10 min at 4°C. The supernatant was removed, and the RNA 
pellet was washed with 1 ml ethanol (70%), followed by centrifugation (12,000 g, 5 min, 
4°C). The supernatant was removed; the RNA pellet was air-dried and then dissolved in 
100 µl DEPC-treated water. To further purify total RNA, the RNeasy® Mini Kit was used 
according to the manufacturer’s protocol. Briefly, 350 µl RLT buffer containing  
1% β-mercaptoethanol and 250 µl ethanol (100%) were added to 100 µl of total RNA 
and mixed thoroughly by pipetting. Samples were then applied to an RNeasy® mini col-
umn placed in a collection tube. Samples were centrifuged at 8,000 g for 30 sec; the 
flow-through was discarded. 350 µl RW1 wash buffer were pipetted into the column, 
which was then centrifuged for 1 min at 8,000 g. The flow-through was discarded.  
80 µl DNase I incubation mix (10 µl DNase I stock solution + 70 µl RDD buffer) were ap-
plied directly onto the RNeasy® silica-gel membrane of the column and let incubate for 
15-30 min at room temperature. 350 µl RW1 wash buffer were added and centrifuged at 
8,000 g for 30 sec, the flow-through was discarded. Then, the column was washed  
2 times with 500 µl RPE buffer and centrifuged at 8,000 g for 15 sec and 2 min, respec-
tively. A new collection tube was applied and RNA was eluted with 10-30 µl RNase-free 
water. RNA yield and purity were determined by measuring optical density (OD). Only 
samples with an OD ratio 260 nm : 280 nm 1.8-2.0 were used. 
 
 
5.2.14 Reverse Transcription 
Reverse transcription (RT) was performed using the GeneAmp® RNA PCR kit.  
1-5 µg total RNA, random hexamers, MuLV reverse transcriptase, dNTPs, RNase inhibi-
tor, MgCl2 and PCR buffer were mixed. The following thermocycler program was used: 
 
 
25˚C for 10 min 
42˚C for 90 min 
95˚C for 5 min 
hold at 4˚C 
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5.2.15 Touch-down PCR 
Primers were designed either manually or by using Primer Express® software, Version 
8.0. Complete mRNA sequences of the corresponding rat genes were obtained from 
PubMed. Primer specificity was confirmed by running the sequences through the  
PubMed BLAST database. Primers were then custom-synthesized by Qiagen. 
For touch-down PCR, 1-5 µl RT product was mixed with forward and reverse primers. 
Then, Taq DNA polymerase, dNTPs, MgCl2, PCR buffer and PCR-grade H2O were 
added. PCR was run using the following thermocycler program: 
 
 
95˚C for 1 min 
95˚C for 30 sec 
65-61˚C for 30 sec 1 cycle each 
72˚C for 30 sec 
95˚C for 30 sec 
60˚C for 30 sec 25-35 cycles 
72˚C for 30 sec 
72˚C for 3 min 
hold at 4˚C
 
 
 
 
 
 
 
 
 
 
 
 
5.2.16 Electrophoresis 
PCR products were electrophoresed on a freshly poured agarose gel (2-4%,  
0.1 µg/ml ethidium bromide, Tris-borate-EDTA buffer). Samples were mixed with gel 
loading buffer and loaded into the wells. Running conditions were 100 V for 45-60 min. 
Bands were visualized under UV and imaged using the BioRad Chemi Doc 2000™ gel 
documentation system. 
 
 
5.2.17 Cloning and Sequencing 
(Bauer et al., 2004) 
 
In order to clone and sequence the PCR product, first the PXR amplicon was extracted 
from the agarose gel, purified and cloned into the His-TOPO® vector, followed by trans-
formation in One Shot® TOP10 chemically competent E. coli cells. Plasmid DNA was 
isolated using the UltraClean™ 6-minute plasmid kit; sequencing PCR was performed 
using the BigDye® DNA sequencing kit. Samples were purified on a spin column and se-
quenced on an ABI Prism 377 DNA sequencer. 
Agarose Gel Extraction: 
The 353 bp amplicon of rat PXR (GenBank Acc.No. AF151377) was electrophoresed on 
an agarose gel. The PCR product was extracted from the agarose gel using the QIAEX 
II agarose gel extraction kit according to the manufacturer’s protocol. Briefly, DNA bands 
were excised from the gel. 3 volumes of QX1 buffer were added to 1 volume of gel. After 
adding 10 µl QIAEX II suspension, samples were incubated at 50˚C for 10 min while vor-
texing every 2 min. 
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After centrifugation (30 sec, 10,000 g), supernatant was removed and the pellets were 
washed once with 500 µl QX1 buffer and twice with 500 µl PE buffer. The pellets were 
air-dried for 10 min and resuspended in 20 µl PCR-grade H2O. After centrifugation  
(30 sec, 10,000 g), supernatant containing purified DNA was transferred into a fresh 
tube. 
Cloning: 
The pcDNAA3.1/V5-His© TOPO® TA expression kit was used to clone the extracted 
PCR product. TOPO® Cloning reaction mixture containing sample, buffer and TOPO® 
vector was prepared according to the manufacturer’s protocol, incubated for 5 min at 
room temperature and for an additional 5 min on ice. 
Transformation: 
Transformation in One Shot® TOP10 chemically competent E. coli cells was performed 
by gently mixing 4 µl of sample with One Shot® TOP10 chemically competent E. coli 
cells followed by 5 min incubation on ice. The cells were heat-shocked for 30 sec at 
42˚C and immediately put back on ice. After adding 250 µl SOC medium, cells were 
plated on LB plates containing 100 µg/ml ampicillin and incubated overnight. 24 hours 
after plating, colonies were picked and cultured in Luria-Bertani Medium (100 µg/ml am-
picillin) overnight at 37˚C. 
Plasmid DNA isolation: 
Plasmid DNA was isolated using the UltraClean™ 6 minute Mini Plasmid Prep kit ac-
cording to the manufacturer’s protocol. Briefly, 2 ml culture medium were added to the  
E. coli cells. Samples were centrifuged (1 min, 10,000 g), supernatant was removed and 
the cell pellets were resuspended in 50 µl Solution 1. 100 µl Solution 2 and 325 µl Solu-
tion 3 were added and the tubes were gently inverted to mix. After centrifugation (1 min, 
10,000 g), the supernatant was pipetted into a spin filter and centrifuged (30 sec,  
10,000 g). The flow through was discarded, 300 µl Solution 4 was added on the spin fil-
ter, which was centrifuged at 10,000 g for 30 sec. Plasmid DNA was eluted with 50 µl 
PCR-graded H2O by centrifugation (10,000 g, 30 sec). Positive clones were selected by 
double-restriction digest with Hind III and Xho I restriction enzymes. 5 µl of the mixture 
for double restriction were added to 10 µl plasmid DNA and let incubate for 1 hour at 
37˚C. Agarose gel electrophoresis was run to check the double-restriction. 
Sequencing: 
Sequencing was performed using the BigDye® Terminator Cycle Sequencing Kit and 
universal T7 and BGH primers. BigDye® Terminator master mix, sample and primers 
were mixed and the PCR reaction was performed using the following parameters: 
 
96˚C for 1 min 
96˚C for 10 sec 
50˚C for 5 sec 25 cycles 
60˚C for 4 min 
hold at 10˚C
 
 
 
 
 
 
 
The PCR products were spin column purified using the DyeEx™ 2.0 Spin kit. Samples 
were transferred to the spin column and centrifuged for 3 min at 750 g. Samples were 
vacuum-dried and sequenced on an ABI Prism 377 DNA sequencer. 
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5.2.18 Transmission Electron Microscopy 
Isolated rat brain capillaries were rinsed in 0.1 M sodium cacodylate buffer and centri-
fuged (300 g, 1 min, 4˚C). The pellet was resuspended in 3 ml fixative (modified Kar-
novsky’s fixative: 2% para-formaldehyde/2.5% glutaraldehyde in 0.1 M sodium cacody-
late buffer) and incubated for 10 min. After centrifugation at 15,000 g for 10 min, the pel-
let was overlaid with fresh fixative and incubated overnight. Then, the pellet was rinsed 
three times for 15 min in 0.1 M sodium cacodylate buffer, followed by 1-hour postfixation 
in 1% OsO4. After three 15-min rinses with distilled H2O, the pellet was dehydrated 
through a graded series of ethanol (50%, 70%, 95% and twice in 100% ethanol, 15 min 
each) followed by two 15-min rinses with propylene oxide. 
The pellet was infiltrated overnight with a 1:1 mixture of propylene oxide and epoxy resin 
(containing 2 % DMP-30 as accelerator) in a desiccator containing Drierite® desiccant; 
specimen vials were left uncapped. The next day, the pellet was given two 4-hour 
changes in epoxy resin (2% DMP-30). For embedment of the pellet in a Beem™ em-
bedding capsule, epoxy resin (2% DMP-30) was also used. Polymerization of the resin 
was conducted at 60˚C for 3 days. The Beem™ capsule was removed using a Beem™ 
capsule press. Semi- and ultra-thin sections (500 and 90 nm, respectively) were cut us-
ing a Leica Ultracut Ultramicrotome. Semi-thin sections were stained using 1% toluidine 
blue in 1% borate to locate areas with densest concentrations of well-preserved capillar-
ies by light microscopy. Ultra-thin sections were placed on 150-mesh Formvar®/carbon-
coated copper grids and stained with 5% uranyl acetate for 20 min at 60˚C and an addi-
tional 15 min at room temperature; numerous droplets of distilled water were used for 
rinsing. To further enhance contrast of the images, the grids were incubated for 15 min 
with Reynold’s stain containing lead nitrate and sodium citrate followed by rinses with 
distilled water. Sections were examined in a FEI Tecnai™ G2 12 electron microscope 
(operated at 80 kV) equipped with Mega View III Soft Imaging System software. 
 
 
 
5.2.19 Statistics 
F- and t-tests were performed using Microsoft® Excel 2002. Data are given as  
means ± SEM. Probability values (P) were calculated for p < 0.05 (∗), p < 0.01 (∗∗) and  
p < 0.001 (∗∗∗) by use of the appropriate paired or unpaired t-test. Exponential efflux con-
stants were obtained using non-linear regression and calculated using GraphPad Prism®, 
Version 4.00. 
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